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The spread of antibiotic resistance is a great threat to medicine. We are in desperate 
need of new antibiotics to replace those for which resistance is widespread. The 
bacterial type two topoisomerases, DNA gyrase and topoisomerase IV, are well 
validated antimicrobial targets. The fluoroquinolone antibiotics target the DNA binding 
site of these enzymes, but no currently available antibiotics target the ATP binding site. 
It is hoped that simultaneously targeting the ATP binding sites of these two bacterial 
enzymes will slow the emergence of resistance.  
This thesis describes the investigation of a series of pyridine 3-carboxamide DNA 
gyrase inhibitors, extending knowledge of the structure activity relationships of these 
compounds and making assessment of their inhibition of the topoisomerase IV enzyme 
in addition to their inhibition of DNA gyrase. Many of the inhibitors proved to be highly 
potent inhibitors of both DNA gyrase and topoisomerase IV with the most potent 
compound having IC50s of 24 nM and 87 nM against the DNA gyrase and 
topoisomerase IV enzymes respectively. These compounds also showed promising 
antibacterial activity with MICs as low as 1 μg/ml against S. aureus. Additionally, in 
vitro ADME profiling of key compounds from this series was carried out. 
A subunit of the DNA gyrase protein was produced for use in crystallisation studies. Co-
crystallisation of the protein with four inhibitor molecules was carried out and four 
crystal structures were solved revealing the binding poses of the pyridine 3-
carboxamide compounds bound in the ATP site of GyrB. 
Efforts were also made to identify a new series of DNA gyrase inhibitors. De novo 
design and virtual high throughput screening were utilised and a number of 
compounds were purchased and assessed for their ability to inhibit DNA gyrase. Two 
of the compounds showed activity in the enzyme assay. A scaffold hopping approach 
was also used to rationally design new series of potential inhibitors. Three compound 
series were designed and synthesis was carried out towards them. A series of 
quinazolinones proved to be the most synthetically tractable and a small library was 
produced and assessed for their biological activity. Several of the compounds were 
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Chapter 1 Introduction 
1.1 Antibacterial resistance and the need for new antibacterial agents 
Antibacterial agents have changed the world, not only transforming medicine and 
healthcare, but also dramatically altering the strains of bacteria that live alongside us. 
First discovered almost a century ago, antibacterial compounds have allowed 
developments in medicine that would have been unthinkable without them. Infections 
that once were seriously debilitating or even fatal can now be cured with a short 
course of an antibacterial compound and being able to administer antibiotics 
prophylactically has allowed many surgical interventions to become routine. However, 
as use of antibacterial compounds has increased, so too has the spread of bacterial 
strains which can resist their effect. The selection pressure that widespread 
antibacterial use has generated has encouraged the emergence and spread of strains 
resistant to all of our commonly used antibacterial agents. If new antibacterial drugs 
are not developed in time to replace ones which are no longer effective, we may face a 
serious healthcare disaster. 
In 2014 the World Health Organisation (WHO) reported that: “A post-antibiotic era—in 
which common infections and minor injuries can kill—far from being an apocalyptic 
fantasy, is instead a very real possibility for the 21st century” in a 256 page report 
detailing the spread of antimicrobial resistance worldwide.1 A report commissioned by 
the UK government has recently issued a similarly stern warning based on models of 
the impact of antimicrobial resistance: if nothing is done to stop the spread of 
resistance, 300 million people will die prematurely due to antibiotic resistance 
between now and 2050.2  
Bacterial resistance is already causing serious difficulties for the treatment of common 
infections. High resistance rates to some of our most important antibacterial drugs, the 
3rd generation cephalosporins and the fluoroquinolones, have been observed in 
Escherichia coli and Klebsiella pneumoniae in all regions which report data to the WHO. 
These bacteria are responsible for common infections such as urinary tract infections 




and pneumonia and due to the spread of resistance often have to be treated with 
carbapenems which are one of our last lines of defence. Even more worryingly, 
carbapenem resistant K. pneumoniae has been reported at levels up to 54%. Another 
serious concern is the spread of methicillin resistant Staphylococcus aureus (MRSA), 
which has become so widespread that second line antibacterials are now relied on to 
treat skin and wound infections.1  
Carbapenem resistance is conferred by the presence of carbapenemase enzymes such 
as K. pneumoniae carbapenemase-2 (KPC-2) and New Delhi metallo-β-lactamase-1 
(NDM-1) which have spread very rapidly across the globe and been transmitted 
between bacterial species via plasmids. Treatment options for carbapenem resistant 
infections are limited to just tigecyclin and colistin. Until recently, the only known 
mechanisms of resistance to colistin and other polymixins were chromosomally 
mediated, but in late 2015 a plasmid mediated colistin resistance mechanism (MCR-1) 
was found in livestock and some human patients in China.3 In the months following 
this report the MCR-1 gene has been detected in E. coli isolates from the Netherlands4, 
Laos, Thailand, France and Nigeria5 and Salmonella isolates from France6 and 
Portugal7. 
Antibiotic resistance places a huge burden on healthcare systems worldwide, as 
resistant infections are harder to treat and lead to worse outcomes for patients. New 
antibacterial compounds are desperately needed to fill the void left by losing the utility 
of our current drugs. 
1.2 Bacteria as drug targets 
Antibacterial compounds target a range of features and processes which are present in 
bacteria, but not in mammalian cells. These include features of the bacterial 
membrane such as the proteins which cross link the peptidoglycan cell wall, and 
processes which are carried out somewhat differently in bacterial cells such as protein 
synthesis and DNA replication. A summary of the key bacterial targets is given in Table 
1.1. 
 




Table 1.1 Targets of common classes of antibacterials. 
Bacterial process targeted Molecular Target Antibacterial Class 
Cell wall synthesis peptidoglycan cross-linking β-lactams 
 peptidoglycan synthesis glycopeptides 
 isoprenyl phosphatase bacitracin 
 enolpyruvyl transferase fosfomycin 
Protein synthesis 30S ribosomal subunit aminoglycosides and 
tetracyclines 
 50S ribosomal subunit chloramphenicol, 
macrolides, lincosamides 
and oxazolidinones 
 elongation factor G fusidic acid 
Nucleic acid synthesis Dihydropterate synthetase Sulfonamides 
 Dihydrofolate reductase trimethoprim 
DNA replication and  Type II topoisomerases Fluoroquinolones 
Transcription RNAP rifamycins 
Bacterial membrane membrane damage polymixins and daptomycin 
 
1.2.1 Gram positive and Gram negative bacteria 
Bacteria can be grouped into two classes, Gram negative and Gram positive, according 
to whether or not they retain crystal violet dye. Gram positive bacteria have a single 
phospholipid membrane surrounded by a thick peptidoglycan layer whereas Gram 
negative bacteria have a thinner peptidoglycan layer which is surrounded by a second 
phospholipid membrane (Figure 1.1). Crystal violet dye binds to the peptidoglycan 
layer of Gram positive bacteria, but cannot pass through the outer membrane of Gram 
negative bacteria, so they remain unstained. The difference in the structures of the cell 
wall between Gram negative and Gram positive bacteria mean that they often respond 
differently to antibiotics. 
The dual membrane structure of Gram negative species can reduce the permeability of 
the cell wall to antibiotics.8 Many antibiotics with good antimicrobial activity against 
Gram positive species are not active against Gram negative organisms. This includes 
many of the β-lactam antibiotics, which act by inhibiting the synthesis of the 
peptidoglycan cell wall. Gram negative bacteria also possess efflux pumps within the 
cell wall, which are able to expel foreign substances from the cell or prevent them 
from passing through the bacterial membrane. Drugs which are unable to diffuse 
through the peptidoglycan cell membranes or are susceptible to efflux will be unable 




to accumulate within Gram negative cells at a sufficient concentration to have an 
antibiotic effect.9  
 
Figure 1.1 Structures of the cell wall in Gram negative and Gram positive bacteria. 
 
The outer membrane of Gram negative bacteria contains a large proportion of 
lipopolysaccharide (LPS) molecules which make up the outer part of the cell 
membrane. Lipopolysaccharides are comprised of a lipid section and a polysaccharide 
section (Figure 1.2). The lipid section is called Lipid A and is comprised of a series of 
fatty acids attached to a pair of glucosamine residues. Lipid A is highly conserved 
among Gram negative species.10 Each glucosamine residue is attached to a phosphate 
group. The oligosaccharide portion of the LPS is comprised of a core oligosaccharide, 
which is bound to lipid A, and an O antigen.8 The composition of this region is highly 
variable between strains of bacteria. The O antigen region is highly endotoxic and 
produces a strong immune response in animals.11 The lipopolysaccharide layer 
hampers the movement of lipophilic small molecules through the membrane as they 
cannot pass the highly charged region near to the surface.8  





Figure 1.2 Lipopolysaccharide composition and chemical structure of lipid A.  
 
The membranes of bacterial cells provide the most daunting challenge to the design of 
effective antibacterial compounds. The membranes are designed to protect bacterial 
cells from environmental threats including toxic chemicals. The degree to which 
bacterial cells are susceptible to an antibacterial compound often depends on whether 
it is able to penetrate the bacterial membrane. 
1.3 Mechanisms of resistance 
The mechanisms by which bacteria resist the effects of antibiotics are numerous and 
varied with some general mechanisms by which bacteria can inure themselves to the 
effects of a broad range of chemical species and some specific mechanisms which 
provide resistance to one specific antibacterial or class of antibacterials. Resistance can 
be innate, acquired or adaptive. An example of innate resistance is the resistance of 
Gram negative bacteria to glycopeptide antibiotics such as vancomycin due to poor 
penetration of their membranes.12 Acquired resistance occurs through acquisition or 
modification of bacterial genes that provide a survival advantage to the bacteria when 
in the presence of an antibacterial, for example the acquisition of a gene coding for a 
β-lactamase which provides resistance to β-lactam antibiotics such as penicillin13. 
Adaptive resistance is a modification of the bacteria’s phenotype that provides a 
survival advantage but is not due to a genetic mutation, for example, an increase in the 
transcription of efflux pump genes14. 




Resistance arises due to the selection pressure placed on bacteria in the presence of 
an antibacterial compound. A variation present in only a small part of a population 
which provides a protective effect in the presence of an antibiotic will provide an 
advantage to those bacteria that possess it and so their population will increase 
relative to other bacteria that do not possess the beneficial mutation. Bacteria do not 
only pass on genetic information when they replicate, they can also pass genes to 
other bacteria in a process called horizontal gene transfer. Genes are packaged into 
small DNA loops called plasmids and passed on to other bacteria in the vicinity.15  
There are many ways in which bacteria can increase their resistance to an antibiotic. 
Some mechanisms are general and provide resistance to a range of antibiotics, for 
example increased production of efflux pumps or decreased production of porins. 
Others are specific to a class of antibiotics, including methods of inactivating the 
antibiotic, modification of the antibiotic’s target site, metabolic bypass so that the 
target of the antibiotic is no longer essential for cell survival and increased production 
of the target protein so that there is enough uninhibited protein for the cell to 
survive.16 Many of these resistance mechanisms have a survival cost in the absence of 
the antibacterial, but they will persist at low levels in a population of bacteria and if 
the antibacterial is reintroduced the resistant strain will rapidly regain prominence. 
Three of the most important types of resistance are described below. 
1.3.1 Modifications to the membrane to control penetration and efflux 
Compounds whose target is within the cytoplasm must be able to penetrate the 
bacterial membrane in order to exert their antibacterial effects. Many species of 
bacteria are intrinsically resistant to certain antibacterial compounds due to the barrier 
that their membrane provides.12 Bacteria can also acquire increased resistance via 
genes encoding modified membrane proteins or develop adaptive resistance by 










Polar small molecules are more easily taken up by the cell than very large or 
hydrophobic molecules due to the presence of porins in the membrane. Porins are β-
barrel proteins that cross the outer membrane of the cell allowing transport of small 
polar molecules into the cell.17 Most porins possess a loop called L3 which bends into 
the channel of the porin creating a constriction zone which limits the size of molecules 
which can pass through the porin and controls the polarity of the pore. Some porins 
are general, allowing transport of a wide range of molecules of the appropriate size 
and hydrophobicity, whilst others are specific to a single molecule or class of 
molecules.9 Porins tend to have size exclusion limits which are close to the average size 
of a number of antibiotics, and so limit the rate at which these antibiotics can diffuse 
into bacterial cells. One of the best studied porins is the OmpF porin from E. coli. It has 
been identified as the main route of entry for the fluoroquinolones and beta-lactam 
antibacterials. The OmpF porin forms trimers in the membrane as shown in Figure 
1.3.18  
 
Figure 1.3 Trimer of OmpF porins from E. coli (PDB 3K19)19. A. View from in the plane of the 
membrane. B. Looking through the membrane with the L3 loops indicated. 
 
Mutations that reduce or prevent the expression of porins or narrow the pore of a 
porin so that antibiotics cannot enter a cell can confer increased resistance to 
antibiotics. Point mutations which prevent the gene for the porin OprD from being 
transcribed in P. aeruginosa have been identified in carbapenem-resistant isolates20. 




Mutations in the loop 3 of porins are frequently found to confer antibiotic resistance. 
For instance, a glycine to aspartate mutation in loop 3 of the OmpF/OmpC-like protein 
of E. aerogenes leads to decreased susceptibility to β-lactams21. Mutations effecting 
porins have been linked to resistance to β-lactams, fluoroquinolones, tetracyclines and 
chloramphenicol.9  
1.3.1.2 Efflux pumps 
Active efflux is a general mechanism of resistance which is of vital importance to 
understanding the actions of antibacterial compounds. Foreign substances, including 
bile salts, dyes and drug molecules, are pumped out of bacterial cells via efflux pumps, 
preventing them from accumulating in the bacterial cell at a high enough 
concentration for them to exert a toxic effect. There are a variety of classes of efflux 
pump which are present in different species and have different mechanisms and 
energy sources.22 Some families of efflux pump, including the ATP-binding cassette 
superfamily (ABC), have members in a wide range of cell types including eukaryotic 
cells as well as Gram negative and Gram positive bacteria, others such as the 
resistance-nodulation-cell division superfamily (RND) are predominantly found in Gram 
negative bacteria with only a small number of examples found in other cell types.23  
The AcrAB-TolC efflux pump is a well-studied efflux pump system from the RND 
superfamily.24 It is found in several Gram negative species including E. coli, E. 
aerogenes and E. cloacae.25-27 It has an intramembrane domain, AcrB, which is able to 
bind to a wide range of compounds including dyes, detergents and many 
antibiotics.28,29 Binding of a small molecule induces a structural change which 
transports the compounds into a transmembrane domain AcrA which can associate to 
the tolC channel in the outer membrane and so expel the compounds from the 
bacterial cell. The process is coupled to a H+ gradient (Figure 1.4).30 
It was recently discovered that a small protein AcrZ can bind to AcrB and modify the 
activity of the pumps, E. coli mutants lacking AcrZ are sensitive to some antibiotics 
which are normally exported by AcrAB-TolC31. Cryo-electron microscopy combined 
with crystal structures of the individual components of the pump has been used to 
determine the structure of the whole pump assembly32. To stabilise the assembly, two 




constructs were prepared, one in which the AcrA and AcrZ components were fused 
and one in which the AcrB and AcrA components were fused. Both constructs were 
designed with flexible linkers which would not interfere with interactions between the 
proteins. The AcrAB-TolC pump is composed in a 3:6:3 ratio of AcrB:AcrA:TolC. An 
expression strain was used to co-produce the fusion proteins AcrA-AcrZ and AcrA-AcrB 
along with TolC enabling the isolation of the assembled pump with all components 
remaining associated after purification thus allowing the complex to be visualised 
using cryo-electron microscopy. 
 
Figure 1.4 Pseudo-atomic model of the AcrABZ-TolC efflux pump. A, reconstructed map from 
cryo-EM and crystal structures, TolC and AcrBZ are homotrimers which interact with 6 AcrA 
protomers. B, A slice through the model shows a continuous conduit from the intermembrane 
space to the outer membrane. Adapted from Du et. al. used with permission.32 
 
Many compounds which show activity in Gram positive bacteria but not in wild type 
Gram negative bacteria do show activity in Gram negative bacteria which have been 
genetically modified to lack the tolC channel. This suggests that the resistance is due in 
great part to the action of the efflux pump.26,33  




Resistance via efflux can be very hard to design around when developing new 
antibacterials. As efflux pumps act in a general fashion, it is hard to rationally design 
compounds which are able to evade efflux. We do not currently know enough about 
the way in which drug molecules are bound to efflux pumps and the structures of the 
binding sites, nor what properties of a molecule will make it susceptible to the action 
of a particular efflux pump, and so designing compounds which can resist efflux is 
generally a matter of empirical “make and test” optimisation. Several studies have 
pointed out a correlation between polarity and efflux, but the correlation is not strong 
enough to enable design of efflux resistant drugs based on physicochemical properties 
alone.34,35  
1.3.2 Resistance via target site modification  
Mutations that confer resistance often involve residues in the active site of the protein 
target of an antibacterial compound. They can provide an advantage by disfavouring 
the binding of the drug whilst still allowing the protein to carry out its normal function. 
These mutations may not provide full resistance on their own, but if the selection 
pressure caused by the presence of the antibiotic persists over extended periods of 
time then several beneficial mutations may arise in sequence eventually giving full 
resistance.12 A mutation that grants resistance may confer a fitness cost, as the 
mutated protein may be less able to carry out its normal function, however this fitness 
cost may be counteracted by a compensatory mutation if the selection pressure 
persists.36 
Selection for resistant mutants by antibiotics can be reduced by using dual-target 
antibiotics or combination therapy, as single mutations are less likely to provide a 
sufficient advantage to the bacteria for the selection pressure to act upon them. Dual-
targeting is not a perfect solution however; bacteria have been able to develop 
resistance to the fluoroquinolones, which target both DNA gyrase and topoisomerase 
IV. Mutations in the primary enzyme target (which varies between different 
fluoroquinolones and bacterial species) have often been shown to confer a small 
selective advantage and so are selected for, mutations in the secondary enzyme target 
can then be picked up, conferring total resistance to the drug.37  




1.3.3 Inactivation of antibiotic molecules 
Enzymes which are capable of altering the chemical structure of an antibiotic so that it 
is no longer able to bind to its target provide a very effective means of resistance. This 
type of resistance mechanism is most clearly demonstrated in bacteria resistant to β-
lactam antibiotics such as penicillin which produce β-lactamase enzymes. β-lactamase 
enzymes hydrolyse the key lactam ring in the antibiotics thus inactivating them. There 
are multiple classes of β-lactamases and they have spread rapidly since β-lactam 
antibiotics first started being used clinically in the 40s. These enzymes may have 
existed in some strains of bacteria for millennia as a defence against penicillin 
producing moulds. In recent years, these enzymes have spread into populations of 
pathogenic bacteria in a response to the selective evolutionary pressure caused by 
antibiotic usage.38  
This type of resistance could be evaded by co-administering a β-lactamase inhibitor 
with a β-lactam drug, thus restoring some of the activity of the β-lactam. Several 
combinations are currently in clinical use, but the β-lactamase inhibitors currently 
available are not active against all β-lactamase enzymes.39  
1.4 Methods for antibacterial drug discovery 
The first antibacterial compounds to be used clinically, Salvarsan and the sulfa drugs, 
were discovered by screening collections of small molecules to look for selective 
antibacterial activity. However, after penicillin became a commercial success in the 
40s, drug companies turned their focus instead to empirical screening of extracts from 
microorganisms. Many drug companies focussed their research efforts on culturing 
bacteria from the soil and screening it against strains of pathogenic bacteria to look for 
any cultures that appeared to kill the bacteria. The antibacterial compounds could 
then be extracted, purified and undergo further testing. This period in the 50s and 60s 
is often referred to as the “golden era” of antibacterial research and many of our 
currently used antibacterial classes originated from the natural product screens of this 
time, including the aminoglycosides, polymixins, tetracyclines, cephalosporins, 
macrolides and glycopeptides.40  




Once this initial rush of discovery was over, finding novel classes of antibiotics became 
more challenging. Extracts which showed antibacterial activity almost always 
contained antibiotics that had already been discovered rather than anything new. In 
order to save time and effort, techniques were developed to quickly identify whether 
the effects of a new culture were due to an already known antibacterial compound. 
These dereplication efforts led to a much greater understanding of the targets and 
mechanisms of action of common antibacterial compounds and companies were soon 
able to screen for effects on specific bacterial processes. These directed screens led to 
the discovery of several more antibacterial classes: monobactams, carbapenems and 
fosfomycin.40  
By the late 70s, discovery of new antibacterials had slowed dramatically and efforts 
began to shift from phenotypic screening to target focussed screening. The 
understanding of bacterial processes had increased dramatically and it was becoming 
possible to make and purify protein targets to screen compounds against. At first, 
natural products were the main chemical material being screened, but this was soon 
overtaken by the rise in popularity of screening large libraries of synthesised small 
molecules, particularly libraries generated during the combinatorial chemistry boom of 
the 90s. 
In the last 20 years scientific advances have provided us with a number of new 
technologies which can aid drug discovery efforts including genomic analysis, 
structural biology, bioinformatics, high throughput screening (HTS) and computational 
design. However, despite the application of all these techniques to antibacterial drug 
discovery, very few new antibacterial classes have been discovered since the 80s.41,42 
In parallel to the discovery of new classes of antibacterial agents, improvements to 
existing classes were being developed. These are often “semi-synthetic” in nature: 
natural products are extracted from a microbial source and then modified chemically 
to give a derivative with slightly different properties. Second generation antibacterial 
compounds have been designed not only to evade mechanisms of resistance but also 
to have improved pharmacological properties. Derivatives often have improved safety 
profiles or an increased spectrum of activity. However, they are often susceptible to 




the rapid emergence of resistance as existing mechanisms of resistance to other 
members of the class are adapted.40  
1.5 DNA topoisomerases 
DNA molecules are huge: the genetic material of even the simplest organism requires a 
DNA molecule which would be many times longer than the organism if arranged as a 
linear strand. In order for an organism’s DNA to fit inside its cells, DNA must be 
compacted. This is achieved by strict control of its topology. Topology is the study of 
the geometrical arrangement of parts of an object relative to eachother. In terms of 
DNA, topology described the ways in which a DNA double helix twists and coils around 
itself when compacted within a cell. In eukaryotic cells, DNA is compacted by 
supercoiling and wrapping of the DNA around histones to form chromatin. In 
prokaryotic cells, DNA is kept in circular rather than linear chromosomes and is highly 
supercoiled.43  Because the ends are attached to eachother in a circular chromosome 
knots and supoercoils cannot spontaneously relax without breaking one or both 
strands of the DNA bouble helix. During replication, daughter chromasomes become 
entangled forming catenanes (Figure 1.5).  
 
Figure 1.5 Circular pieces of DNA can exist in supercoiled and knotted topologies. Seperate 
circular chromosomes can become entagled in catenanes.  
 




Topoisomerase enzymes are responsible for managing the topology of DNA.44 DNA 
must be locally relaxed allow transcription and replication to occur and chromosomes 
must be separated prior to cell division.44 The type I topoisomerases relax supercoils 
by making single strand breaks so that tension can be relieved by free rotation of the 
helix around the unbroken strand. This process reduces the energy of the system and 
so is ATP independent. The type II topoisomerase increase the level of supercoiling by 
making double strand breaks and intertwining two strands before relsealing the break; 
this is an ATP dependent process. The same process is used by type II topoisomerases 
which separate catenated chromasomes following replication (Figure 1.6). 
 
Figure 1.6 General mechanisms of topoisomerase enzymes. Type I topoisomerases (red) make 
single strand breaks and allow supercoils to relax by free rotation around the intact DNA 
strand. Type II topoisomerases (blue) make a double strand break and pass another piece of 
DNA through the break before resealing it. This process can induce supercoils or decantenate 
chromasomes. 




The topoisomerases are a large class of enzymes with examples characterised from a 
wide range of species. These enzymes have been well studied in the search for drugs 
and there are several topoisomerase inhibitors on the market. Cancer drugs that target 
human topoisomerases include topotecan, a topo I inhibitor and etoposide, 
mitoxantrone and doxorubicin which are topo II inhibitors. The flouroquinolones are 
antibiotics which target the bacterial topoisomerases DNA gyrase and topoisomerase 
IV.45  
 
1.5.1 Structure of type II topoisomerases 
DNA Gyrase and topoisomerase IV are the two type II topoisomerase enzymes found in 
bacteria. DNA Gyrase is predominantly responsible for generating negative supercoils 
and Topoisomerase IV is predominantly responsible for separating entangled DNA 
strands following replication. DNA gyrase is also able to decatenate chromosomes, but 
is less efficient than topoisomerase IV.46 The two enzymes have a high degree of 
structural and sequence similarity. Both are A2B2 heterotetramers. In DNA Gyrase the 
two subunits are called GyrA and GyrB and in topoisomerase IV the two subunits are 
ParC and ParE. ATP hydrolysis occurs in the GyrB and ParE domains and DNA binding 
occurs in the GyrA and ParC domains. The segment of DNA which is cleaved and 
resealed by the enzyme is called the gate-segment (or g-segment) and the segment of 
DNA which is passed through the g-segment is called the transfer segment or t-
segment.47  
The general organisational structure of the DNA gyrase and topoisomerase IV 
holoenzyme is shown in Figure 1.7. The N-terminal domain of GyrB/ParE (purple) is 
responsible for ATP hydrolysis. The C-terminal domain of GyrB/ParE (turquoise) 
interacts with the GyrA/ParC and with the g-segment of DNA. This domain, also called 
the TOPRIM domain is conserved between several other classes of DNA-associated 
proteins including type IA topoisomerases and DnaG-type primases.48 The N-terminal 
domain of GyrA/ParC (yellow) interacts with the g-segment DNA and initiates cleavage 
of the DNA and religation of the DNA following strand passage of the t-segment. The C-




terminal domain of GyrA/ParC (green) is responsible for wrapping of the DNA around 
the enzyme and controlling passage of the t-segment.49  
 
Figure 1.7 Subunit arrangement of the DNA Gyrase and topoisomerase IV holoenzymes. Image 
comprised of ParE N-terminal domain (purple) from E. coli topo IV (1S16)50, ParE C-terminal 
domain (cyan) and ParC N-terminal domain (yellow) from S. pneumonia topo IV (3KSA)51 and 
GyrA C-terminal domain (green) from B. burgdorferi DNA Gyrase (1SUU)52. 
 
1.5.1.1 Sequence similarity between DNA Gyrase and topoisomerase IV 
DNA Gyrase and topoisomerase IV have a high degree of sequence similarity 
particularly in the ATP and DNA binding regions, meaning that they are possible to 
target simultaneously. The sequence similarity with human topoisomerase II is only 
12%, which is sufficiently different for the design of compounds selective for DNA 
gyrase and topo IV over human topo II.50 An alignment of the GyrB and ParE sequences 




from E. coli is shown in Figure 1.8. The ATP binding region is highly conserved as can be 
seen from the overlay of the crystal structures of the ATP binding site of GyrB and ParE 
from E. coli shown in Figure 1.9. An alignment of the GyrA and ParC sequences from E. 
coli is shown in Figure 1.10. The sequence is highly conserved in the N-terminal domain 
(NTD) which is responsible for binding DNA and is much less conserved in the C-
terminal domain (CTD) which is responsible for wrapping DNA. 
 
Figure 1.8 Alignment of the GyrB and ParE protein sequences from E. coli (UniProt codes 
P0AES6 and P20083 respectively). Conserved residues are shown in blue. 
 





Figure 1.9 Overlap of the ATP binding regions of GyrB in green (1EI153) and ParE in turquoise 
(1S1650) from E. coli showing residues within 6 Å of the bound ADPNP (a non-hydrolysable 
analogue of ATP). 
 
 
Figure 1.10 Alignment of the GyrA and ParC protein sequences from E. coli (UniProt codes 
P0AES4 and P0AFI2 respectively). Conserved residues are shown in blue. 
 




There is a significant difference in sequence between the C-terminal domains (CTD) of 
ParC and GyrA. This reflects the different roles of the enzymes. In DNA gyrase the C-
terminal domain of GyrA is responsible for wrapping the DNA from the g-segment 
around the enzyme in order to present the t-segment to GyrB. The conformation of 
the CTD domain changes upon binding of the g-segment and 120-140bp of DNA is 
wrapped by the enzyme.54 In topoisomerase IV the t-segment is from a different strand 
of DNA to the g-segment, so DNA does not need to be wrapped around the enzyme to 
present the t-segment.55 The CTD of ParC is able to wrap DNA, but not as effectively as 
GyrA, this partial binding may facilitate orientation of two separate DNA strands to 
allow decatenation. The CTD of DNA gyrase adopts a β-pinwheel conformation, 
whereas topoisomerase IVs CTD adopts a conformation that has been described as a 
broken β-propeller (Figure 1.11).52,56  
 
Figure 1.11 C-terminal domains of DNA gyrase (1SUU)52 and topoisomerase IV (1WP5)56. A. 
front view of GyrA C-terminal domain showing β-pinwheel fold structure. B. front view of ParE 
C-terminal domain showing broken β-propeller structure. C. Side view of GyrA CTD. D. Side 
view of ParE CTD. 




1.5.2 Mechanism of type II topoisomerases 
The key steps in the mechanism of the type II topoisomerases are shown in Figure 
1.12. First, the g-segment of DNA is clamped within a saddle-like groove between the 
GyrB/ParE subunits and the GyrA/ParC subunits. The t-segment of DNA then enters the 
gap between the GyrB/ParE subunits (Figure 1.12, conformation A). The presence of 
the t-segment of DNA and the binding of a molecule of ATP to each of the two 
GyrB/ParE units induces a conformational change, which closes the GyrB/ParE clamp 
thus trapping the t-segment (Figure 1.12, conformation B).53 A further conformational 
change induces cleavage of the g-segment and pulls the cleaved ends apart to create a 
gap through which the t-segment passes (Figure 1.12, conformation C). The GyrA/ParC 
N-terminal gate then opens to allow release of the t-segment (Figure 1.12, 
conformation D) and the enzyme then resets to its initial conformation.47  
 
 
Figure 1.12 Conformational changes in type II topoisomerases. A) the GyrB/ParE domains are 
in an open clamp position and the t-segment has entered between the GyrB/ParE domains. B) 
The GyrB/ParE clamp has closed around the t-segment. C) A double strand break has been 
made in the g-segment and a conformational change has pulled the cleaved ends of the DNA 
apart and moved the t-segment through the gap. D) The g-segment has been religated and the 
GyrA/ParC clamp has opened to allow the t-segment to leave. In the case of DNA gyrase, the g- 
and t-segments are part of the same DNA moleculewith 120-140 base pairs separating them. 
In the case of topoisomerase IV, the g- and t-segments are from separate chromasomes. 
 




The following sections will give a more detailed account of the molecular processes 
involved in the each of the steps involved in the mechanism of these enzymes. 
1.5.2.1 Conformational changes in GyrB/ ParE 
Figure 1.13 shows S. pneumoniae topoisomerase IV with the ParE N-terminal domains 
in the open clamp position. The ATP binding domain (in the N-terminal portion of ParE, 
purple) and the DNA binding domain of ParE (in the C-terminal portion of the protein, 
cyan) are connected by a flexible hinge which allows the protein to undergo a 
significant conformational change upon binding of the t-segment of DNA and two 
molecules of ATP. 
 
Figure 1.13 Crystal structure of S. pneumoniae topoisomerase IV with the ParE clamp in the 
open position (4I3H)49. ParE N-terminal domain in purple, ParE C-terminal domain in cyan, ParC 
N-terminal domain  in yellow and g-segment DNA in red. The ParC C-terminal domain is 
omitted. 
 
In the crystal structure of topoisomerase IV in the open clamp configuration, several 
loops near the ATP binding pocket are disordered (Figure 1.14, A). This indicates a high 
degree of conformational flexibility in these chains in the absence of ATP. An α-helix at 
the entrance to the ATP binding domain moves significantly upon dimerization of the 




subunits and the N-terminal tail from the opposing subunit takes its place (Figure 
1.12). 
 
Figure 1.14 Conformational changes in the ParE ATP binding domain upon binding of ATP. A) 
ParE N-terminal domain in open clamp conformation (4I3H). B) GyrB dimer with ADPNP (a non-
hydrolysable analogue of ATP) bound. Several loops have adopted different conformations. 
 
Dimerisation of the N-terminal domains of GyrB/ ParE is favoured in the presence of 
ATP by hydrogen bonds which can form between a tyrosine residue near the N-
terminus of one monomer and an ATP molecule bound in the ATPase pocket of the 
other monomer (Figure 1.15). This creates a very tight binding pocket for ATP and 
prevents diffusion of other small molecules into or out of the binding pocket. The 
triphosphate chain binds in a highly polar channel within the ATP binding site forming 
a large number of hydrogen bonds to residues and water molecules. A magnesium ion 
coordinates to oxygen atoms in the phosphate chain aiding the attack of a water 
molecule to the γ-phosphate and thus generating ADP and Pi.53  





Figure 1.15 A. GyrB dimer from E. coli (4WUD)57 ADPNP is present in the active site. B. The key 
residues involved in binding to ATP including coordination of a Magnesium ion (green) by the 
phosphate oxygens of ADPNP. 
 
Recent crystallographic studies by Stanger et al have suggested that hydrolysis of ATP 
to ADP and Pi induces a conformational change in GyrB/ ParE, widening the gap 
between monomers close to the DNA binding domain (Figure 1.16). This 
conformational change is likely to be coupled to the opening of the gate-segment and 
passage of the transfer-segment. In the open configuration (Figure 1.16, B) the 
phosphate channel appears less open suggesting that the phosphate ion is unable to 
leave the ATP binding site in this conformation and that the conformation must reset 
before the phosphate can leave through the phosphate channel. The GyrB/ParE 
monomers would then separate to allow a new t-segment to bind.58  
 






Figure 1.16 Hydrolysis of ATP causes a conformational change in GyrB. A. Non-hydrolysable 
ATP mimic ADPNP bound in the active site of E. coli GyrB (4WUD)57. B. ADP and Pi bound in the 
active site of GyrB (4PRX)58. 
 
1.5.2.2 Mechanism of DNA cleavage  
The gate segment of DNA is bound across the interface between GyrB/ParE and 
GyrA/ParC in a U-shape. A tyrosine residue from each GyrA/ParC monomer (Tyr-117 in 
E. coli ParE and Tyr-122 in E. coli GyrB) attacks the phosphate oxygen bond in the DNA 
backbone and forms a covalent bond to the phosphate at the 5’ end of the cleaved 
DNA strand (Scheme 1.1).  
 
Scheme 1.1 Mechanism of strand cleavage and re-ligation, a phosphodiester bond forms 
between the DNA and a tyrosine residue in the active site leaving the 3’ hydroxyl end of the 
DNA free. 
 
The breaks in the DNA strands are staggered by four base pairs. A magnesium ion 
coordinated by the three residues in the TOPRIM domain of ParE/GyrB aids in the 




reaction by stabilising the –OH 3’ leaving group and the tyrosyl phosphate group 
(Figure 1.17).51 
 
Figure 1.17 Cleavage of DNA by type II topoisomerases. A. S. pneumonia topoisomerase IV 
crystal structure (3KSA)51, showing the binding of DNA (orange) to the C-terminal TOPRIM 
domain of ParE (turquoise) and the N-terminal domain of ParC (yellow). B. Close up of the 
cleaved DNA strand showing the residues involved in DNA cleavage and re-ligation. C. The key 
hydrogen bonding interactions involved in DNA cleavage and re-ligation. 
 
The mechanisms by which the GyrA/ ParC terminal gate opens to allow the t-segment 
to leave are less well understood and no crystal structures have been solved with this 
gate in the open configuration. 
1.6 Type II topoisomerases as antibacterial drug targets 
1.6.1 Inhibition of the DNA binding site – the quinolones 
In 1962, Sterling Drug Inc. reported nalidixic acid 1 as an antibacterial compound 
derived from an impurity generated in the synthesis of chloroquin. This compound was 
the first of the quinolone antibiotics59. Nalidixic acid is still in use today, but has a fairly 
narrow spectrum of activity, it is active against E. coli and many Gram negative species, 
but shows little activity against the majority of Gram positive species.60 In the following 
years several related compounds were developed, all with broadly similar activities, 




but these first generation quinolones were mostly superseded in the late 70s by the 
discovery that introducing a fluorine atom to the central ring and adding a basic amine 
containing heterocycle greatly improved the antimicrobial potency and spectrum of 
activity of these compounds. Norfloxacin 2 was the first of these second generation 
quinolones.61 Over the years, successive generations of these fluoroquinolones have 
been developed with improved pharmacokinetics, safety, potency and spectrum of 
activity over previous generations. More recently developed compounds, including 
levofloxacin 3 and moxifloxacin 4, are active against some Gram positive bacteria as 
well as Gram negative bacteria.62  
 
New compound series which target the DNA binding region are in development. Both 
GSK and Entasis have DNA gyrase inhibitors in clinical trials for the treatment of 
gonorrhoea. Entasis’s ETX0914 563 (formerly AstraZeneca’s AZD0914)64 is in phase 1 
clinical trials and GSK’s Gepotidacin (GSK2140944) 6 is in phase 2 clinical trials65. 
 
1.6.2 Inhibition of the ATP binding site – a brief history 
1.6.2.1 Coumarins and cyclothialidines: natural product based inhibitors 
During the Golden era of antibiotic drug discovery, most major pharmaceutical 
companies were working on antibacterial drug discovery and between 1955 and 1956 
Upjohn, Pfizer, Lepetit and Merck all discovered the same antibacterial natural 




product: Novobiocin 7. Novobiocin was marketed by Upjohn in the 60s as Albamycin 
for treatment of penicillin resistant S. aureus. Novobiocin was active against Gram 
positive bacteria and a few species of Gram negative bacteria and could be 
administered orally or in solution for IV dosing. However, resistance emerged quickly 
and side-effects including rash were seen fairly frequently. As second generation 
penicillins, such as methicillin, and the first cephalosporins became available during 
the late 60s, novobiocin fell out of favour. At this time, several drug companies were 
investigating structurally similar antibiotics. In 1965, both Roche and Bristol-Myers 
reported coumermycin 8 and in 1969 Rhone-Poulenc reported chlorobiocin 9. 
Following disappointing clinical results, all three companies abandoned their efforts at 
developing novobiocin like antibiotics during the 70s.  
  
Just as investigation of this class of agents as antibiotics was being abandoned, 
research into the target of these drugs started taking off. In 1976 the DNA gyrase 
enzyme from E coli was first identified and its inhibition by novobiocin and the other 
coumarin drugs was reported.66,67 The following year it was discovered that nalidixic 
acid also inhibited its activity.68,69 It was quickly understood that the enzyme was 
comprised of two subunits, one of which was inhibited by the coumarins and the other 
of which was inhibited by the quinolones, and that it was able to supercoil DNA in an 
ATP dependent manner via a strand passage mechanism.66,70 Research into improved 
quinolone antibacterials was still being carried out at this time and results of assays 
against DNA gyrase began being reported along with MICs against various bacterial 




species in reports on the activities of the newly discovered second generation 
quinolones.71  
In the early 90s, Roche reported the discovery of cyclothialidine 10 from a screen of 
20,000 culture broths using a DNA gyrase based supercoiling assay. This was the first 
example of a non-coumarin inhibitor of the ATPase site of DNA gyrase. Cyclothialidine 
displayed only weak antimicrobial activity despite being a more potent inhibitor of 
DNA gyrase than novobiocin.72,73 Medicinal chemistry efforts to improve the 
antimicrobial activity of this class of inhibitors continued for several years with both 
Roche and Bayer pursuing analogues of the initial natural product.74,75 Roche has 
continued to work on this series through the 2000s and in 2011 reported on 
derivatives, such as 11, with good MICs and improved physicochemical properties, 
many of which showed promise in an animal model of infection.76  
  
1.6.2.2 Dual-targeting, crystallography and the rise of non-natural product 
inhibitors 
Topoisomerase IV was first identified in 1990 following sequencing of parts of the E. 
coli  genome77 and its role in the decatenation of bacterial chromosomes was soon 
fully elucidated78-80. The inhibitory effects of known quinolone drugs on topoisomerase 
IV were soon investigated and compared to their activities against DNA gyrase81,82. 
Over the following years it became apparent that the extent of inhibition of each 
enzyme by quinolone antibiotics varied between bacterial species. In Gram negative 
species, DNA gyrase tended to be the main target and in Gram positive species 
topoisomerase was usually the primary target.83 Studies of fluoroquinolone resistant 
bacterial strains suggested that a mutation in the primary target for that species 
conferred a significant increase in resistance with an additional mutation in the 




secondary target conferring complete resistance. It was suggested that compounds 
which were equally potent inhibitors of both proteins might prove to be harder to 
develop resistance to, as simultaneous mutations in both enzymes would be needed to 
confer enough resistance to encourage a selective pressure.37  
It was also at around this time that the first crystal structure of the ATPase domain of 
DNA gyrase was published. In 1991, a 43 kDa fragment of the N-terminal portion of 
GyrB was crystallised in the presence of ADPNP and showed the arrangements of the 
two subunits in a dimer.84 Crystal structures of a 24 kDa fragment of GyrB bound to 
novobiocin, GR1222X (a cyclothialidine analogue discovered independently by Glaxo) 
and chlorobiocin, were all published a few years later.85,86 Crystal structures of the 
43 kDa subunit have been used to gain insight into the ATP hydrolysis mechanism53, 
whereas the 24 kDa subunit has much more frequently been used to assess binding of 
inhibitors to the ATP binding site, as the binding site is more accessible in this subunit.  
Figure 1.18 shows the differences between the 43 kDa subunit and the 24 kDa subunit. 
Panel A shows an overlay of the 24 kDa crystal structure with one protein molecule 
from the 43 kDa subunit and panels B and C show the subunits separately. As can be 
seen from panel C, in the 43 kDa crystal structure the N-terminal arm of the other 
protein molecule in the dimer closes around the ATP binding site.  
The crystal structure of the GyrB 24 kDa subunit used to produce Figure 1.18 (3G7E)87 
is the only crystal structure of the 24 kDa subunit of GyrB or ParE, out of 52 which had 
been deposited in the PDB as of the 10th April 2016, in which all the loops surrounding 
the ATP binding site are fully resolved. Usually a loop adjacent to the ATP binding site 
is either unresolved or has been removed by mutagenesis. Loop deleted mutants of E. 
coli ParE50 and S. aureus GyrB88 have been reported and the S. aureus GyrB mutant has 
been frequently employed in the place of the native S. aureus GyrB unit which does 
not crystallise as readily89-91. 
 





Figure 1.18 Comparison of 24 kDa and 43 kDa subunits of GyrB. A) Overlay of a crystal 
structure of the 24kDa subunit (3G7E92, cyan) and one monomer from a crystal structure of the 
43 kDa subunit (4WUD57, green) of DNA gyrase. B) An inhibitor (pink) bound in the ATP binding 
site of the 24 kDa subunit. C) ADPNP (yellow) bound in the ATP binding site of the 43 kDa 
subunit with dimer partner in red. 
 
The crystal structures revealed the presence of a few key residues within the ATP 
binding site which are now known to form interactions with most published inhibitors. 
There is a conserved water molecule in the active site which forms a hydrogen bond 
network between an aspartate residue in the active site (Asp-73 in E. coli GyrB, Figure 
10; Asp-78 in S. pneumoniae ParE) and the amine and a nitrogen atom from the 
adenosine ring of ATP. These interactions were described earlier (Figure 1.15). All 
inhibitors of the ATP binding site of DNA gyrase and topoisomerase IV which have 
been reported in the literature possess a similar hydrogen bond donor/ acceptor motif 
which is able to mimic the interaction between ATP and the conserved water molecule 
and the Asp residue (Figure 1.19). This hydrogen bonding network is so important for 
binding ATP that no resistant mutants have been found in which this Asp residue has 
been modified.93  




Another common feature in many published inhibitors is an aromatic ring positioned 
so as to form a π-stacking interaction to an arginine residue adjacent to the active site. 
This arginine residue forms a π-stacking interaction with the N-terminal tyrosine 
residue of the other protein unit in the ATP bound conformation of the protein (Figure 
1.15). Many topoisomerase inhibitors also exhibit a group able to form a hydrogen 
bond to Arg-140. A crystal structure published recently by AstraZeneca showing one of 
their pyridylurea inhibitors 12 is shown in Figure 1.19 indicating these key interactions. 
   
Figure 1.19 Interactions between a pyridylurea inhibitor 12 and some key residues in the 
binding site of S. pneumoniae ParE. (a) schematic showing important interactions and (b) 
crystal structure showing key interactions between the inhibitor and residues within the 
binding pocket (4LPB).94  
 
The combination of new structural information and the presumed advantages of dual-
target inhibitors combined to generate a surge in interest in the development of 
ATPase inhibitors in the mid-90s which has continued to the present day. 52 crystal 
structures of the GyrB or ParE subunit with a small molecule inhibitor bound in the ATP 
binding site were available in the PDB as of the 10th of April 2016 (35 of GyrB and 17 of 
ParE). Crystal structures have been solved of the 24 kDa subunit of GyrB and ParE from 
a number of bacterial species: GyrB and ParE from E. coli, S. aureus and E. faecalis; 
GyrB from M. smegmatis, and ParE from S. pneumoniae and F. tularensis. A wide 
variety of inhibitor structures have been investigated in the last 25 years. A brief 
summary of some of the key scaffolds is given below. For a more comprehensive 
review of ATPase inhibitors see Bisacchi and Manchester 2015.93  
 
 




Triazines and pyrimidines 
Zeneca was the first pharmaceutical company to report a medicinal chemistry project 
investigating GyrB/ParE inhibitors which weren’t based on natural products. Their 
triazine series was developed from a hit from a high throughput screen of the Zeneca 
corporate compound collection against DNA gyrase. These compounds, including 13, 
displayed moderate enzyme inhibition and MICs and were not pursued further.95 
AstraZeneca later reported a series of somewhat similar amino aryl pyrimidines 
identified by HTS and optimised to give 14 which had good enzyme activity and 
antibacterial potency. Both the Zeneca triazines and the AstraZeneca pyrimidines 
suffered from poor physicochemical properties.96 
 
Indazoles and pyrazoles 
Several companies have reported inhibitors containing an indazole or pyrazole motif. 
The first of these emerged from a “needle” screening effort by Roche which afforded 
15 as their lead from that series.97 At about the same time, Dainippon struck upon a 
pyrazole hit in a screening campaign and investigated a range of pyrazole derivatives 
combining features from their hit and Roche’s to give 16.98 In the following years, 
Vertex, Quorex and Cubist also investigated similar pyrazole 17, indazole 18 and 
pyrazolopyridone 19 inhibitors respectively.87,90,99,100 Last year Cubist reported a series 
of indazole inhibitors 2091. 





Pyrrolamides and imidazolamides 
A pyrrolamide series developed by AstraZeneca is one of the only series of ATPase 
inhibitors to have produced compounds which progressed as far as phase I clinical 
trials. Beginning with a pyrrolamide fragment from an NMR-based fragment screen, 
AstraZeneca developed two candidate molecules that went into phase I trials. 
AZD1279 21 was the first into the clinic, but was not taken forward due to high 
clearance.101 A later derivative AZD5099 22 was also taken into phase I, but was 
similarly unsuccessful.102 Daiichi Sankyo have patented imidazole variants of this series 
23103 and a group at the University of Ljubljana have also reported a series of 
pyrrolamides 24104-106. 
 





Ethyl urea based inhibitors have been very fashionable in the last 15 years. The first 
report of an aromatic ethyl urea series came from Vertex. Compound 25 is an example 
of their second generation of benzimidazole inhibitors. They have continued to 
develop this series through several generations with several candidate inhibitors 
almost making it into the clinic.89,107-109 Scaffold hops to closely related benzothiazoles 
26, imidazopyridines 27, and triazolopyridines 28 have been reported by Prolysis (and 
developed further by Biota),110-112 Pfizer113 and Evotec respectively.114 Different ring 
structures have also been investigated with isoquinolones 29 reported by Actelion115, 
pyridines 12 reported by AstraZeneca94 and azaindoles reported by Cubist 30116. 
 
Ethyl urea mimics 
A few recent disclosures at conferences have featured compounds with a similar 
arrangement of hydrogen bond acceptor and donors as seen in the ethyl-urea 




compounds. These include a series of amidoazaindoles 31 reported by AstraZeneca117 
and a quinazolinone series 32 reported by Cubist.93,100 
 
Pyrrolopyrimidines and tricyclic variants 
Trius has reported two series of inhibitors, pyrrolopyrimidines 33 and tricyclic 
pyrrolopyrimidine derivatives 34. These compounds evolved from a hit from a 
crystallographic fragment screen and have been developed into highly potent dual-
targeted inhibitors with potent MICs against a wide range of both Gram negative and 
Gram positive bacteria.92,118,119  
 
Coumarins and other natural products 
There has also been a resurgence of interest in natural product antibiotics. A natural 
product with a similar structure to the coumarin antibiotics such as Novobiocin was 
discovered separately by two research groups and named amycolamicin120 and 
kibdelomycin121 35. Neither group have developed the compound beyond elucidating 
its structure and target of action. Another recently discovered natural product 
inhibitor of DNA gyrase is closthioamide 36, which was isolated from the anaerobic 




bacteria Clostridium cellulolyticum and identified as acting by inhibition of DNA gyrase 
via the GyrB subunit.122 
 
1.6.3 Summary 
Despite the wide ranging efforts by many drug companies to discover useful 
antibacterial drugs that target the ATPase sites of GyrB and ParE, no inhibitors have yet 
progressed beyond phase I clinical trials. Reasons given for discontinuing research into 
these compound series have been varied and include poor solubility, high plasma 
protein binding, rapid in vitro clearance, formation of reactive metabolites and hERG 
liability. From this wide range of reported reasons for projects being suspended, it 
would seem that inhibitors of the ATPase site aren’t failing due to a common problem 
which might indicate an underlying difficulty with inhibiting this target. It should be 
possible to discover an inhibitor of DNA gyrase and topoisomerase IV that doesn’t 
succumb to the same difficulties as previous inhibitors and can be successful in the 
clinic.
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1.7 Project aims and objectives 
The project was broadly divided into two parts. In the first, efforts were made to 
further explore a series of pyridine 3-carboxamide inhibitors previously developed at 
the University of Leeds. The second part of the project focused on the identification of 
inhibitor series with novel structures. 
 
1.7.1 To develop a series of pyridine-3 carboxamides 
A series of pyridine-3-carboxamides was previously developed at Leeds.123,124 These 
compounds showed potential as inhibitors of DNA gyrase, but their topoisomerase IV 
activity was never assayed. Further development of this series was undertaken as 
follows: 
 Synthesis of additional members of the series 
 Assessment of activity against both DNA gyrase and topoisomerase IV 
 Assessment of the in vitro ADME profile of representative inhibitors 
 Co-crystallisation of inhibitors in the GyrB protein 
 
1.7.2 The discovery of novel inhibitor series’ 
Several approaches were used to discover novel inhibitor series: 
 De novo design using SPROUT 
 vHTS using Glide and ROCS 
 Scaffold hopping to rationally design novel inhibitor structures 
 Synthesis of designed compounds was carried out 
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Chapter 2 Investigation into pyridine-3-carboxamide inhibitors 
2.1 Background to pyridine-3-carboxamide inhibitors 
As discussed earlier (Chapter 1), a common motif seen in ATPase inhibitors of DNA 
gyrase and topoisomerase IV is a heteroaromatic ring with an ethyl urea substituent 
adjacent to a nitrogen atom in the ring with two other substituents branching from the 
ring. These common structural features are shown in Figure 2.1. Previous work at the 
University of Leeds identified a promising compound class which shares these 
structural features.123,124  
 
Figure 2.1 Inhibitors containing an ethyl urea motif have been published by Vertex107, 
Prolysis111, Pfizer113, AstraZeneca94, Actelion115 and Evotec114. These inhibitors all have 
a number of structural features in common including a heteroaromatic ring system 
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with a ring nitrogen adjacent to the urea substituent and two other substituents on the 
ring. 
 
Computational design using SPROUT125 identified a series of compounds of the form 37 
based upon a pyridine ring as the central heteroaromatic group with a carboxamide 
linkage to an additional aromatic group at the 3-position of the central pyridine ring 
and with further substitution branching from the 4-position (Figure 2.2). 
 
Figure 2.2 A series of pyridine-3-carboxamides with features in common to known inhibitors 
was designed using SPROUT. 
 
Although initial investigation of the SAR around these compounds was performed, the 
full scope of substituents at the 4- position was not fully ascertained. Therefore, it was 
decided to further explore the effects of altering the substituent in the 4- position of 
the pyridine core. In the previous study, compounds were not assessed for their 
inhibition of the topoisomerase IV enzyme, and no in vitro ADME profiling was carried 
out, so it was decided to carry out assays against topoisomerase IV and in vitro ADME 
profiling for selected compounds. 
2.2 Choice of avenues of investigation 
As was mentioned in Chapter 1, a 24 kDa subunit of the GyrB or ParE protein has 
usually been used to obtain crystal structures of inhibitors bound in the ATP binding 
site. A short loop of the protein adjacent to the ATP binding site is almost always 
disordered in the crystal structures with the exception of one crystal structure, 3G7E 
(Figure 2.3, C). Mutagenesis has been used to generate a 24 kDa construct of GyrB with 
this flexible loop deleted as they crystallise more readily. Figure 2.3 shows three crystal 
structures: one with the full flexible loop resolved (A), one with part of the loop 
resolved and part of the loop disordered (B) and one with the flexible loop removed 
using mutagenesis (C). This flexible loop poses a challenge to the rational design of 
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inhibitors which bind to this site, as docking experiments will not be able to accurately 
predict interactions between a designed inhibitor and the highly flexible loop. 
Interactions between the inhibitor and protein residues in the rest of the protein 
structure can be more reliably predicted using docking experiments. 
 
Figure 2.3 Comparison of flexible loop positions in different crystal structures. A) 24 kDa 
subunit of E. coli GyrB with all loops surrounding the ATP binding site are fully resolved 
(3G7E)87. B) 24 kDa subunit of E. coli with a disordered loop unresolved (4DUH)106. C) 24 kDa 
subunit of S. aureus GyrB with flexible loop deleted using mutagenesis (3G7B)87. The red circles 
indicate the region of the binding site in which interactions between an inhibitor and the 
protein cannot be accurately predicted using docking. 
 
The most potent DNA gyrase inhibitor synthesised as part of the previous work at 
Leeds was the bis-pyridyl compound 38. It was noted that inhibitors such as compound 
38 (Figure 2.4), which possess an amino aryl substituent at the C4- position of the 
pyridine ring, tended to be more potent DNA gyrase inhibitors than compounds with a 
directly-linked heterocycle at this position, such as compound 39.  
 
Figure 2.4 Biological activities of two previously synthesised pyridylurea inhibitors. The variant 
with an aminopyridine substituent in the C4 position 41 has better biological activity than the 
variant without the amine linker to the pyridine substituent at the C4 position 42. 
 
Compounds 38 and 39 were docked into the GyrB binding site from E. coli (4HYP), with 
38 scoring -8.6 and 39 scoring -8.4. The poses generated by AutoDock126 are shown in 
Figure 2.5. The difference in the structures of compounds 38 and 39 is the substituent 
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at the C-4 position of the central pyridine ring which is positioned in the region of the 
crystal structure in which the protein is disordered. This makes it hard to rationalise 
the greater inhibitory activity of compound 38 compared to compound 39. Docking 
predicts that both compounds are able to form hydrogen bonds to Asp-73, Arg-140 
and the conserved water molecule in the binding site which is consistent with crystal 
structures of other known inhibitors which have been reported in the literature. 
 
Figure 2.5 Predicted binding poses of compound 38 (A) and compound 39 (B) to E. coli GyrB 
(4HYP) generated using AutoDock. 
 
Another pair of inhibitors exhibited activities which contrasted in an interesting way. 
The pyrazole-containing compound 40 had greater antibacterial activity against S. 
aureus than the imidazole-containing compound 41, despite compound 40 exhibiting 
greater inhibitory activity against the DNA gyrase enzyme (GyrB) (Figure 2.6).  
 
Figure 2.6 Two inhibitors which are geometrical isomers, but have different biological 
activities. 
 
Computational docking of these compounds into E. coli GyrB was carried out using 
AutoDock in an attempt to rationalise the IC50s measured in the enzyme assay, but 
both compounds had very similar docking scores (compound 40 scored -8.1 and 
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compound 41 scored -7.9) and were predicted to bind in very similar poses, with the 
only difference being the orientation of the chloro-substituted phenol ring (Figure 2.7). 
The imidazole and pyrazole rings are positioned in the part of the binding site which is 
adjacent to the flexible loop which is disordered in the crystal structures. 
Computational docking cannot predict interactions between the imidazole or pyrazole 
ring and the residues in this flexible loop. 
 
Figure 2.7 Predicted binding poses of compound 40 (A) and compound 41 (B) to E. coli GyrB 
(4HYP) generated using AutoDock. 
 
The differences in these compounds’ inhibitory activity against the DNA gyrase enzyme 
is most likely due to differences in the ways the imidazole and pyrazole rings interact 
with the flexible loop near the binding site. The differences in these compounds 
antibacterial activity could be attributable to a number of different factors: differences 
in the ability of these compounds to cross the bacterial membrane; differences in their 
activities against the topoisomerase IV enzyme compared to the DNA gyrase enzyme; 
different levels of activity against the DNA gyrase enzyme of S. aureus compared to the 
DNA gyrase enzyme from E. coli or an unknown off-target effect. Compounds 40 and 
41 have different lipophilicities (compound 40 has a clogP of 2.62, whereas 41 has a 
clogP of 1.86) and this may influence their ability to cross bacterial membranes, but as 
these effects are difficult to predict, the best way to understand this difference is to 
make more compounds with similar substitution patterns and test them for their 
activities. 
Based on the observations described above, it was decided to focus synthetic efforts 
on producing inhibitors of the form 42 in which the substituent in the C-4 position was 
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varied and the rest of the molecule kept the same as the most potent inhibitor from 
the series, compound 38 (Figure 2.8). It was assumed that inhibitors with this general 
structure would maintain the same hydrogen bond contacts to the enzyme as were 
predicted for compound 38. The effect of varying the substituent at the C-4 position 
was difficult to predict computationally, so the only way to determine whether 
improvements in activity could be achieved by altering this substituent was by making 
and testing compounds with different substituents at the position. It was decided to 
synthesise two groups of inhibitors. One in which the R group was an amino aryl 
substituent, as these had been shown to have the most potent enzyme activities in the 
previous work. This work will be discussed in Section 2.3. In the second group of 
inhibitors, R would be a 5-membered heterocycle, as it was hoped synthesising more 
variants of this type would shed more light on the properties needed for antibacterial 
activity. This work will be discussed in Section 2.5. 
 
Figure 2.8 General structure of the inhibitors investigated during this project. 
 
It was also decided to produce some derivatives which featured aliphatic substituents 
in the C4 position. They will be discussed in Section 2.6. 
Initial assessment of the in vitro ADME properties for compounds in the pyridine 4-
carboxamide series will be discussed in Section 2.7. 
2.3 C-4 aminoaryl derivatives of the pyridine 3-carboxamide series 
A six step synthesis of pyridine-3-carboxamides from acetone dicarboxylate 43 had 
been developed at the University of Leeds.123 This route was used without 
modification to synthesise the first pyridine-3-carboxamides in this project.  
First, an ester of 4,6-dihydroxynicotinate 45 was formed in two steps from diethyl-1,3-
acetone dicarboxylate 43, trimethyl orthoformate and ammonia. This was followed by 
Chapter 2  Pyridine-3-carboxamide inhibitors 
  44  
 
chlorination using POCl3 to give compound 45 (Scheme 2.1). The first step proceeded 
with a yield of 86% and the second step with a yield of 55%.  
 
Scheme 2.1 Formation of ethyl- 4,6-dichloronicotinate 45.  
 
Selective substitution of a chlorine for a urea at the 2-position via a Buchwald-Hartwig 
amination reaction had been reported in the literature.127 This reaction was carried out 
according to the literature conditions. However, at 100 °C the reaction was not 
selective for the C2 position and a mixture of starting material and mono- and di-
substituted material was formed. The selectivity of the reaction was improved by 
reducing the temperature of the reaction to 80 °C (Scheme 2.2) affording the ethylurea 
substituted compound 46. 
 
Scheme 2.2 Selective Buchwald reaction to insert ethyl-urea at the 6-position of ethyl 4,6-
dichloronicotinate 47. 
 
The next step according to the previously established synthetic route was installation 
of an aniline at the C4 position of the pyridine ring via an SNAr reaction. 4-
Hydroxyaniline underwent SNAr reaction in moderate yield to give 47. This was 
followed by hydrolysis which proceeded in good yield to give the carboxylic acid 48 
which was coupled to 3-amino pyridine 49 using amide coupling reagents EDC and 
HOBt to give the final product 50 (Scheme 2.3). 
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Scheme 2.3 Formation of compound 50. 
 
The most potent DNA gyrase inhibitor synthesised as part of the previous work at 
Leeds was the bis-pyridyl compound 38 (Figure 2.4).56 Therefore, 4-aminopyridine, 2-
aminopyridine and 2-aminopyrimidine variants were chosen as the next derivatives to 
make in order to determine whether changing the position of the ring nitrogen would 
improve the biological activity of the inhibitors. 
However, the amino pyridines and amino pyrimidine chosen proved to be unreactive 
under the previously described SNAr conditions (Scheme 2.3). The electron deficient 
nature of the pyridine and pyrimidine rings reduces the nucleophilicity of the amine so 
that it is unable to attack the Ar-Cl bond of 46 under these conditions. The reaction 
was then attempted using DMF in place of ethanol, as it is a good solvent for reactions 
such as nucleophilic aromatic substitutions that follow polar mechanisms. However, no 
reaction was seen under these conditions (Scheme 2.4). 
 
Scheme 2.4 Conditions of attempted SNAr reactions of amino pyridine and aminopyrimidines. 
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More activated anilines were investigated, and the SNAr reaction was successful with 
2-hydroxy-, 3-hydroxy- and 3,4-dimethoxyaniline to afford 51, 52 and 53 respectively. 
However the reactions were performed on a small scale and following the hydrolysis 
and amide coupling steps, insufficient material was isolated to allow full 
characterisation or biological evaluation of the isolated compounds ( 
Scheme 2.5) However, formation of the desired products 55, 56 and 57 was indicated 
by LC-MS and NMR of the crude reaction mixture.  
 
Scheme 2.5 SNAr, hydrolysis and attempted amide formation using hydroxy- and dimethoxy- 
substituted anilines. 
 
The major impurity seen in the amide coupling step was the HOBt adduct of the 
starting material, suggesting that displacement of the HOBt by the aniline was slow. An 
alternative coupling reagent was sought. Propane phosphonic acid anhydride (T3P) has 
been shown to be an effective and convenient amide coupling reagent.61 The reaction 
of 3-aminopyridine 49 with nicotinic acid 58 to give compound 59 was chosen as a 
model system to investigate whether switching to T3P as an amide coupling reagent 
had the potential to give improved yields. When using HOBt and EDC as the amide 
coupling reagents, a yield of 12% was obtained. The HOBt adduct 60 was detected as a 
major impurity by NMR of the crude reaction mixture, but was not isolated. Using T3P 
as the coupling reagent resulted in a significantly higher yield of product which did not 
require purification using chromatography (Scheme 2.6). 
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Scheme 2.6 Investigation of T3P as an alternative coupling reagent to HOBt and EDC. 
 
The T3P coupling conditions were then tested using the 2-hydroxyaniline compound 
55, but instead of the expected amide product 61 a lactonisation reaction occurred to 
give compound 62, which contained a 7-membered ring lactone, in 56% yield (Scheme 
2.7). Although somewhat unexpected, this compound was submitted for biological 
testing, as it represented an interesting variation of the existing core. 
 
Scheme 2.7 Attempted amide coupling of compound 55 and 3-aminopyridine 49 using T3P. 
 
Re-ordering of the steps in the synthetic route was attempted as a way to improve the 
efficiency of the synthesis by moving the diversification step to the end of the 
synthetic route. Hydrolysis of the ester 45 gave the acid 63. 3,4-dimethoxyaniline 64 
was used as the amine in the coupling step for the first attempt at using the new 
amide coupling conditions in the re-ordered route, as this aniline is more electron rich 
than 3-aminopyridine and so was expected to react more readily with the activated 
intermediate derived from compound 63. The reaction successfully afforded the 
desired amide 65. 3,4-dimethoxyaniline 64 was used again to test the SNAr conditions 
in the revised synthetic sequence, as use of this amine had been shown previously to 
give the highest yields of the anilines tried in the earlier version of the synthetic route ( 
Scheme 2.5), and indeed it reacted readily to give the desired product 66 (Scheme 2.8).  
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Scheme 2.8 First iteration of a re-ordered synthetic route in which the amide coupling reaction 
precedes the SNAr reaction. 3,4-dimethoxy aniline 64 was used as the coupling partner for both 
reactions due to the high nucleophilicity of its amine. 
 
Having established the re-ordered route and the usefulness of T3P as an amide 
coupling agent, the ester hydrolysis and amide coupling reactions were repeated using 
3-aminopyridine 49 as the amine coupling partner to the acid 63 to give compound 67. 
Nucleophilic aromatic substitution of 67 with a number of anilines was then carried 
out to afford final compounds 57, 61, 68 and 69 for biological testing (Scheme 2.9). 
 
Scheme 2.9 Synthesis of final compounds with 3-pyridyl amide functionality and various 
arylamine substituents at the C4 position of the central pyridine ring. 
 
Nucleophilic aromatic substitution of 67 with electron deficient anilines was 
unsuccessful. 4-aminobenzoic acid, 2-aminothiazole, 4-nitroaniline and 4-
aminopyridine all proved insufficiently reactive to displace the chlorine of 67 under the 
established acid catalysed conditions (Scheme 2.10).  
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Scheme 2.10 SNAr reactions using electron deficient amines are unsuccessful using the 
established reaction conditions. 
 
Formation of the 4-aminopyridine-substituted variant 70 was also attempted under 
base catalysed and Buchwald conditions (Scheme 2.11), but neither of these conditions 
successfully produced the desired product 70.  
 
Scheme 2.11 Formation of compound 70 from compound 67 and 4-amino pyridine was 
unsuccessful under base catalysed, acid catalysed and Buchwald conditions. 
2.4 Biological assessment of inhibitors 
Assessment of the biological activity of the inhibitors synthesised during this project 
was initially carried out by Biota Ltd. in Oxfordshire. Later in the project responsibility 
for biological evaluation of compounds was transferred to the author. A brief summary 
of the assays used will be given to explain the different assay protocols used during the 
project. 
The antibacterial activity of inhibitors was determined using standard protocols for the 
determination of the minimum inhibitory concentration (MIC) as described in Chapter 
7, Section 7.2.6 and was performed using comparable protocols both at Biota Ltd at 
the start of the project and by members of the O’Neill research group at the University 
of Leeds in the later stages of the project. 
Inhibition of the DNA gyrase and topoisomerase IV enzymes was assayed by Biota Ltd 
using a malachite green assay which is described in Chapter 7, Section 7.2.4. Use of the 
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malachite green assay was later investigated at the University of Leeds, but the assay 
proved to lack robustness and reliability. The malachite green assay is a colourimetric 
assay which measures the concentration of inorganic phosphate by observing the 
change in colour of malachite green dye which is added to the assay mixture after a 
fixed period of incubation (Scheme 2.12). The concentration of inorganic phosphate 
indicates the amount of ATP which has been converted to ADP and thus the rate of 
enzyme turnover during the incubation period. However, the malachite green dye is 
prone to aggregation under the assay conditions making the absorbance 
measurements unreliable and the activity of the enzyme can only be measured at a 
single time point. 
 
Scheme 2.12 Reaction of inorganic phosphate with ammonium molybdate under acidic 
conditions triggers a colour change in malachite green dye from yellow to green. 
 
An alternative assay protocol couples the turnover of ATP with the rate of turnover of 
NADH, allowing the activity of the enzyme to be monitored continuously by measuring 
the change in absorbance at 340 nm. This allows enzyme activity to be monitored 
continuously over a given time period. Pyruvate kinase (PK) and lactate dehydrogenase 
(LDH) are added to the assay mixture along with phosphoenol pyruvate (PEP) and 
NADH (Scheme 2.13). This assay protocol is described in Chapter 7, Section 7.2.5.  
 
Scheme 2.13 Cascade of reactions in the coupled assay. Turnover of DNA gyrase converts ATP 
to ADP and Pi which begins a cascade of reactions coupling turnover of DNA gyrase with 
conversion of NADH to NAD+ which can be monitored by measuring absorbance at 340 nm.  
Compounds whose IC50s had been determined using the malachite green assay at the 
University of Leeds were had their IC50s re-determined using the “coupled” assay and 
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the results from the coupled assay are given in the thesis as they were more consistent 
with previously determined IC50s. Where assays were carried out by Biota Ltd. using 
the malachite green method it will be indicated. 
 
2.4.1 Biological activity of C-4 aminoaryl pyridines 
Table 2.1 shows the activity of the compounds described above against DNA gyrase 
(GyrB) and topoisomerase IV (ParE) and their antibacterial activity against S. aureus 
and E. coli. 
Table 2.1 
 
Biological activity of selected pyridine urea carboxamide compounds. 
Compound R1 R2 clogP IC50s (µM) MICs (µg/ mL) 
    GyrB ParE SA EC 
50 
  
3.15 0.028a 0.94a 8 >64 
57 
  
3.15 0.036a 0.78a n. d. >64 
61 
  
3.15 0.41 0.22a >64 >64 
66 
  
4.04 0.093a 42a 1 >64 
68 
  
3.13 0.036a 31a 1 >64 
69 
  
3.29 0.019 n/d 4 >64 
clogP calculated using the calculator plugins from MarvinSketch
128
; GyrB, E. coli DNA gyrase; ParE, E. coli 
topoisomerase IV; SA, S. aureus ATCC 29213; EC, E. coli ATCC 25922; a assays carried out by Biota Ltd 
using the Malachite green method. 
 
Several of these compounds are highly potent inhibitors of DNA gyrase, with many of 
the compounds showing IC50 values lower than 93 nM, which was the IC50 of 
compound 38, the most potent pyridine 3-carboxamide DNA gyrase inhibitor 
synthesised previously at Leeds. However, with the exception of compound 61, all the 
compounds were significantly more active against DNA gyrase than topoisomerase IV 
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and although compound 61 was a little more potent against topoisomerase IV than the 
other compounds in the series, it was much less active against DNA gyrase.  
AutoDock was used to predict the binding poses of the compounds. The binding poses 
of 50, 57 and 61 in E. coli GyrB and ParE are shown in Figure 2.9. Compounds 50 and 57 
were docked in similar poses to the inhibitors already described, but compound 61 was 
docked in a different pose. This is consistent with the lower activity of this compound. 
According to the docking model, the ortho-hydroxyl substituent present in compound 
61 causes a steric clash with the amide carbonyl causing the amide bond to flip into a 
different orientation. In this conformation compound 61 is less optimally positioned to 
make hydrogen bond contacts with the protein. The docking model doesn’t suggest 
any obvious cause for the differences in activity between DNA gyrase and 
topoisomerase IV. 
 
Figure 2.9 Docking poses for compounds 50 (cyan), 57 (green) and 61 (orange) into E. coli GyrB 
(A, B and C) (4HYP) and E. coli ParE (D, E and F) (4HZ0)92. 
 
The greatest selectivity for DNA gyrase over topoisomerase IV was seen with 
compounds 66 and 68, both of which have a 3,4-dimethoxyaniline substituent in the C-
4 position of the central pyridine ring, this suggests that these larger substituents may 
disfavour binding to topoisomerase IV. Computational docking predicted the opposite 
result for these two compounds with both compounds predicted to be unable to adopt 
favourable binding poses in the GyrB binding site (Figure 2.10). This inconsistency is 
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likely due to interactions with the flexible loop; in the GyrB crystal structure more of 
the loop is resolved than in the ParE crystal structure. The docking may predict that the 
residues from the flexible loop which are present in the GyrB crystal structure would 
prevent the compounds adopting a conformation that favours binding, when in the 
enzyme assay the flexible loop would adopt a different conformation allowing the 
inhibitor to bind.  
 
Figure 2.10 Docking poses for compounds 66 (magenta) and 68 (purple) into E. coli GyrB (A and 
B) (4HYP) and E. coli ParE (C and D) (4HZ0)92. 
 
Despite the high levels of enzyme inhibition exhibited by these compounds, only 
moderate antibacterial activity was observed. The most potent compounds were 66 
and 68 which both exhibited an MIC of 1 μg/ml against S. aureus. These two 
compounds showed the least activity against topoisomerase IV, which indicates that 
good activity against DNA gyrase is sufficient for antibacterial activity. Compounds 66 
and 68 had the highest and lowest lipophilicities of the compounds tested with clogPs 
of 4.04 and 3.13 respectively. This is not a very wide range of lipophilicities, so it is 
hard to say whether the lipophilicity of these compounds has a significant impact on 
their ability to cross bacterial membranes. 
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None of the compounds tested showed any activity against E. coli. This is most likely to 
be due to difficulties penetrating the Gram negative outer membrane of E. coli. 
Compounds 50, 57, 66 and 68 were assessed for their antibacterial activity against a 
wider panel of bacterial species, but showed no activity against K. pneumoniae, A. 
baumannii or P. aeruginosa.  
These compounds were also screened for their inhibitory activity against the DNA 
gyrase and topoisomerase IV enzymes from S. aureus in order to determine whether 
differences in antibacterial activity could be due to different activities against the 
enzymes from different bacterial species. These results are given in Table 2.2 along 
with the selectivity of each compound for GyrB over ParE in each of the two species 
investigated.  
Interestingly, these compounds showed much greater activity against the S. aureus 
topoisomerase IV enzyme than they did against the E. coli topoisomerase IV enzyme. 
This may be one factor which contributes to these compounds having antibacterial 
activity against S. aureus and not E. coli, as they are closer to having equal activity 
against both enzymes in S. aureus. 
Table 2.2 
 
Biological activity of selected pyridine urea carboxamide compounds. 
   E. coli  S. aureus  
Cmpd R1 R2 IC50s (µM) Selectivity IC50s (µM) Selectivity 
   GyrB ParE ParE/GyrB GyrB ParE ParE/GyrB 
50 
  
0.028 0.94 34 0.024 0.087 3.6 
66 
  
0.093 42 450 0.071 0.81 11 
68 
  
0.036 31 860 0.041 0.82 20 
GyrB, DNA gyrase; ParE, topoisomerase IV; assays carried out by Biota Ltd using the malachite green 
method. 
 
Compound 62 was also assessed for its biological activity which is shown in Figure 2.11. 
It exhibited low enzyme activity, particularly against topoisomerase IV and had no 
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antibacterial activity. This is not unexpected as its structure is significantly different to 
those of the other inhibitors assayed. Although it is able to form the same hydrogen 
bond contacts to the aspartate residue and conserved water that are formed by other 
compounds described in this chapter, it lacks an aromatic group able to form a key π-
stacking interaction with an arginine residue in the active site. 
    
Figure 2.11 Biological activity of compound 62. GyrB and ParE enzymes from E. coli assessed at 
Biota Ltd. using the malachite green method. Docking pose for compound 64 into F. tularensis 
ParE (4HXZ)92. 
 
2.5 C-4 heterocyclic derivatives of the pyridine 4-carboxamide series 
Synthesis of C-4 heterocycle-substituted derivatives of the pyridine 4-carboxamide 
compounds began with the same steps described previously in this chapter (Scheme 
2.1, Scheme 2.2 and Scheme 2.9) and diverged from the 4-chlorosubstituted 
intermediate 67. Installation of 5-membered ring heterocycle units at the C-4 position 
of the 4-chloro substituted intermediate 67 via SNAr reaction was carried out 
successfully with yields of 11-74% (Scheme 2.14). The 1,2,3- and 1,2,5-triazole 
substituted derivatives 73 and 74 were produced using the same reaction of 
compound 67 with 1,2,3-triazole and the products separated using column 
chromatography.  
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Scheme 2.14 Synthesis of heterocyclic derivatives of the pyridine carboxamide series via SNAr 
reaction. 
 
Both pyrrole and imidazole failed to react with compound 67 using the conditions 
described above. Changing the base from sodium hydride to potassium tert-butoxide 
also failed to give the desired product, as did the use of Buchwald conditions (Scheme 
2.15). 
 
Scheme 2.15 Installation of imidazole and pyrrole using the same conditions as described in 
Scheme 2.14 was unsuccessful, as were a change of base and the use of Buchwald conditions. 
 
Installation of these moieties at an earlier point in the synthetic route was investigated 
as a possible way of accessing these compounds. However, neither the carboxylic acid 
intermediate 63 nor the ester intermediate 46 were able to successfully undergo 
reaction with imidazole under the conditions investigated (Scheme 2.16). 
 
Scheme 2.16 Attempted installation of imidazole at two earlier points in the synthetic route. 
Imidazole failed to react with either intermediate. 
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The reaction of imidazole with the di-chloro substituted intermediate 45 was 
successful, affording compound 76 and compound 76 was then able to successfully 
undergo a Buchwald reaction to give the urea substituted intermediate 77. However, 
none of the carboxylic acid intermediate 78 was isolated from the hydrolysis reaction 
and so the amide coupling reaction to give the desired product 79 could not take place 
(Scheme 2.17). 
 
Scheme 2.17 Attempted synthesis of imidazole substituted derivative 79. Reaction of 
imidazole with compound 45 to give compound 76 was successful as was the Buchwald 
reaction to give compound 77, but the hydrolysis reaction was unsuccessful. 
 
2.5.1 Biological activity of C4-amino heterocyclic pyridines 
Biological activities for these compounds are shown in Table 2.3. The bromopyrazole 
substituted compound 72 had the most potent antibacterial activity with an MIC of 16 
µg/ml against S. aureus. This compound showed a sub-micromolar level of enzyme 
inhibition with an IC50 of 0.037 µM against DNA gyrase. Compounds 71 and 73 
displayed antibacterial activity at 64 µg/ ml. All of the compounds tested had sub-
micromolar enzyme activity. The least potent inhibitors in the series were the 1,2,3- 
and 1,2,5-triazoles 73 and 74. 
Docking of these compounds to the E. coli GyrB protein predicted that they should all 
bind very similarly in the ATP site (Figure 2.12). The main difference in the predicted 
poses was that compounds 72 and 73 were predicted to bind with their amide bonds 
at a tilted angle which positions the pyridine ring in a configuration that prevents the 
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formation of a hydrogen bond to Arg-140. This may not reflect the true binding poses 




Biological activity of selected pyridine urea carboxamide compounds.  
Compound R clogP IC50s (µM) MICs (µg/ mL) 
   GyrB SA EC 
71 
 
0.79 0.086 64 >64 
72 
 
1.56 0.037 16 >64 
73 
 
-0.02 0.15 64 >64 
74 
 
0.41 0.20 n.d. n.d. 
75 
 
0.11 0.082 >64 >64 
clogP calculated using the calculator plugins from MarvinSketch
128
; GyrB, E. coli DNA gyrase; SA, S. 
aureus ATCC 29213; EC, E. coli ATCC 25922.  
 
 
Figure 2.12 Predicted binding poses of compounds 71 (purple), 72 (orange), 73 (yellow), 74 
(turquoise) and 75 (magenta) to E. coli GyrB (4HYP)92. 
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The IC50s of these compounds don’t show any correlation with their clogPs, posing a 
challenge to the rationalisation of the IC50 values of these compounds using 
computational predictions. The clogPs of these compounds were not particularly well 
correlated with their antibacterial activity either. 
2.6 Pyrrolidine substituents 
All of the inhibitors in the series described so far have had a high proportion of 
aromatic character and a low proportion of sp3 carbons. It has been shown that the 
ratio of sp3 carbons to non-sp3 carbons in a potential drug molecule correlates with the 
chance of that molecule successfully progressing towards becoming a drug.129 
Replacing aromatic rings with aliphatic rings can lead to an increase in solubility for 
example. It was therefore decided to synthesise a derivative with a higher fraction of 
sp3 carbons. Reaction of compound 67 with pyrrolidine furnished compound 80 in 
good yield (Scheme 2.18). 
 
Scheme 2.18 Reaction of compound 67 with pyrrolidine to afford a derivative with an 
unsaturated ring substituent at the C4 position 80. 
 
A series of DNA gyrase inhibitors had been reported by Trius Therapeutics Inc., 
including compound 33, which contain a substituted pyrrolidine ring in a position 
analogous to the C4 substituent in the pyridine carboxamide series (Figure 2.13).119 
Having a primary amine which is protonated at biological pH may influence the ability 
of a compound to penetrate the membranes of bacteria. It has been shown that 
compounds with activity against Gram negative bacteria tend to have much lower 
clogPs than compounds which are only active against Gram positive bacteria.34 It was 
decided to synthesise a variant, 81, with an analogous aminopyrrolidine substituent. It 
was decided to synthesise the compound as a racemate in the first instance, as the 
racemic starting material was more readily available. An asymmetric synthesis could be 
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carried out later in the case that the racemic compound proved to have particularly 
promising biological activity.  
 
Figure 2.13 An inhibitor containing aminopyrrolidine substituent at the C4 position of the 
pyridine ring 81 would have a similar substitution pattern to an inhibitor reported by Trius 
33119. 
 
The benzyl protected amino pyrrolidine compound 82 was commercially available and 
there were literature conditions for the required protection and deprotection steps 
needed to generate compound 84130. Boc protection of compound 82 to give 
compound 83 was successful, as was the benzyl deprotection reaction to give 
compound 84. Reaction of compound 84 with compound 67 afforded the boc-
protected derivative 85 and deprotection with TFA afforded the desired product 81 as 
a TFA salt (Scheme 2.19).  
 
Scheme 2.19 Change of protection groups afforded the substituted pyrrolidine 84 in two steps 
from compound 82. This underwent reaction with compound 67 followed by deprotection to 
afford the aminopyrrolidine derivative 81. 
 
The biological activities of compounds 80, 81 and the boc-protected intermediate 85 
along with their clogPs are given in Table 2.4.  
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Biological activity of selected pyridine urea carboxamide compounds.  
Compound R clogP IC50s (µM) MICs (µg/ mL) 
   GyrB SA EC 
80 
 
1.22 0.12 64 >64 
81 
 
-0.03 0.089 >64 >64 
85 
 
1.46 0.21 n/d n/d 
clogP calculated using the calculator plugins from MarvinSketch
128
; GyrB, E. coli DNA gyrase; SA, S. 
aureus ATCC 29213; EC, E. coli ATCC 25922. 
 
Despite all three compounds showing sub-micromolar enzyme inhibition, only 
compound 80 showed any antibacterial activity with an MIC of 64 µg/ml against S. 
aureus. Compound 81 had the most potent enzyme activity, but displayed no 
antibacterial activity at 64 µg/ml against either bacterial strains tested. This suggests 
that increasing the polarity alone is insufficient to increase antibacterial activity. 
2.7 Investigation of ADME 
The importance of early determination of the “drug-likeness” of inhibitor compounds 
has been increasingly highlighted as being of vital importance to the ultimate success 
of a drug discovery project.131 The ability of a molecule to be an effective drug depends 
on many factors; simply being a good inhibitor of the target of interest is not sufficient. 
A drug molecule must also be able to be easily absorbed in the body, distributed 
around the body to reach the place that it needs to act, resist metabolism enough to 
maintain active levels in the blood between doses, and be safely excreted so that it 
doesn’t accumulate to toxic levels in the body. These properties are often referred to 
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together as ADME (absorption, distribution, metabolism and excretion) and are also 
often grouped together with toxicity to give ADMET. 
There are many assays and experiments that can be carried out to help measure the in 
vitro ADME properties of a potential drug compound at an early stage before it is 
subjected to any trials in animals. These in vitro experiments can be vital in ensuring 
that resources are not wasted in later parts of a drug discovery project on animal 
studies that show poor efficacy due to problems with ADME that could have been 
spotted earlier. Preliminary in vitro ADME studies were carried out on four 
compounds: 69, 71, 72 and 86. The synthesis and biological evaluation of compounds 
69, 71 and 72 was described earlier in this chapter. Compound 86 was originally 
synthesised as part of previous work at the University of Leeds123 and was 
resynthesised for these studies in one step from intermediate 65 (Scheme 2.20). The 
results of the ADME assessments are shown in Table 2.5.  
 
Scheme 2.20 Previously reported DNA gyrase inhibitor 86 was resynthesised in one step from 
compound 63 by reaction with 2 equivalents of m-toluidine. 
 
Aqueous solubility is important, as compounds which have low aqueous solubility are 
hard to administer and will not be able to achieve a high concentration in blood. 
Additionally, solubility has an impact on the ADME of compounds as increased 
solubility may improve absorption and distribution. However, compounds with high 
aqueous solubility are often highly polar and this can increase their rate of metabolism 
and excretion. The aqueous solubility of compounds 69, 72 and 86 was very low 
suggesting they would be challenging to administer orally. This is mirrored by the high 
levels of plasma protein binding seen for these compounds. However, compound 71 
showed a much higher aqueous solubility and correspondingly lower plasma protein 
binding. 
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An estimate of the ability of these compounds to cross biological membranes was also 
carried out using the Caco-2 permeability assay which uses a human intestinal cell line 
to model absorption of a compound from the gut132. The rate of transfer of compound 
is measured in both directions across the cell membrane. The rate of transfer in the A-
B direction (mimicking transfer from the gut to the blood) and the efflux ratio (an 
indicator that a compound will fail to be absorbed due to efflux) are given in the Table 
2.5. Compounds 69 and 71 performed the best in this assay showing a moderate 
permeability and lower efflux ratios than the other compounds. Compound 72 had a 
low permeability and a high efflux ratio. Full data are not available for compound 86, 
as it was not present in the reservoirs at a high enough concentration for reliable 
measurements to be made. 
Microsomal stability assays were carried out in mice liver microsomes and human liver 
microsomes. The liver is responsible for metabolism of small molecules so that they 
can be more easily excreted from the body and liver microsome cells are the cells 
mostly responsible for this metabolism. These assays give an indication of the speed 
with which a drug molecule will undergo primary metabolism. The more quickly a drug 
is metabolised the more frequently it would have to be dosed, so a half-life of several 
hours is preferred.  The half-life (t1/2) of a drug molecule is used as a standard measure 
of metabolic stability. Understanding the difference between rate of metabolism 
between human and mice cells is useful if a compound is going to be used in a mouse 
model of the disease in question.  
In the human liver microsome assay the most stable compound tested was compound 
71 which had a half-life (t1/2) of 290 minutes. Compounds 69 and 86 were the least 
metabolically stable. This suggests that the aryl amine groups are less metabolically 
stable than the pyrazoles. Addition of functional groups known to slow metabolism, 












































19 4 2.4 97.2 11.83 2.82 20 n/d 
71 
 
63 64 88.5 50.2 4.02 2.78 290 n/d 
72 
 
27 16 32.6 90.5 1.23 30.8 128 24 
86 
 
99a 1 4.26 99.9 <2.67C n/a 46 58 
GyrB, S. aureus DNA gyrase; SA, S. aureus ATCC 29213; a. assays carried out by Biota Ltd using the Malachite green method; b. assays carried out by 
Shanghai ChemPartner Ltd. c. Papp values were expressed as “<” than the values that were calculated using the minimum concentration of the standards for 
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Cytochrome P450 enzymes (CYPs) are the major enzymes involved in drug metabolism 
as they oxidise small organic molecules allowing them to be more easily excreted from 
the body.134 Inhibition of CYPs can cause adverse drug interactions by preventing the 
metabolism and clearance of a large number of drug molecules. Molecules which 
inhibit CYPs may be harder to progress to a successful drug due to their increased 
chance of adverse interactions. In order to assess the potential of this compound 
series to inhibit CYPs, compound 86 was assessed against a panel of cytochrome 
P450s. It showed an IC50 greater than 10 μM against CYP1A2, CYP2C9, CYP2C19 and 
CYP2D6. These four enzymes are known to be responsible for the primary metabolism 
of 90% of drugs.135  
One measurement of toxicity was also carried out. The hERG (human ether a-go-go) 
gene codes for the α-subunit of a vital ion channel in the heart. Inhibition of this 
channel causes long QT syndrome, a heart disorder which can lead to dangerous 
arrhythmias, so compounds which inhibit the channel can cause serious side effects.136 
Compound 86 was assayed for its inhibition of hERG, but it showed no inhibition at 30 
µM which was the highest concentration tested. This suggested that the compounds in 
this series do not possess a significant hERG liability. 
2.8 Summary 
Compounds were synthesised and assessed for their antibacterial activity against S. 
aureus and E. coli and their inhibitory activity against DNA gyrase. Some compounds 
were additionally profiled against a broader range of bacterial species and against 
topoisomerase IV. Four compounds were additionally profiled for their in vitro ADME 
properties. 
Several compounds showed more potent activity against DNA gyrase than any 
inhibitors previously reported in this series, in particular compound 69 which had an 
IC50 of 19 nM against E. coli DNA gyrase. Some compounds showed moderate 
antibacterial activity against S. aureus; the most active compounds were 66 and 68 
which had MICs of 1µg/ ml. However, none of the compounds tested showed any 
activity against E. coli. 
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Despite the highly potent inhibitory activity of these compounds, they show only 
moderate antibacterial activity. This suggests that the physicochemical properties of 
these compounds might be reducing the ability of these compounds to reach a 
sufficiently high concentration within the bacterial cell. This was particularly evident 
when looking at Gram negative bacteria, against which these compounds showed no 
activity. 
Attempts to prepare compounds with more polar substituents, particularly pyridines, 
were hampered by the lower reactivity often demonstrated by the heterocyclic 
molecules.  
Preliminary profiling of the in vitro ADME properties of these compounds showed 
some areas of promise and some room for improvement. However, of the four 
compounds tested for their in vitro ADME profiles, the compound with the least 
potent enzyme and antibacterial activity, compound 71, proved to have to most 
promising ADME properties. 
2.9 Future work 
Chapter 3 details the solution of X-ray crystal structures of these compounds bound to 
the DNA gyrase protein and discusses their binding mode and the potential to 
rationally design inhibitors with greater binding affinity. However, as the compounds 
detailed in this chapter demonstrate, highly potent enzyme activity does not 
necessarily correlate with potent antibacterial activity and so focusing on improving 
the physicochemical properties of the compounds rather than their enzyme inhibition 
might lead to more promising candidates. 
The ADME analysis indicated many compounds in this series are not sufficiently soluble 
and are readily metabolised. Addition of solubilising groups and metabolism blocking 
groups may improve the properties of these compounds. 
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Chapter 3 Crystallisation of inhibitor enzyme complexes 
3.1 Introduction 
The ability of medicinal chemists to rationally design drug molecules, in order to 
optimise their interactions with a given enzyme or receptor, has been transformed by 
the development of X-ray crystallography. Rather than blindly investigating SAR by trial 
and error without being able to explain why one change increases activity while 
another decreases it, X-ray crystal structures of protein-ligand complexes have allowed 
scientists to rationalise the binding modes of molecules and therefore make more 
informed choices about which derivatives to make.137 
As described in Chapter 1, two truncated versions of the GyrB protein are commonly 
used in crystallographic experiments. Inhibitor co-crystal structures are most often 
acquired using the 24 kDa subunit of the protein (GyrB24) which crystallises in a 
monomeric form, whereas co-crystal structures with ATP and non-hydrolysable 
analogues of ATP are most often acquired using the 43 kDa subunit of the protein 
(GyrB43) which crystallises as a protein dimer.  
In order to explore the binding mode of the inhibitors described in Chapter 2, it was 
decided to produce the 24 kDa subunit of GyrB and generate crystal structures of 
several key inhibitors within the GyrB protein. 
3.2 Production of the 24 kDa subunit of GyrB 
3.2.1 Cloning of the GyrB24 gene into a vector with a hexahistidine-tag1 
The pAM24 plasmid which codes for the 24 kDa subunit of E. coli GyrB was kindly 
supplied by the Maxwell group at the John Innes Centre. It was decided to transform 
the gene into a vector with a hexahistidine tag (“his-tag”) for ease of purification. 
Polyhistidine tags are most frequently added to the N-terminal end of a protein and 
allow the protein to be purified simply by Ni-resin affinity chromatography.  
Ligation independent cloning (LIC) was used to transfer the gene coding for the 24 kDa 
subunit of GyrB into a pNIC plasmid which includes the his-tag as well as a GB1 tag to 
                                                     
1 Cloning experiments carried out with the assistance of Dr. Gemma Wildsmith. 
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increase the solubility of the protein during purification138. An overview of the LIC 
process is given in Figure 3.1. Ligation independent cloning uses the 3’ to 5’ 
exonuclease activity of the T4 DNA polymerase to generate long “sticky” ends in both 
the vector and the insert. Mixing the T4 polymerase treated vector and insert in a 1:2 
ratio allows the two to anneal. There is no need to use a DNA ligase, as the sticky ends 
ensure that the vector and insert remain annealed until they are transformed into 
ultra-competent E. coli cells which will seal the nicks in the plasmid and reproduce it. 
 
Figure 3.1 Overview of ligation independent cloning (LIC). The vector plasmid is linearised by 
treatment with BsaI and sticky ends produced by T4 polymerase digestion. The gene of interest 
is amplified by PCR using primers with complementary sequences to the sticky ends in the 
vector, so that digestion with T4 polymerase produces complementary sticky ends. When the 
vector and the insert are mixed they anneal and transformation into E. coli cells causes the 
nicks to be sealed and the plasmid to be replicated. 
 
The pNIC-GB1 vector was linearised by digestion with BasI and sticky ends generated 
by treatment with T4 polymerase in the presence of only one 
deoxynucleotidetriphosphate (dNTP), in this case dGTP (deoxyguanidinetriphosphate). 
The GyrB24 gene was amplified via PCR using primers that contained a complementary 
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overhang to the pNIC vector and then complementary sticky ends were generated by 
treatment with T4 polymerase, this time with only dCTP (deoxycytosinetriphosphate). 
The two components were then mixed in a ratio of 1:2 vector:insert. The annealing 
product was then transferred into E. coli XL10-gold ultracompetent cells which sealed 
the nicks in the plasmid and were cultured to produce many copies of the plasmid. 
Sanger sequencing confirmed the correct sequence in the new plasmid and the DNA 
was transformed into BL21-Gold (DE3) cells for expression.  
3.2.1.1 Production and purification of GyrB24 protein 
The histidine residues cause the tagged protein to bind strongly to divalent metal ions. 
Passing the cell lysate over a resin with appropriate chelating groups bound to nickel 
ions will cause the protein of interest to be retained on the resin allowing all other 
proteins from the cell lysate to be washed off the column. The protein of interest can 
then be eluted using a high imidazole buffer as imidazole will displace the histidines 
from the nickel on the resin. Figure 3.2 shows a his-tagged protein interacting with a 
Ni-NTA agarose affinity resin. 
 
Figure 3.2 Interactions between his-tagged protein and Ni-NTA agarose resin. Agarose resin 
functionalised with nitrilotriacetic acid (NTA) groups (red) can be loaded with a divalent metal, 
in this example Ni (green), which will strongly bind to histidine groups in a protein (blue). A 
chain of adjacent histidine groups ensures a strong interaction with the resin. 
 
 Once purified, the his-tag can be removed from the tagged protein using the tobacco 
etch virus (TEV) protease. This enzyme is a serine protease which recognises the 
following sequence ENLYFQ\S, where “\” denotes the position of the cleaved peptide 
bond. Inclusion of this sequence between the his-tag and the GyrB24 protein allows 
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the his-tag to be removed leaving only the native protein sequence with one extra N-
terminal serine residue. There is a large area of contact between the TEV protease and 
the protein chain being cleaved which allows for a high degree of specificity.139 
The GyrB24 protein was overexpressed and purified according to the methods 
described in Chapter 7. The protein was overexpressed and purified using Ni-NTA 
chromatography and the his-tag cleaved using TEV protease. A second Ni-NTA column 
separated the cleaved protein from the tag. Size exclusion chromatography was used 
as a final purification step. The UV trace from the column and an SDS-PAGE gel of the 
combined protein containing fractions are shown in Figure 3.3.  
 
Figure 3.3 Purification of GyB24. A) Size exclusion chromatography trace of fractions 
containing GyrB24. B) SDS-PAGE gel showing GyrB24 after purification by size exclusion 
chromatography, lane one is GyrB24 at a concentration of ~12 mg/ml and lane two is diluted 
to ~4 mg/ml. 
 
A slight impurity was seen at about 8 kDa on the gel at high concentrations of GyrB24 
and this was also seen using mass spectroscopy. High resolution mass spectrometry 
gave a spectrum with a major and a minor peak. Upon deconvolution of the major 
peak, a mass of 24243 Da, corresponding to the GyrB24 protein, was observed. The 
minor peak had a mass of 8081 Da corresponding to the cleaved tag (Figure 3.4). As 
the concentration of the tag was significantly lower than that of the desired protein, it 
was decided to proceed with this protein in the crystallography experiments. The 
protein yield was approximately 20 mg L-1 of culture. Aliquots were stored in a high 
glycerol buffer (Tris pH 7.5 50 mM, EDTA 1 mM, DTT 5 mM, glycerol 30%) at -80 °C. 




Figure 3.4 Deconvoluted MS peaks from GyrB24 sample. A) major peak corresponding to 
GyrB24 protein; B) Minor peak corresponding to the cleaved tag. 
 
3.3 Crystallography2 
Crystallisation trials of GyrB24 in the presence of four inhibitors were set up. The 
inhibitors chosen were compounds 69, 71, 72 and 86 (Figure 3.5) as they are 
representative of the main inhibitor groups discussed in Chapter 2 and had been 
thoroughly characterised in terms of their biological activity. 
 
Figure 3.5 Inhibitors chosen for use in crystallisation trials with their IC50s against E. coli DNA 
gyrase. 
 
                                                     
2 The first round of optimisation was carried out by the author with the assistance of Dr. Clare 
Stevenson at the John Innes Centre. Further rounds of optimisation were carried out by 
Dr. Clare Stevenson. 
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Based on previously reported conditions for the crystallisation of GyrB24 in the 
presence of novobiocin, optimisations were set up using 25-40% PEG400 and 100 mM 
Hepes pH 6.5 for GyrB24 in the presence of each of the four inhibitors 69, 71, 72 and 
86. In the first round of optimisations crystals formed in the presence of compound 72 
after a few days. Only microcrystals or spherulites were formed in the presence of the 
other inhibitors. However, by using a seed stock made from the crystals obtained in 
the presence of compound 72, improved crystals were obtained in the presence of the 
other three inhibitors in similar conditions. The crystals were harvested and X-ray 
diffraction data recorded at the Diamond Light Source in Oxfordshire. 
Figure 3.6 shows a droplet containing protein crystals formed in the presence of 
compound 72 in a 96 well plate and a crystal in a LithoLoop in the Diamond Light 
Source beamline, and the resultant diffraction pattern. 
 
Figure 3.6 A representative example of protein crystals co-crystallised with inhibitors. A) 
crystals formed in a drop in a 96 well sitting drop plate in the presence of compound 72; B) A 
crystal in a LithoLoop photographed in the beamline at the Diamond Light Source C) the 
diffraction pattern recorded from the crystal. 
 
Diffraction data were collected for several crystals for each inhibitor to find the best 
dataset. The highest resolution dataset for each inhibitor was chosen that processed 
with good statistics. Full data collection and refinement statistics for the best dataset 
for each inhibitor can be found in Chapter 7, Table 7.2. 
3.4 Structure solution3 
Previously solved crystal structures of GyrB24 in the presence of an inhibitor have 
been in the P212121
92,140, P1211
106,141 and C12187,89,90,116,142,143 space groups. However, 
                                                     
3 Crystal structures were solved by Dr. Clare Stevenson and Dr. David Lawson at the John Innes 
Centre. 
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the crystals formed in the presence of compounds 69, 71, 72 and 86 were in space 
group P3221. Molecular replacement was used to solve the crystal structure of GyrB24 
crystallised with compound 72. A crystal structure of S. aureus GyrB crystallised in the 
presence of Novobiocin (4URO)141, which was in the P1211 space group, was used as 
the template for molecular replacement. Clear density could be seen for the presence 
of the inhibitor and the structure of compound 72 was built into the density. Further 
refinement was carried out using programs from the CCP4 suite144.  
During the model refinement process, difference maps are generated by subtracting 
the electron density calculated from the model from the “real” electron density from 
the crystal in order to check that the model has not become biased.  Difference maps 
show electron density for components of the map which have not been accounted for 
by the model, or that have not been modelled correctly. The presence of specific 
features, such as inhibitor molecules, can be confirmed using an omit map in which the 
feature of interest is removed from the model before generating the difference map. 
The presence of the feature in the omit map confirms that it is not an artefact caused 
by model bias. Figure 3.7 shows an omit map created by refining the model of the 
compound 72 crystal structure without including the inhibitor in the model, and the 
corresponding model with the inhibitor molecule present.  
 
Figure 3.7 A) An omit map generated by refinement of a model of the compound 72 crystal 
structure in the absence of the inhibitor molecule, showing an area of electron density (green) 
which corresponds to the missing inhibitor molecule. B) the corresponding model with the 
inhibitor present. 
 
The structure of the protein with compound 72 bound was then used as the starting 
model for refinement of the other three structures. All four structures contained 
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electron density which corresponded to the bound inhibitor. Density maps from the 
modelled crystal structures are shown in Figure 3.8. The inhibitor binding site is shown 
with the electron density around the inhibitor molecules. 
 
Figure 3.8 Maps of electron density (blue) overlayed with the corresponding model of the 
crystal structure (green). A) 69, B) 71, C) 72 and D) 86. 
 
The crystal structures of GyrB24 with compounds 69, 71, 72 and 86 bound were 
determined to 1.90, 1.95, 2.35 and 2.50 Å resolution respectively. The models each 
consisted of one monomer of protein in the asymmetric unit with one molecule of 
inhibitor bound in the ATP binding site. Each asymmetric unit also contained one PEG 
molecule and a number of water molecules: 84 in the crystals with compounds 71 and 
72 bound, 73 in the crystal with compound 69 bound and 53 in the crystal with 
compound 86 bound.  
3.5 Analysis of crystal structures 
All four crystal structures conform to the known structure of this subunit of GyrB with 
an 8-stranded β-sheet, two relatively long α-helices and three relatively short α-
helices, with the ligand bound between two α-helix regions. As with previously 
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described crystal structures, the loop between Leu-98 and Gly-117, which is adjacent 
to the inhibitor binding site, is disordered.  Figure 3.9 shows a cartoon representation 
of the crystal structure with compound 72 bound.  
 
Figure 3.9 Cartoon view of the GyrB24 crystal structure with compound 72 bound (green). A) 
Binding site between α-helices (cyan) and missing loop region; B) β-sheet region (magenta). 
 
The crystal structures confirmed that the inhibitors were bound in the ATP binding site 
of the enzyme as had been computationally predicted. Figure 3.10 shows the binding 
poses from the co-crystal structures (top) and the corresponding docking poses 
predicted using Glide145 (bottom) for each of the inhibitors along with the key residues 
that these inhibitors interact with in the protein.  
As with other known inhibitors, a hydrogen bonding network involving Asp-73 and a 
conserved water molecule in the binding site can be seen. The hydrogen bond 
donation from the urea moiety and hydrogen bond acceptance from the pyridine rings 
within the inhibitor molecules closely mirror the poses predicted by computational 
docking, although the docking predicted a slightly tilted angle for the central pyridine 
ring in the cases of compounds 69 and 86 and very tilted in the case of compound 72. 
This tilt positions the C-4 substituent closer to the hydrophobic region of the binding 
site, possibly allowing the substituents to interact with hydrophobic residues such as 
Ile-94. 
Computational docking predicted a π-stacking interaction between Arg-76 and the 
pyridyl rings of compounds 69, 71 and 72 or the corresponding tolyl ring in compound 
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86. However, these rings are seen to be tilted in the crystal structures at an angle 
which would not form an optimal π-stack. Additionally, in the docking model, the 
amide bond is in the same plane as the central pyridine ring, but in the crystal 
structure the amide bond has twisted away from the plane of the central pyridine ring 
in order to form a hydrogen bond with the backbone carbonyl of Gly-77. Formation of 
this hydrogen bond may compensate for the loss of the π-stacking interaction, 
especially as the aromatic ring is able to form other interactions. This twist may 
improve the orientation of the ring nitrogen present in compounds 69, 71 and 72 to 
form a hydrogen bond to Arg-134. This is not in the case for compound 86, as the tolyl 
ring does not have a nitrogen atom able to form the hydrogen bond.  
The tolyl ring of compound 86 is in a different conformation compared to the docked 
pose with the methyl substituent pointing towards the wall of the cavity rather than 
up into the solvent exposed region. This may be due to an improved hydrophobic 
interaction with Pro-79. 
The orientations of the C-4 substituents were the least well predicted aspect of the 
binding poses, except in the case of compound 69 which matches fairly closely. There 
is an approximately 90° difference in the torsional angle between the pyridine and 
pyrazole rings of compound 71 and 72 compared to this angle in their docking poses. 
This may be accounted for by the change in the torsional angle between the pyridine 
ring and the amide carbonyl. In the docking pose the amide bond is in the same plane 
as the pyridine ring and the pyrazole ring is twisted to avoid a clash, whereas in the 
crystal structure the amide bond had moved out of the plane and the pyrazole ring had 
moved closer to being in the plane.  
Of the four compounds investigated, compound 86 was the least active in the enzyme 
assay. This may be due to the inability of the tolyl ring to form a hydrogen bond to Arg-
136. Compound 69 was the most potent inhibitor of E. coli DNA gyrase of the 
compounds described in Chapter 2, this may be due to hydrophobic interactions 








Figure 3.10 Comparison of predicted binding poses of inhibitors in E. coli GyrB with X-ray co-crystal structures with the key residues which form interactions 
with the inhibitors shows in green and the protein surface in grey. Dashed lines indicate a hydrogen bond where the interatomic distance is <3.5 Å. A) 
compound 69 co-crystallised; B) Compound 71 co-crystallised; C) Compound 72 co-crystallised; D) Compound 86 co-crystallised; E) Compound 69 docked; F) 














A variant of the gene for the 24 kDa subunit of E. coli GyrB was produced with an N-
terminal his-tag for ease of purification, a GB1 tag for increased solubility during 
purification and a TEV protease cleavage site for removal of the tag following 
purification. A pNIC vector containing this gene was prepared by ligation independent 
cloning.  
The protein was then produced by growth in E. coli. GyrB24 was purified from the 
soluble fraction of the cell lysate by Ni-resin affinity chromatography and the tag 
cleaved by incubation with TEV protease. A second Ni-resin column removed the tag 
and size exclusion chromatography used as a final purification step. Approximately 20 
mg of protein were produced per litre of culture. 
Protein was crystallised in the presence of four inhibitors: compounds 69, 71, 72 and 
86. Crystals formed in the presence of compound 72 under conditions close to those 
previously established. Crystals formed in the presence of compound 72 were used to 
seed optimised conditions from which crystals formed in the presence of the other 
inhibitors. Crystals were harvested and transported to the Diamond Light Source in 
Oxfordshire. 
Diffraction data were collected for a number of crystals formed with each inhibitor and 
the most promising dataset for each inhibitor was solved to give crystal structures 
which were resolved to between 1.9 and 2.5 Å. The crystal structures all showed a 
region of electron density which corresponded to a bound inhibitor molecule. 
Analysis of the inhibitor binding poses showed some similarities and some differences 
when compared to the predicted binding poses. The hydrogen bonding network 
between the urea nitrogens, the nitrogen of the central pyridine ring, Asp-73 and the 
conserved water molecule was very similar to the interactions predicted using 
computational docking. The amide bond was twisted compared with the predicted 
pose and was thus able to form a hydrogen bond to the carbonyl of Gly-77. The 
positions of the C-4 substituents of the central pyridine ring were less well modelled 
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and were angled in a way which may allow them to form hydrophobic interactions 
with residues in the binding site. 
3.7 Future work 
The crystal structures described above have shed light on the binding mode of these 
inhibitors and suggest some potential routes for optimisation of their structures. The 
urea group, the central pyridine ring and the amide bond all form hydrogen bonds to 
the protein and modifications of these groups are unlikely to improve the binding of 
these inhibitors. Some improvements in binding may be seen from optimisation of the 
aromatic group on the left hand side of the molecule to improve the hydrogen bonding 
interaction with Arg-136. A different ring system or a substituent extending from the 
ring may increase the strength of this interaction. 
Acquiring crystal structures of these inhibitors bound to the topoisomerase IV enzyme 
would be a great asset as it would guide the design of inhibitors with less selectivity for 
DNA gyrase over topoisomerase IV. It would also be useful to acquire crystal structures 
of inhibitors bound to these proteins from other bacterial species, as the results 
described in Chapter 2 suggest that these compounds interact less favourably with the 
topoisomerase IV enzyme from E. coli than they do with that from S. aureus.  
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Chapter 4 Use of computational methods for hit identification 
4.1 Introduction 
Over the last few decades, computational power has increased dramatically. 
Computational and medicinal chemists have been keen to put this increased 
calculating ability to good use.146 While computational methods are not yet capable of 
fully predicting the complex network of effects a small molecule may have on a living 
organism, they can increasingly provide approximate guidance for many of the 
problems encountered in drug discovery. Computational methods are seen as valuable 
tools to complement the experiments carried out in the lab, and new and improved 
methods are being continually developed to provide assistance throughout the drug 
discovery process. This chapter will focus on the computational tools most commonly 
used at the very start of a medicinal chemistry project to help identify molecules to 
assess within initial screens against a given biological target.  
Over the years, many different computational approaches have been developed to aid 
in the identification of molecules which are predicted to bind favourably to a specific 
biological target. Most of the software tools can be grouped into broad classes based 
on how they search for structures or how they assess the potential of these structures 
to bind to the target of interest. The two most common approaches to the search for 
molecular structures are de novo design and virtual high throughput screening (vHTS). 
De novo design approaches procedurally generate novel chemical structures that are 
predicted to interact favourably with the target protein, whereas vHTS approaches 
search databases of pre-existing small molecules to identify appropriate structures. 
Ranking or scoring small molecules for their potential to favourably interact with the 
target of interest can been approached by either ligand-based or target-based 
methods. Target-based approaches begin with the structure of the target itself and 
base their assessments on the ways in which a given small molecule might interact 
with that target. Ligand-based approaches assess the potential of a chemical structure 
by its similarity to the chemical structure of a known ligand of the target (Figure 4.1). 




Figure 4.1. Schematic representation of the different approaches to computational hit 
identification. A) ligand-based vHTS; B) structure-based vHTS; C) ligand-based de novo design 
and D) structure-based de novo design. Adapted from Lolli et. al. used with permission.147 
 
In the present work, target-based de novo design and both ligand-based and target-
based vHTS have been used to search for new chemical structures to investigate as 
potential inhibitors of DNA gyrase and topoisomerase IV. 
4.2 De novo design 
There are several programs available for de novo design148. In this work, SPROUT has 
been used125. The SPROUT software is comprised of several modules (Scheme 4.1) 
which are used sequentially: first to define a receptor within the crystal structure of a 
protein; then to select residues within that receptor in which to bind small structural 
fragments and finally to connect the fragments to give a series of potential ligand 
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structures. The program can rank the results by estimated binding affinities, size, 
ligand efficiency or complexity.  
 
Scheme 4.1 Description of the purpose of each of the modules present in the de novo 
molecular design program SPROUT. 
 
The design of a new series of potential inhibitors of DNA gyrase and topoisomerase IV 
was attempted using SPROUT with the aim of identifying novel structures. Based on 
inhibitor structures which have been reported in the literature, three key interactions 
were chosen as being important to good inhibitor binding: a hydrogen bond acceptor 
able to interact with the conserved water molecule in the active site; a hydrogen bond 
donor able to form a hydrogen bond to Asp-82 and an aromatic group able to form a 
π-stacking interaction with Arg-85. These features are common to almost all of the 
most active inhibitors reported in the literature including the natural product 
novobiocin 750, inhibitors published by Vertex 1787, AstraZeneca 21101, Evotec 26114 and 
Trius 3792, and compounds from the series previously designed at Leeds such as 
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Figure 4.2 Three structural features are common to all reported GyrB/ ParE inhibitors: a 
hydrogen bond acceptor (blue) which interacts with a conserved water molecule in the active 
site; a hydrogen bond donor (orange) which interacts with an aspartate residue and an 
aromatic ring (red) which forms a π-stacking interaction with an arginine residue. 
 
It was chosen to use a crystal structure of ParE from E. coli (4HZ092) for the de novo 
design process in SPROUT. Previous inhibitors synthesised at Leeds have been less able 
to inhibit topoisomerase IV when compared to their activities against DNA gyrase. By 
beginning the design process with compounds designed to bind well to topoisomerase 
IV and then assessing designed molecules for their predicted binding to both enzymes 
it was hoped to design inhibitors with less selectivity for one enzyme over the other.  
The Asp-82 residue was selected as one “target site” using the HIPPO module of 
SPROUT and designated as a hydrogen bond acceptor site. SPROUT can recognise 
water molecules in the active site of a protein, but does not always predict the optimal 
hydrogen bonding vector which was the case in this instance. It also isn’t able to 
recognise sites with the potential to form π-stacking interaction. In order to position 
fragments to correctly form π-stacking interactions or hydrogen bonds to water if the 
correct vectors have not been predicted correctly, SPROUT allows the creation of 
“spheric sites” within the binding site and their designation as hydrogen bond 
acceptors, donors or hydrophobic sites. Spheric sites were generated at appropriate 
positions in the binding site to represent the hydrogen bond to the conserved water 
molecule and the π-stacking interaction to Arg-85. Starting fragments bearing the 
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appropriate hydrogen bond donors, acceptors and aromatic rings were docked into 
these “target sites” using the SPIDER module in SPROUT (Figure 4.3). 
 
Figure 4.3 Docking of starting fragments into selected “target sites” using SPROUT. Benzene 
rings (turquoise) have been docked into the spheric sites which are shown in solid purple and 
an amine (blue) has been docked into the hydrogen bond acceptor site which is shown in blue 
wireframe. 
 
Thousands of possible scaffolds were generated by connection of these fragments 
using linkers such as carbon chains, amide bonds and aromatic rings. However SPROUT 
was unable to connect the desired fragments into any scaffolds that scored higher 
than the pyridine 3-carboxamide compounds already designed, and upon redocking 
with AutoDock none of the scaffolds were able to adopt a pose in the active site that 
would allow the desired interactions to occur. The four scaffolds given the highest 
scores by SPROUT are shown in Figure 4.4. The hydrogen bond donor and acceptor 
moieties have been placed too far apart from each other to make the desired contacts 
and an overly complex ring system is used to connect to the aromatic group that can 
form a π-stack to Arg85. 
 
 




Figure 4.4 The four best scored SPROUT designed scaffolds in the pose predicted by SPROUT. 
The fragments chosen to form interactions to the protein have been connected via complex 
ring systems which would make them difficult to synthesise and the hydrogen bond donors 
and acceptors have been placed too far apart to make the desired interactions. 
 
Use of the spheric sites to provide “target sites” for hydrogen bonding to non-protein 
atoms and π-stacking, did not allow the docked fragments to orient themselves 
correctly to form the desired interactions, so when connected into a full scaffold the 
designed structures did not have the desired features. SPROUT was unable to 
successfully design π-stacking interactions or hydrogen bonds to non-protein atoms 
and so specifically designing compounds able to form the desired interactions using 
SPROUT proved challenging. It was decided to focus instead on virtual screening 
approaches to design novel DNA gyrase and topoisomerase IV inhibitors. 
4.3 vHTS 
4.3.1 Structure based vHTS 
When searching for starting points for a drug discovery project, it is common to screen 
very large catalogues of small organic molecules using automated assays to look for 
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any that interact favourably with the biological target of interest. High throughput 
screening (HTS) of this type can single out a few promising candidates from amongst 
thousands of compounds and then these “hits” can be followed up with further 
biological assessment and chemical exploration. However, HTS campaigns are very 
costly and require a lot of time and resources. An alternative approach to find hit 
molecules from large compound collections is to utilise molecular docking. Screening 
large databases for molecules that are predicted to bind well can give a short list of 
compounds with a higher chance of being active than taking a small sample at random. 
Screening a small number of compounds is much quicker and cheaper. 
Most suppliers of small molecule screening collections provide digital versions of their 
collections which can be used for vHTS. These databases can be searched individually 
or combined and searched together. The ZINC database is a combined database 
containing the compound collections of over 200 commercial suppliers. The database 
contains almost 100 million unique chemical compounds. This number is too big to be 
screened in a reasonable time frame, but several subsets of the database are also 
available that narrow the full compound set based on calculated properties such as 
size, current availability or “drug likeness” (based on Lipinski’s rule of 5). In this project 
the “drug-like” subset that contained >10000 compounds was used, but first it was 
further narrowed down using a diversity filter in Pipeline Pilot to give 10000 
compounds.149  
There are a number of docking programs available to assess the binding of a small 
molecule to a biological target. For this project, Glide, the docking module of 
Schrodinger’s Maestro software package145, was chosen to dock the compounds as it 
was able to exactly reproduce the binding pose of a known inhibitor of DNA Gyrase 
and topoisomerase IV into its crystal structure (4HZ0, which is ParE from E. coli) Figure 
4.5. Other features of Glide that were taken into account when choosing it over other 
docking programs were its speed and the ease with which it can be used in 
combination with parallel computing resources. 




Figure 4.5 Original crystal structure 4HZ092 and docking of the ligand by Glide. The Glide 
generated pose perfectly overlaps with the pose of the native ligand. 
 
The top 500 ranked docking poses were visually inspected looking for structures which 
made at least two of the three key binding interactions described earlier in this 
Chapter. Seven structures, which had high scores and appropriate binding modes, 
were chosen for purchase. Their scores and binding modes are shown in Table 4.1. 
The library was also docked into a crystal structure of DNA gyrase (3G7E, GyrB from E. 
coli) and the top 500 compound were again visually inspected. This time six 
compounds were selected. Their binding poses and Glide scores are shown in Table 
4.2. The Glide scores were higher against this target compared with those docked 
against topoisomerase IV, and so less emphasis was placed on choosing inhibitors 
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Table 4.1 Shortlisted compounds from docking of the ZINC database against the 
topoisomerase IV crystal structure 4HZ0. Binding poses and Glide scores are given. 
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Table 4.2 Shortlisted compounds from docking of the ZINC database against the DNA gyrase 
crystal structure 3G7E. Binding poses and Glide scores are given. 
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The purchase of the shortlisted compounds is discussed in Section 4.4 and their 
biological activities are discussed in Section 4.5. 
4.3.2 Ligand-based vHTS 
Another approach to virtual screening is to look at a known ligand and search for 
similar molecules. Compounds with similar structural features are more likely to 
interact well with the biological target than those with very different features. The 
ROCS (rapid overlay of chemical structures) program provided by OpenEye was used 
for ligand-based vHTS in this project.150 
The natural product DNA gyrase inhibitors novobiocin 7 and cyclothialidine 10 were 
used as the initial query molecules and chemical libraries from three suppliers 
(Maybridge, ChemBridge and Peakdale) were screened against them. However, ROCS 
was unable to find good shape matches. This is likely due to the size of these 
molecules, as the average size of molecules in the screening collections was 
significantly smaller than the natural products. An overlay of the natural products 
(green) and the highest scoring matches found by ROCS (pink) are shown in Figure 4.6. 
 
 
Figure 4.6 The natural products Novobiocin 7 and Cyclothialidine 10 (green) overlaid with the 
highest scoring matches found by ROCS (pink). 
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To better match the sizes of molecules present in the compound screening collections 
a truncated version of novobiocin 100 was tried as an alternative query for ROCS along 
with the cyclothialidine derivative reported by Roche 11 which was smaller than 
cyclothialidine76. Better shape matches were found for these smaller versions of the 




Figure 4.7 A truncated version of Novobiocin 100 and a cyclothialidine derivative reported by 
Roche 1176 (green) with their highest scoring matches from a ROCS screen of the Peakdale, 
Maybridge and ChemBridge compound libraries (pink). 
 
Although some structures with good overlap to known natural product inhibitors had 
been discovered it was decided to also look for matches for some of the many small 
molecule inhibitors which have been reported in the literature. Six known small 
molecule inhibitors were chosen to use as queries for the search (Figure 4.8). These 
inhibitors were chosen as they represented a structurally diverse set of examples from 
most of the previously described compound series. They all possess the three 
structural features identified in Section 4.2 as being key to binding. Crystal structures 
of these inhibitors bound to DNA gyrase were available for all of these compounds 
with the exception of compound 38. The structures of the inhibitors in their bound 
conformation were extracted from the published crystal structures and used for the 
ROCS search as this allowed the ROCS search to match compounds with the right 
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shape to fit into the active site in this configuration. The conformation of compound 38 
when bound to the enzyme was predicted using docking. 
 
Figure 4.8 Six query molecules from the scientific literature were selected for use in ROCS 
searches. These compounds were published by Evotec 26114, Biota and the University of Leeds 
38123, AstraZeneca 101 and 102117,143, Vertex 10387 and Trius 10492. 
 
Overlays of these structures with their highest scored match from the ROCS search are 
shown in Figure 4.9 (query structures are shown in green and matches in pink). The 
program was able to find matches with very similar shapes for each structure. 
However, key hydrogen bond acceptors and donors were often not matched, as this is 
not prioritised by the software.  
 
Figure 4.9 Overlays of the six structures chosen as queries for ROCS (green) with their highest 
scoring matches (pink) from the ChemBridge, Peakdale and Maybridge compound libraries. 
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The 100 best matches were chosen from each ROCS search. The hits from all the 
searches were combined and duplicates removed using OpenBabel151 to give a total of 
276 compounds. Secondary docking was used to identify which of the best compounds 
from the ROCS search were likely to form good binding interactions as well as having 
good shape complementarity with the active site. The compounds were docked into 
the E. coli topoisomerase IV crystal structure (4HZ0) using Glide and the 191 
compounds which scored lower than -5 were visually inspected to determine whether 
they were binding in a favourable conformation. Upon visual inspection the shortlist 
was narrowed to 4 compounds. Their binding modes and ROCS scores are shown in 
Table 4.3, along with their Glide scores and the structure they were initially aligned to. 
Table 4.3 Shortlisted compounds from a ROCS search of the Maybridge, ChemBridge and 
Peakdale libraries against six known inhibitors followed by docking into the topoisomerase IV 
crystal structure 4HZ092 using Glide. Binding poses, ROCS scores and Glide scores are given. 
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ROCS can also be used to search for molecules that align well with a pharmacophore 
model rather than an individual inhibitor molecule. Pharmacophore models provide a 
more general query than searching with a specific inhibitor molecule. vROCS can be 
used to generate pharmacophore models by combining features of a number of known 
inhibitors. The pharmacophore model will have a shape that encompasses all of the 
inhibitors used and will highlight chemical features such as ring systems and hydrogen 
bond donors and acceptors in order to search for compounds which match these 
features.  
It was decided to carry out a pharmacophore search in addition to the single molecule 
queries that had been carried out. A pharmacophore model was created using the six 
inhibitors which had previously been used as individual queries. However, simply 
aligning the structures and retaining all points at which vROCS suggested a structural 
alignment could be made gave a pharmacophore model with too many match points 
(Figure 4.10, A). Docking against this did not give matches which scored highly. 
In order to focus the pharmacophore on the key areas of overlap between the 
inhibitors rather than including the points at which they were less similar, the 
overlapped inhibitors were truncated leaving only the regions that overlapped well. 
And only the three key structural features that have been described earlier in the 
chapter were selected as match points (Figure 4.10, B). However, ROCS was able to 
find even higher scoring matches if the ring systems were not highlighted as match 
points for ROCS (Figure 4.10, C). This search was much more closely focused on finding 
matches with the correct arrangement of hydrogen bond donors and acceptors.  




Figure 4.10 Development of a useful pharmacophore model. A model generated by aligning 
compounds from six different inhibitor classes. B. Model generated by using truncated 
versions of inhibitors from four known classes, highlighting only the key structural features. C. 
Model generated using truncated versions of inhibitors from four known compound classes 
highlighting only the key hydrogen bonding interactions. 
 
As in the previous ROCS searches, the top 100 hits from the ChemBridge, Maybridge 
and Peakdale libraries were docked with Glide into the E. coli ParE crystal structure 
4HZ0 and a shortlist selected by visual inspection. The top six hits are shown in Table 
4.1 with their binding pose, Glide score and ROCS score. Hits from this search had 
better Glide scores than the hits from the previous ROCS searches, suggesting that the 
pharmacophore model was a more useful query than the individual inhibitors. 
 
Chapter 4  Use of computational methods 
96 
 
Table 4.4 Shortlisted compounds from a ROCS search of the Maybridge, ChemBridge and 
Peakdale libraries against a pharmacophore model followed by docking into the 
topoisomerase IV crystal structure 4HZ0 using Glide. Binding poses, ROCS scores and Glide 
scores are given. 
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4.4 Choice of ligands for purchase 
The most promising structures from both structure-based and ligand-based virtual 
screening campaigns were combined to give a shortlist of 22 compounds; seven from 
the target based vHTS screen against ParE; six from the target based vHTS screen 
against GyrB; four from the ligand based vHTS using individual inhibitor molecules and 
five from the ligand based vHTS using a pharmacophore model. The availability of 
these compounds was checked using the eMolecules website which allows ordering of 
compounds from all of the vendors whose compounds are included in the ZINC 
database. Of the 22 compounds in the search, only 15 were listed as available. Because 
structure based vHTS was carried out using a subset of the ZINC database, the shortlist 
contained molecules from eight different suppliers, as shown in Table 4.5. In order to 
limit costs, only compounds available from ChemBridge were chosen for purchase as 
this was the supplier with the most compounds from the list and included compounds 
from each of the vHTS searches. Six compounds were purchased. 
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4.5 Biological results 
The six purchased compounds were initially assessed for their biological activity in an 
ATPase assay against DNA gyrase. The compounds were screened at a concentration of 
100 µM and the activity of the enzyme monitored over half an hour. Novobiocin was 
used as a control inhibitor. The assay protocol is as described in Chapter 7. The activity 
of the enzyme in the presence of inhibitor at a concentration of 100 µM relative to its 
activity in the absence of an inhibitor is shown in Table 4.6. Determination of IC50 
values for the two most active compounds 110 and 112 was attempted, but the 
compounds were insoluble at concentrations higher than 100 μM, so an IC50 curve 
could not be recorded.  
Table 4.6 Activities of compounds against DNA gyrase. 
Compound Structure % residual activity at 100 µM 
88 
 
93 ± 1 
94 
 
100 ± 12 
99 
 
95 ± 5 
110 
 
66 ± 11 
111 
 
85 ± 4 
112 
 
67 ± 18 
 
Based on their percentage inhibition at 100 µM it would be expected that the two 
most active compounds would have IC50 values of around 70 µM. This level of activity 
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was considered too low for it to be worth attempting to optimise their activity through 
the synthesis of analogues.  
4.6 Conclusions and future work 
Several different computational methods have been used with the aim of identifying 
novel inhibitors of DNA gyrase and topoisomerase IV. Use of SPROUT to carry out de 
novo design of inhibitors which would be able to make specific binding interactions 
within the active site was unsuccessful. vHTS was attempted using both structure-
based and ligand-based approaches. A number of compounds which were predicted to 
bind favourably to DNA Gyrase and topoisomerase IV were identified, but only a small 
number were purchased and none of those purchased showed sufficiently potent 
activity to be worth further investigation. 
Future computational efforts to identify inhibitors of DNA gyrase and topoisomerase IV 
should focus on vHTS rather than de novo design. As only a small number of 
compounds were purchased initial efforts could be focused on acquiring and 
biologically assessing other compounds from the shortlist of compounds chosen from 
the vHTS studies. 
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Chapter 5 Rational design of a new inhibitor series using a scaffold-
hopping approach 
5.1 Introduction 
The design of novel inhibitors does not necessarily have to be carried out using 
computational analysis or searching for hit molecules in high throughput screens to 
then be optimised. Another approach is to rationally design novel inhibitors based on 
knowledge of the active site of the enzyme and of the features of known inhibitors. 
Scaffold-hopping is an approach often used by medicinal chemists to search for 
compounds which are similar to compounds known to have good activity in the hope 
that a structurally related molecule may have similar or improved properties. Scaffold-
hopping approaches can be grouped into four categories: heterocycle replacement, 
ring opening or closure, peptidomimetics and topology based hopping.152  
In this chapter the rational design of three compound series using information 
gathered from the scientific literature along with knowledge of the features of the 
binding site of DNA gyrase and topoisomerase IV will be discussed. Additionally, 
synthetic efforts towards these compounds and initial assessment of their biological 
activities will be presented. 
5.2 Pyrimidines 
5.2.1 Background 
In 2013, a series of GyrB/ParE inhibitors was published by Trius Therapeutics which 
showed good activity against Gram negative bacteria (2-64 μg/ml) in addition to 
potent activity against Gram positive bacteria (<0.06-64 μg/ml). These compounds 
were among the first inhibitors of the ATP binding sites of DNA gyrase and 
topoisomerase IV to demonstrate activity in Gram negative bacteria.92,118,119 Two of 
these compounds, 33 and 34, are shown in Figure 5.1. These compounds were 
developed from a hit compound derived from a crystallographic screening program, 
and several co-crystal structures from various points during the project were 
published. 





Figure 5.1 Representative examples of a series of GyrB/ParE inhibitors published by Trius Ltd 
which demonstrated low µg/ml MICs against Gram negative species. 92,118,119 
 
5.2.2 Compound design 
Based on these compounds a new series of potential GyrB/ ParE inhibitors was 
designed incorporating some features from the previously discussed pyridine-3-
carboxamide series along with features from the Trius compounds giving the general 
structure 115 (Figure 5.2). It was thought that retaining the N-ethyl urea motif and the 
adjacent nitrogen atom of the pyrimidine ring would allow these compounds to form 
the same hydrogen bonding network within the ATP binding sites of GyrB and ParE as 
for compounds from the pyridine-3-carboxamide series. It was hoped that this would 
result in molecules with similar enzyme potency to compounds from the pyridine-
carboxamide series. Furthermore, it was reasoned that incorporating a saturated ring 
system with a primary “anime substituent” at the C4 position of the central pyrimidine 
ring, as seen in the Trius compounds, could increase the ability of these compounds to 
penetrate the membrane of Gram negative cells and thus lead to compounds with 
antimicrobial activity in Gram negative organisms (Figure 5.2). 
 




Figure 5.2. A new series of potential GyrB/ParE inhibitors was designed by combining features 
from the Trius compounds with those from the pyridine carboxamide series. 
 
A small library of compounds corresponding to this designed scaffold was docked into 
the crystal structure of E. coli GyrB using AutoDock, in order to investigate the 
potential for compounds corresponding to this scaffold to act as inhibitors of these 
enzymes. The docking pose generated using AutoDock for compound 116, the lowest 
scoring compounds from this set, is shown in Figure 5.3. The results for the whole 
library are shown in Table 5.1 in order of AutoDock score, along with calculated logPs. 
 
Figure 5.3. Docking pose of compound 116 generated using AutoDock, with the key polar 
contacts to the GyrB enzyme from E. coli (4HXZ)92 indicated. 
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Table 5.1  
 
AutoDock scores and calculated logPs for C4 amino pyrimidine ureas. 































Docking studies carried out using AutoDock
126





Compounds 116 and 118, which contain amino pyrrolidine species similar to those 
seen in the Trius compounds, had the highest AutoDock scores and lowest clogPs. 
Compounds 117, 119 and 120, which also contained protonatable amines, had 
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comparable scores. This supports the idea that compounds of this type with 
protonatable amines could be good inhibitors of the GyrB and ParE enzymes. Slightly 
lower scores were seen in similar species which contained oxygen in the place of 
nitrogen, 121, 122 and 124. Aromatic groups without a hydrogen bond donor, 123 and 
125, also scored relatively poorly.  
The AutoDock scores of these compounds are not as good as the binding scores 
calculated for compounds from the pyridine-3-carboxamide series (Chapter 2, Table 2), 
which would suggest that these compounds may exhibit lower enzyme inhibition, but 
it was hoped that the relative increase in polarity of the compounds in this series will 
lead to an increase in the antimicrobial activity against Gram negative species.  
As the single enantiomers 116 and 118 were both predicted to bind well, it was chosen 
to first synthesise and test a racemic mixture of the two, with the aim of synthesising 
the separate enantiomers if the racemate showed sufficient activity. The amino 
pyrrolidine substituent was chosen as it scored very highly in the docking studies and 
had a substituent which was analogous to an equivalently positioned substituent seen 
in some of the Trius compounds, including 35. Compounds 116 and 118 had a clogP of 
0.94, suggesting that a racemate of these compounds might have improved 
physicochemical properties to enable it to penetrate Gram negative bacteria. 
5.2.3 Synthesis 
A synthetic route was envisioned (Scheme 5.1) from the commercially available 6-
amino-2,4-dichloropyrimidine 126. It was hoped that SNAr reactions could be used to 
insert the substituents at the 2- and 4- positions. Although insertion of the ether linked 
heterocycle at the 2-position to get from 127 to 128 was expected to be challenging, 
there was a precedent in the patent literature for carrying out SNAr reactions using 3-
hydroxypyridine as the nucleophile and 2-chloropyrimidine as the electrophile153. In 
the pyridine carboxamide series, formation of the ethyl urea had been carried out 
successfully by reaction of animopyridines with ethyl isocyanate,124 and it was hoped 
that this reaction could be carried out using aminopyrimidines to afford 129 from 128.  




Scheme 5.1 Retrosynthesis of designed pyrimidine compounds from commercially available 
pyrimidine 126. 
 
Formation of the boc protected aminopyrrolidine 84 from the commercially available 
benzyl protected amino pyrrolidine 82 was previously described in Chapter 2 and is 
shown in Scheme 5.2. 
 
 
Scheme 5.2 Change of protecting groups on 3-aminopyrrolidine 84 to afford compound 86. 
 
The Boc protected pyrrolidine 86 was then used in an SNAr reaction with 6-amino-2,4-
dichloropyrimidine 126 to give compound 130. The reaction occurred in a reasonable 
yield and was selective for the C-4 position of 6-amino-2,4-dichloropyrimidine (Scheme 
5.3). 
 
Scheme 5.3 Substitution of the C-4 position of compound 126 with compound 86 via SNAr to 
afford compound 130. 
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Introduction of the N-ethyl urea moiety at the C-6 position of compound 130 was 
intended to be the next step. Reaction of 6-amino pyridine with ethyl isocyanate had 
been shown previously to be effective124. However, the C-6 amino pyrimidine scaffold 
proved to be insufficiently reactive under the established conditions and none of urea-
substituted compound 131 was formed. The reaction was attempted under microwave 
conditions and in the presence of several different bases and solvents to no effect 
(Scheme 5.4). 
 
Scheme 5.4 Formation of the ethyl urea 131 by reaction of compound 130 with ethyl 
isocyanate failed under a range of experimental conditions. 
 
It was thought that the boc-protected amino pyrrolidine moiety might be causing 
interference in the presence of strong bases, so a simpler variant 132, which had an 
unsubstituted pyrrolidine moiety at the C-4 position was synthesised by reaction of 
compound 126 with pyrrolidine (Scheme 5). Unfortunately, compound 132 failed to 
react with ethylisocyanate to give compound 133 under a range of conditions.  
Scheme 5.5 Synthesis of compound 132, a simpler variant of compound 130 was carried out, 
but the resulting aminopyrimidine 132 did not undergo successful reaction with ethyl 
isocyanate to give compound 133 under the conditions tested. 
 
Reaction of ethyl isocyanate with the unsubstituted 2,4-dichloro-6-aminopyrimidine 
126 was also attempted, but under the reaction conditions oligomerisation of 
compound 126, presumably via SNAr, was observed rather than reaction with 
ethylisocyanate (Scheme 5.6). 
 




Scheme 5.6 Aminopyrimidine 126 underwent oligomerisation under the reaction conditions. 
 
As reaction at the 4-chloro position of compound 126 was interfering with attempts to 
form the desired urea, it was thought that compound 134, a precursor to compound 
126 which lacks chlorine substituents, and so was incapable of undergoing an SNAr 
reaction, might be able to react with ethyl isocyanate under forcing conditions. It was 
reasoned that chlorine could be installed in the 2- and 4- positions later in the route 
via reaction with POCl3. Formation of compound 134 from urea and ethylcyanoacetate 
was carried out in reasonable yield. However, compound 134 was also unreactive 
under the conditions investigated and none of the urea substituted product 135 was 
formed (Scheme 5.7). 
 
Scheme 5.7 Synthesis of compound 134 was carried out by reaction of urea with ethyl 
cyanoacetate, but attempts to form the N-ethyl urea 135 by reaction of compound 134 with 
ethyl isocyanate were unsuccessful. 
 
As none of the aminopyrimidine variants investigated (126, 130, 132 and 134) were 
sufficiently nucleophilic to react with ethylisocyanate, more reactive electrophiles 
were investigated. Reaction of 126 and 134 with carbonyl diimidazole (CDI) was 
attempted to no effect, and reaction of 126 and 132 with phosgene was also tried 
(Scheme 5.8), with none of the desired urea substituted compounds 133, 135 or 136 
were isolated from any of these reactions. 




Scheme 5.8 Attempted formation of N-ethyl urea substituted pyrimidines by reaction of 
compounds 126, 132 and 134 with CDI and phosgene. 
 
As the installation of the urea group had proved to be a challenge it was decided to 
focus instead on alternative compound series.  
5.3 Triazolopyrimidines 
5.3.1 Background 
There have been a large number of published GyrB/ParE inhibitors which feature a 
fused 5,6 heterocycle ring system with N-ethyl urea substituent on the 5-membered 
ring. Examples of these compounds developed by Vertex89, Evotec/Prolysis114, Pfizer113 
and Prolysis/Biota111 are shown in Figure 5.4. These compounds display a range of 
activity levels against the topoisomerase enzymes and against bacteria.  




Figure 5.4 DNA Gyrase and topoisomerase IV inhibitors containing an N-ethyl urea substituted, 
fused-5,6-heterocycle. 
 
AutoDock was used to dock each of the compounds shown in Figure 5.4 to understand 
the binding poses of these molecules. Their predicted binding poses are shown in 
Figure 5.5. The compounds are all predicted to bind in approximately the same 
configuration, making the expected hydrogen bonds to the conserved water molecule 
and aspartate residue and π-stack to the arginine residue. They all form a hydrogen 
bond to Arg-132 and compound 25 forms two. 




Figure 5.5 Predicted binding poses of inhibitors bearing a urea-substituted fused 5,6 
heterocyclic ring to E. coli ParE (4HZ0), generated by AutoDock. A) compound 25, B) compound 
26, C) compound 27, D) compound 28. 
 
5.3.2 Compound design 
It was decided to investigate a heterocycle replacement approach to generate related 
compounds. Substitution of an extra nitrogen into the 6-membered ring of 137 
(analogous to compound 26) to give a triazolopyrimidine core 138 (Scheme 5.9) 
produced compounds which were scored well by AutoDock and had promising clogPs 
(Table 5.2).  
 
Scheme 5.9 A triazolopyrimidine core 138 was chosen to investigate heterocycle replacement. 
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When choosing putative inhibitors to dock, R1 was initially kept as phenyl and a range 
of heterocycles were investigated as R2. For the most active compound from the initial 
docking, R1 was then varied. All the docked compounds are shown in Table 5.2, in 
order of docking score. 
Table 5.2  
 
AutoDock scores and clogPs for triazolopyrimidine compounds. 



































Dockings carried out using AutoDock
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Compound 139 had the best score, but compound 140 was chosen as the first example 
to be synthesised, as the pyridine ring present in the 5-position of the 
triazolopyrimidine core in compound 139 was expected to pose a significantly greater 
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synthetic challenge when compared to the benzene at this position in compound 140 
and the AutoDock scores were fairly similar for both compounds. Both compounds also 
had clogPs close to zero which may increase their chances of being able to penetrate 
Gram negative bacteria, as high polarity is often associated with compounds able to 
cross Gam negative membranes.34 The docking pose for compound 140 is shown in 
Figure 5.6. 
 
Figure 5.6 Docking pose of compound 140 generated using AutoDock. 
 
5.3.3 Synthesis 
Retrosynthetic analysis of the designed molecular scaffold 140 suggested that 
synthesis should be able to proceed from initial formation of the triazolopyrimidine 
ring from ethyl benzoyl acetate 148 and 3,5-diamino-1,2,4-triazole 149 to give 
compound 150154. The ethyl urea could then be inserted by reaction with ethyl 
isocyanate to give compound 151. Chlorination of compound 151 using POCl3 should 
then provide compound 152 which could furnish the final product 140 via nucleophilic 
substitution of an appropriate group at the C5 position (Scheme 5.10). 




Scheme 5.10 Retrosynthetic analysis of designed Triazolopyrimidine compound 143. 
 
As expected, formation of the triazolopyrimidine 153 from ethyl benzoyl acetate 151 
and diaminotriazole 152 was carried out in high yield. However, the subsequent 
reaction with ethyl isocyanate to give compound 154 was unsuccessful (Scheme 5.11).  
 
Scheme 5.11 Formation of the triazolopyrimidine ring to give compound 150 proceeded in 
good yield, but formation of the urea substituted compound 151 by reaction with ethyl 
isocyanate was unsuccessful. 
 
It was hoped that re-ordering the synthetic steps might get around this problem. 
Formation of the urea prior to the cyclisation reaction via reaction of diaminotriazole 
149 with ethyl isocyanate was investigated. At first, the reaction of diaminotriazole 149 
with ethyl isocyanate was attempted using 1.5 equivalents of ethyl isocyanate and 
heating. However, only a bis-substituted product 153 was isolated. Repeating the 
reaction with 0.9 equivalents of ethyl isocyanate and conducting the reaction at room 
temperature, gave a mono-substituted product 154. However, substitution occurred 
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on the ring nitrogen rather than on one of the primary amines (Scheme 5.12) and so 
this approach could not be progressed forward to form the triazolopyrimidine 150.  
 
Scheme 5.12 Reaction of 3,5-diamino-1,2,4-triazole 149 with ethyl isocyanate gave a bis-
substituted product 153 when 1.5 equivalents were used and substitution occurred on the ring 
nitrogen to give compound 154 when 0.9 equivalents of isocyanate were used. 
 
Chlorination of the triazolopyrimidine 150 prior to the reaction with ethyl isocyanate 
to give 155 was attempted. The reaction was low yielding when carried out with 
phosphorus oxychloride as the chlorinating agent, so phenylphosphonic dichloride was 
investigated as an alternative chlorinating agent (Scheme 5.13). However, the yield 
was still very low. The product was highly insoluble which made its purification 
challenging and precluded the use of any of the usual solvents that might be employed 
in the subsequent reaction with ethyl isocyanate. 
 
Scheme 5.13 Chlorination of compound 150 was attempted using two chlorinating agents, but 
the yield was low in both reactions. 
 




A series of GyrB/ ParE inhibitors was reported by Cubist at the Interscience Conference 
on Antimicrobial Agents and Chemotherapy (ICAAC) in 2013 which contained a 
quinazolinone scaffold93,100. An example of these, compound 32 is shown in Figure 5.7. 
Although this series was in the early stages of development, compound 32 showed 
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very promising biological activity, including moderate activity against E. coli. The 
quinazolinone core represents a novel way of providing the desired pattern of 
hydrogen bond donors and acceptors to bind tightly to the enzyme active site. Little 
has been published or patented on this compound series other than the report at 
ICAAC. A crystal structure was reported at ICAAC, but is not available online, so the 
compound was docked into the active site of E. coli ParE using AutoDock, so that its 
binding mode could be visualised. It was given a score of -8.02 by the program. The 
predicted binding pose is given in Figure 5.7. 
     
Figure 5.7 Structure and activity of a quinazolinone inhibitor 32 reported by Cubist at ICAAC in 
2013 (left). And its binding pose in E. coli ParE (4HZ0) as modelled using AutoDock (right). 
 
The binding pose shows that compound 32 is able to form the key interactions which 
have been described previously (hydrogen bonds to a conserved water and an 
aspartate residue and a π-stack to an arginine residue), as well as an additional 
hydrogen bond to another arginine residue near the entrance of the binding pocket. 
5.4.2 Compound design 
An alternative linking group to connect the quinazolinone core to an aromatic group 
capable of forming the desired π-stacking interaction was sought. An amide linkage 
was used in the pyridine carboxamide series, so replacement of the piperidine linker of 
32 with an amide was contemplated which gave the general structure 156 (Scheme 
5.14). Variation of the aromatic group was prioritised for the initial investigation, but 
further derivatives could be substituted at the 7- position of the quinazolinone ring, 
which projects into a solvent exposed area of the binding site analogous to 
substituents at the C4 position in the pyridine carboxamide series. 




Scheme 5.14 Design of a series of compounds with a quinazolinone core analogous to an 
inhibitor series published by Cubist, but with an amide linkage rather than a piperidine linker. 
 
A selection of potential inhibitor structures containing a quinazolinone ring with an 
amide linked aromatic group was docked using AutoDock (Table 5.3). The amide was in 
the reverse conformation compared to the pyridine carboxamide series, as docking of 
a variant with the amide bond the other way around indicated that the compound 
would be unlikely to adopt a binding pose which would make analogous contacts to 
the Cubist compounds (Figure 5.8). 
 
Figure 5.8 Binding pose of quinazolinone compound with reversed amide bond. The docking 
pose is different to that seen for the Cubist compounds. 
 
The compound with the best AutoDock score was 157 and docking indicated that it 
would be able to form the additional hydrogen bond to arginine-132 as well as forming 
the hydrogen bonding network with Aps-69 and the conserved water molecule in the 
active site. The docking poses for compounds 157 and 158 are shown in Figure 5.9. The 
compounds are predicted to bind similarly to the Cubist compounds. An initial library 
of five compounds 158, 161, 162, 163 and 164 were chosen for synthesis as they gave 
a broad sampling of different sized groups and a range of clogPs. 





AutoDock scores and calculated logPs for amino ethyl quinazolinones. 
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Figure 5.9 AutoDock poses for compounds 157 and 158 showing key binding interactions to 
the ATP binding site of E. coli ParE (4HZ0)92. 
 
 




There are a number of published methods for the synthesis of 2-
alkylaminoquinazolinones155, but the most useful in terms of the requirements of this 
synthetic route was a modification of the Ullman reaction, using ethyl guanidine 
sulphate 167 and a 2-chlorobenzoic acid compound, reported by Huang et. al.156 It was 
hoped that this reaction would be compatible with 2-amino-5-chlorobenzoic acid 168 
and allow access to compound 167 which bears an amine substituent at the 5-position 
of the resulting quinazolinone ring, thus allowing access to the desired inhibitor 
structures 156 via an amide coupling reaction (Scheme 5.15). 
 
Scheme 5.15 Retrosynthesis of quinazolinone compounds 156. 
 
2-amino-5-chlorobenzoic acid 168 was commercially available and reaction of this with 
ethyl guanidine sulphate 167 under the conditions described successfully afforded the 
quinazolinone 169156, although the yield was fairly low (16%) (Scheme 5.16). The low 
yield was partly attributed to the presence of the primary amine which likely gave 
challenges to isolation and purification of the product. The reaction was also 
attempted under microwave conditions, but very little of the desired product was 
detected in the crude reaction mixture, and so microwave conditions were not 
investigated further. 
 
Scheme 5.16 Formation of quinazolinone 169 via a copper catalysed reaction between 2-
amino-6-chlorobenzoic acid 168 and ethyl guanidine sulfate 167. 
 
Compound 163 was chosen as the first inhibitor to synthesise in this series. Nicotinic 
acid 170 was reacted with thionyl chloride to afford nicotinyl chloride 171 which was 
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used immediately in a reaction with aminoquinazolinone 169. However, none of the 
desired product 163 could be isolated (Scheme 5.17). 
 
Scheme 5.17 Attempted coupling between 5-aminoquinazolinone compound 169 and nicotinyl 
chloride 171 which was generated immediately prior to the reaction from nicotinic acid 170. 
 
Reordering of the steps, so that the amide coupling reaction was carried out first was 
then attempted. Amide coupling reactions between 2-amino-6-chlorobenzoic acid 168 
and an appropriate acid chloride, which was generated immediately prior to use, 
generally proceeded in moderate to good yield (Scheme 5.18) giving amides 172, 173, 
174, 175 and 176. The cyclisation reaction to generate the quinazolinone ring 
proceeded in generally higher yield following the amide coupling reaction than it had 
done with 2-amino-6-chlorobenzoic acid 168 and successfully furnished the small 
library of compounds 158, 161, 162, 163 and 164 which had been chosen following the 
computational docking studies (Scheme 5.18).  
 
Scheme 5.18 Formation of a small library of compounds via an amide coupling reaction 
followed by cyclisation with ethyl guanidine sulfate 167 to give quinazolinones 158, 161, 162, 
163 and 164. 
 
Synthesis of 157, a derivative with an acidic group in the position predicted to mimic 
that within the Cubist compound 32, was also attempted. Initially, 
monomethylterephthalate 177 was chosen as the starting material. This was coupled 
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to 2-amino-6-chlorobenzoic 168 acid using T3P as an amide coupling reagent rather 
than forming an acid chloride. This was based upon the expectation that reaction of 
compound 177 with thionyl chloride would not be selective for the carboxylic acid and 
there would also be reaction with the methyl ester. This reaction proceeded in 
moderate yield to give compound 178. However, the Ullman-like reaction with ethyl 
guanidine sulfate 167 which followed did not afford a sufficient quantity of compound 
179 to allow full characterisation, although its formation was confirmed using LC-MS. 
Therefore, hydrolysis of the ester 179 to give compound 157 could not be attempted 
(Scheme 5.1). 
 
Scheme 5.19 Amide coupling between monomethyl terephthalate 177 and 2-amino-6-
chlorobenzoic acid 168 gave compound 178. However, formation of the quinazolinone ring to 
give compound 179 was unsuccessful and ester hydrolysis to afford compound 157 could not 
be attempted. 
 
An alternative route to this product was envisioned wherein the final step would 
involve hydrolysis of a nitrile group rather than an ester. However, the synthesis of the 
desired amide precursor proved challenging. Formation of an acid chloride from 4-
cyanobenzoic acid 180 followed by reaction with 2-amino-6-chlorobenzoic acid 168 
was attempted as these conditions had been used successfully with other derivatives 
(Scheme 5.18). However, the reaction gave a mixture of products with very little of the 
desired amide 181 present (Scheme 5.20) and it was decided to focus efforts on a 
different route to the desired compound. 




Scheme 5.20 Attempted formation of nitrile substituted compound 181 gave a mixture of 
products. 
 
Finally, oxidation of an aldehyde was considered as a method for accessing the desired 
carboxylic acid functionality. Reaction of 4-formyl benzoic acid 182 with 2-amino-6-
chlorobenzoic acid 168 was carried out successfully to give compound 183. However, 
the subsequent Ullman-type reaction to generate the quinazolinone intermediate 184 
was unsuccessful, and therefore oxidation of 184 to give the desired carboxylic acid 
substituted derivative 157 could not be carried out. 
 
Scheme 5.21 Amide coupling between 4-formylbenzoic acid 182 and 2-amino-6-chlorobenzoic 
acid 168 via an acid chloride intermediate gave compound 183. However, formation of the 
quinazolinone ring to give compound 184 was unsuccessful and oxidation to afford compound 
157 could not be attempted. 
 
No further attempts to form the carboxylic acid derivative were made. 
5.4.4 Biological evaluation of initial compound library 
The results from the biological evaluation of compounds 158, 161, 162, 163 and 164 
are shown in Table 5.4. These compounds were assessed for their enzyme inhibition 
using an ATPase assay against the E. coli DNA gyrase enzyme and for antibacterial 
activity against S. aureus and E. coli. 
These compounds all showed activity against the enzyme in the low µM range, with 
the exception of 161, which suggests that either the quinoline ring system does not fit 
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well into the ATP binding site of GyrB, or the presence of the nitrogen atom in the ring 
favours a different conformation of the inhibitor which doesn’t bind as efficiently. The 
most potent inhibitors were 163 and 164 which possess a simple six membered ring. 
This suggests further optimisation should focus on substituted phenyl and pyridyl rings 
at this position. Unfortunately, none of these compounds showed antibacterial activity 
against S. aureus or E. coli. This may be due to their low aqueous solubility. The 
addition of solubilising groups may provide compounds with antibacterial activity. 
Table 5.4 
 
Biological activity of substituted quinazolinones 











4.52 20 >256 >256 
161 
 
3.42 900 >256 >256 
162 
 
4.37 33 >256 >256 
163 
 
1.66 3.3 >256 >256 
164 
 
2.87 1.1 >256 >256 
a. clogP calculated using the calculator plugins from MarvinSketch
128
; S. aureus SH1000 and E. coli 
BW25113 
 
5.4.5 Efforts towards the synthesis of quinazolinone derivatives with 
improved solubility 
Morpholine rings are commonly used in medicinal chemistry as solubilising groups and 
it was decided to attempt the synthesis of a quinazolinone derivative containing a 
morpholine substituent at the 7- position of the quinazolinone ring 180. Docking of this 
derivative into the ParE binding site indicated that the morpholine ring would be 
positioned in the solvent-exposed portion of the binding site and should not disrupt 
the hydrogen bonding interactions formed by the rest of the molecule to the protein 
(Figure 5.10). 




Figure 5.10 Predicted binding pose of compound 180 bound to E. coli ParE generated using 
AutoDock. 
 
A retrosynthetic analysis of compound 180 was performed. Amide coupling would be a 
potential final step in this synthesis after reduction of a nitro group in intermediate 
181. The Ullman-type reaction to generate the quinazolinone ring would precede this 
step from bromo-substituted compound 182. The morpholine ring would be installed 
relatively early in the route via an SNAr reaction from the dibromo compound 183 
which could be formed by the bromination of the commercially available compound 
184 (Scheme 5.22). 
 
Scheme 5.22 Retrosynthetic analysis of morpholine substituted compound 180 from the 
commercially available 2-nitrobenzoic acid 184 in five steps. 
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Unfortunately, compound 184 failed to undergo bromination under standard 
bromination conditions, most likely due to the electron poor nature of the ring 
(Scheme 5.23). 
 
Scheme 5.23 Attempted bromination of compound 184 under standard conditions did not 
produce the desired compound 183. 
 
Bromination of a more electron-rich phenolic variant of compound 184 had been 
reported in the literature and so the phenolic variant 185 was produced using an SNAr 
reaction from the chloro-substituted variant 186 and brominated under standard 
conditions to give compound 187 (Scheme 5.24).157 Reaction of compound 187 with 
morpholine was attempted, but the substitution was unsuccessful under acid catalysed 
and base catalysed conditions investigated, and no formation of compound 188 was 
detected. 
 
Scheme 5.24 The dibromo-substituted compound 187 was produced in two steps from 186. 
However, reaction of compound 187 with morpholine to give compound 188 was unsuccessful 
under the conditions investigated. 
 
Due to time constraints, this avenue of investigation was not pursued any further. 
5.5 Conclusions and future work 
Three novel inhibitor scaffolds were designed and attempts were made to synthesise 
all three. The pyrimidine and triazolopyrimidine scaffolds proved to be synthetically 
intractable, but an exploratory library of quinazolinones were produced and 
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biologically assessed. Several of the synthesised compounds showed promising 
enzyme activity, but the compounds were not antibacterial at low concentrations and 
were insoluble at higher concentrations.  
Several synthetic routes to compound 157, which was predicted to have the best 
binding of the designed quinazolinone compounds, were investigated, but none were 
successful. Further optimisation of the Ullman-like quinazolinone ring forming reaction 
may facilitate the production of compound 157, as this step was low yielding and in 
several cases did not produce enough material for isolation and characterisation. 
Variants of the quinazolinone compounds bearing a solubilising group were designed, 
but there was not time to fully investigate synthetic approaches to these compounds. 
Further investigation of this synthetic route could furnish quinazolinone compounds 
with improved properties. 




Chapter 6 Conclusions and Future Work 
This project was broadly divided into two sections. Firstly, further exploration of the 
pyridine 3-carboxamide inhibitors which had been previously discovered at the 
University of Leeds and, secondly, efforts to identify a novel series of DNA gyrase and 
topoisomerase IV inhibitors. 
6.1 Development of Pyridine-3-carboxamides as inhibitors of DNA 
gyrase and topoisomerase IV 
6.1.1 Summary 
A library of pyridine 3-carboxamide derivatives were synthesised and assessed for their 
biological activity. All of the synthesised inhibitors had IC50s of ≤210 nM against E. coli 
DNA gyrase. Several compounds showed antibacterial activity against S. aureus, but 
none were active against E. coli. The structures of some representative DNA gyrase 
inhibitors are shown in Figure 6.1 along with their biological activities. These 
compounds are highly potent inhibitors of DNA gyrase and topoisomerase IV, but their 
antibacterial activities were not as good as might be hoped for such potent enzyme 
inhibitors. This suggests that the physicochemical properties of these compounds 
might be reducing their ability to reach a sufficiently high concentration within the 
bacterial cell. Alternatively, the lower activity of these compounds against the 
topoisomerase IV enzyme from E. coli relative to the same enzyme from S. aureus may 
be a factor in the different activities of the compounds against the different bacterial 
strains. 




Figure 6.1 Structures of some representative pyridine 3-carboxamide compounds which 
exhibit potent inhibition of DNA gyrase and topoisomerase IV. 
 
Four compounds were assessed for a number of in vitro ADME properties. Three of 
which were synthesised as part of this project, and one which was produced originally 
as part of previous work at the University of Leeds and which was resynthesised for 
this project. The compounds produced for this project generally had more favourable 
in vitro ADME properties than the compound which was designed prior to the 
commencement of the project. Two of the compounds had low aqueous solubility, but 
the other two were moderately soluble. The compound with the lowest aqueous 
solubility had very high levels of plasma protein binding and performed very poorly in 
the Caco-2 membrane permeability assay. The other compounds performed better in 
the Caco-2 assay, but the compounds were not predicted to have a very strong ability 
to be taken up from the gut. The metabolic stability of these compounds was assessed 
using a liver microsome assay. They displayed moderate metabolic stability, but would 
benefit from increased stability going forward. Unfortunately, the compound with the 
most favourable ADME profile was the compound with the least potent antibacterial 
activity. 
In order to assess the binding mode of these compounds and also to confirm that they 
definitely bind to the ATP site of DNA gyrase, crystallography experiments were carried 
out. The 24 kDa construct of GyrB which is often used for crystallographic experiments 
in the presence of inhibitors was produced and crystallisation experiments produced 
crystals with all four inhibitors which were selected for this study. The crystals 
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diffracted well and all showed electron density corresponding to the inhibitor they 
were crystallised with. The structures were solved using molecular replacement to a 
good resolution.  
The hydrogen bond contacts which had been predicted using computational docking 
were all shown to be in the expected configuration. The configuration of the 
substituent at the C-4 position of the central pyridine ring was not as closely matched 
to the poses predicted by computational docking, but this was not unexpected as this 
region of the protein is flexible when ATP is not bound. The residues in the flexible 
loop are usually disordered in crystal structures. This makes computational docking 
less able to predict interactions in this region of the biding site. 
 
6.1.2 Future work 
The results from the in vitro ADME profiling of these compounds and from the 
crystallographic experiments suggest a number of additional avenues to explore. 
Improvements in the metabolic stability of these compounds would be highly 
beneficial, so the addition of functional groups known to increase metabolic stability, 
such as fluorine of trifluoromethane, should be investigated.  
Synthesis of the pyrrole and imidazole derivatives which was not completed during this 
project should be carried out, along with other similar derivatives in order to explore a 
range of compounds with very similar shapes, but different polarities. Assessment of 
the biological activities of these compounds will help in understanding the relationship 
between hydrophilicity and antibacterial activity in this series. A wider range of 
derivatives bearing primary amines, and derivatives bearing carboxylic acid groups 
should be produced in order to further understand the effects of charged groups. 
Additional antibacterial screening against a wider range of Gram negative and Gram 
positive bacterial species, in particular the ESKAPE pathogens (E. faecium, S. aureus, K. 
pneumoniae, A. baumannii, P. aeruginosa, and Enterobacter species) which are the 
most clinically relevant strains158, should be carried out. It would also be of interest to 
determine the activity of these compounds against strains of Gram negative bacteria 
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which have impaired efflux pumps in order to determine the degree to which these 
compounds lack activity against these species due to active efflux. 
Compounds bearing aniline substituents have a high propensity to be mutagenic when 
tested in vivo. The Ames test is an in vitro model for mutagenicity. At least one 
member of the series which contains an aniline substituent should be subjected to the 
Ames test in order to establish whether the aniline is likely to pose a mutagenic risk, 
and if so, further investigation of derivatives with an aniline substituent should be 
avoided. 
Co-crystal structures are very useful to guide design of compound structures. It would 
be useful to compare the binding of inhibitors into the ATP site of ParE with their 
binding mode in GyrB. Therefore production of the 24 kDa subunit of ParE should be 
carried out in order to compare the binding poses of these compounds in both 
proteins.  
6.2 Design of novel chemical series as inhibitors of DNA Gyrase and 
Topoisomerase IV 
6.2.1 Summary 
De novo design using SPROUT was carried out with the aim of designing novel inhibitor 
scaffolds with an appropriate acceptor/donor motif to form hydrogen bonds to the 
conserved water molecule and aspartate residue in the ATP binding site of the DNA 
gyrase and topoisomerase IV enzymes. However, in the searches which were carried 
out, SPROUT did not find solutions which linked the hydrogen bond donor and 
acceptor groups in a configuration which would allow them to form the desired 
interactions, and the designed scaffolds were too complex to be synthetically 
tractable. 
Two vHTS approaches were used to search commercial databases for potential 
inhibitors of the DNA gyrase and topoisomerase IV enzymes. Glide was used to carry 
out structure based vHTS screening of the ZINC database using GyrB (3G7E) and ParE 
(4HZ0) crystal structures. ROCS was used to carry out ligand based vHTS screening 
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using a diverse selection of known DNA gyrase and topoisomerase IV inhibitors as 
queries. A pharmacophore model was also generated using vROCS and used as the 
query for a further ROCS search. The hits from all of the vHTS searches were visually 
assessed and a shortlist of potential inhibitors generated. This shortlist comprised 
compounds from a number of suppliers, and the compounds which were available 
from ChemBridge were purchased and assayed for their inhibition of DNA gyrase. Two 
of the compounds displayed some activity at a concentration of 100 µM, but this was 
not considered sufficient to be worth investigating the SAR of these compounds. 
Rational design was also carried out. A scaffold hopping approach was used to design 
analogues of known inhibitor series. Pyrimidines 129, triazolopyrimidines 138, and 
quinazolinones 156 were designed which were predicted to form binding interactions 
with the GyrB and ParE ATP binding sites and synthesis was carried out towards the 
production of these compounds.  
 
The quinazolinone compounds proved to be the most synthetically tractable and a 
small library of compounds was produced and the compounds assessed for their 
inhibition of the DNA gyrase enzyme. The most potent compound had an IC50 of 1.1 
µM, but none of the compounds displayed antibacterial activity against E. coli or S. 
aureus. The compounds which had been synthesised had very low aqueous solubility, 
so a variant was designed with a morpholine substituent in the hope it would 
demonstrate improved solubility, but only a preliminary effort towards its synthesis 
was carried out. 
6.2.2 Future work 
The shortlisted hits from the vHTS studies were available from a number of different 
suppliers and only those available from ChemBridge were purchased and biologically 
assessed. The purchase of a wider selection of molecules would allow a better 
assessment of the effectiveness of the different vHTS approaches used and provide 
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additional opportunities to identify a hit molecule with sufficient activity against the 
DNA gyrase and topoisomerase IV enzymes to be worth carrying out an SAR study. 
The pyrimidine and triazolopyrimidine compounds which were designed proved to be 
synthetically intractable. The design of variants of these compounds with improved 
synthetic tractability might prove to be a source of potent inhibitors. 
Only a few examples of the quinazolinone inhibitor series were synthesised. The 
copper catalysed, Ullman-like reaction used to form the quinazolinone ring was low 
yielding and posed a challenge to the production of a number of derivatives. 
Optimisation of this reaction or the identification of an alternative route to this 
scaffold would likely enable the production of a larger library of quinazolinones in 
order to establish more of the SAR of these compounds. 
The quinazolinone inhibitors synthesised to date have had insufficient aqueous 
solubility for the successful formation of an inhibitor-protein co-crystal for X-ray 
crystallography. The synthesis of derivatives with improved aqueous solubility would 
facilitate the acquisition of an X-ray crystal structure of a quinazolinone inhibitor 
bound in the ATP binding site of GyrB or ParE. The acquisition of a crystal structure 
would guide further optimisation of these inhibitors. 
Chapter 7  Experimental 
133 
 
Chapter 7 Experimental 
7.1 Chemical methods 
7.1.1 Instrumentation and General Methods 
All reagents were obtained commercially and used directly without further 
purification. Petrol refers to petroleum ether (bp. 40-60 °C). Solvents were removed 
under reduced pressure using an aspirator pump connected to a Buchi rotary 
evaporator; this was followed by drying under high vacuum at 0.5 mmHg using a rotary 
oil pump.  Flash chromatography was performed using geduran silica gel 60 (particle 
size 40-63 μm) supplied by Merck. Thin layer chromatography (TLC) was performed 
using aluminium precoated silica plates (MacheryNagek 818133, 0.20 mm thickness) 
supplied by Merck. Infrared (IR) spectra were recorded on a Perkin Elmer Spectrum 
One FTIR spectrometer or on a Bruker Alpha Platinum ATR, as solid samples unless 
stated. Vibrational frequencies are reported in wavenumbers (cm-1). Melting point 
determination was carried out on a Reichert Hot Stage apparatus and are reported 
uncorrected. Highresolution mass spectrometry was carried out using a Bruker MaXis 
Impact Time of Flight spectrometer using ESI. Elemental analysis was carried out using 
a Carlo Erba 1108 Elemental Analyzer. HPLC analyses were carried out on a Dionex 
HPLC system using a Thermo Electron Corporation Hyperprep HS C18 column (8 µm, 
250 × 4.6 mm) and a diode array as a detector. A gradient of water and acetonitrile (5-
95%) was used as solvent at a flow rate of 1 ml/min for 40 mins. 1H and 13C NMR 
spectra are recorded on a 300 / 75 MHz Bruker DPX300 spectrometer, a 400 / 100 MHz 
Bruker AV3-400  spectrometer or a 500 / 125 MHz Bruker Advance 500 spectrometer 
as indicated, using an internal deuterium lock. Chemical shifts were recorded with 
reference to tetramethylsilane (TMS) as an internal standard. Coupling constants are 
given in Hertz (Hz). Proton and carbon assignment has been carried out based on 
HMBC and HMQC spectra analysis where appropriate.  
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7.1.2 General Methods 
The general methods described below exemplify frequently performed reactions. The 
molarities are representative of a specific example and where referenced are scaled 
accordingly. 
General method A – Acid catalysed nucleophilic aromatic substitution 
The appropriate aryl chloride (40 mg, 0.13 mmol, 1.0 eq) and amine (19 mg, 0.13 
mmol, 1.0 eq) were dissolved in EtOH (2 ml) and cHCl (1 drop) was added. The 
resulting solution was heated to 80 °C overnight and then cooled to 0 °C and basified 
to pH 4 by careful addition of aqueous NaOH (2M). The resulting precipitate was 
collected using filtration and purified as specified. 
General method B – Base catalysed nucleophilic aromatic substitution 
The appropriate heterocycle (55 mg, 0.38 mmol, 1.2 eq) was dissolved in DMF (2 ml) 
and cooled to 0 °C. NaH (60% suspension in oil, 19 mg, 0.47 mmol, 1.5 eq) was added 
portion wise and the mixture stirred for 1 h under N2. The appropriate aryl chloride 
(100 mg, 0.31 mmol, 1.0 eq) was added and the reaction mixture heated to 70 °C for 
18 h. The reaction mixture was allowed to cool to room temperature, quenched by 
addition of water (10 ml) and purified as specified. 
General method C – amide coupling using T3P 
The appropriate carboxylic acid (100 mg, 0.41 mmol, 1.0 eq) and amine (85 mg, 0.91 
mmol, 2.2 eq) were suspended in pyridine (5 ml) and T3P solution (50% in EtOAc, 0.50 
ml, 0.82 mmol, 1.2 eq) added. The reaction was stirred for 18 hours and the 
concentration reduced in vacuo. Water (5 ml) was added and the reaction stirred for 
15 minutes. The resultant precipitate was collected by filtration and purified as 
specified. 
General method D – amide coupling via an acid chloride intermediate 
The appropriate carboxylic acid (1.44 g, 11.7 mmol, 2.00 eq) was suspended in thionyl 
chloride (10 ml). The reaction mixture was heated to 70 °C until the carboxylic acid was 
no longer detected by TLC. Thionyl chloride was removed in vacuo and the appropriate 
amine (1 g, 5.84 mmol, 1.00 eq) and pyridine (5 ml) added and the reaction heated to 
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80 °C for 16 hours. The pyridine was removed in vacuo and the resulting residue 
acidified by addition of HCl (2 M, 20 ml) and extracted into EtOAc (3 x 20 ml). The 
combined organics were dried over MgSO4 and concentrated in vacuo. The resulting 
residue was purified as specified. 
General method E – quinazolinone formation 
The appropriate 2-chlorobenzoic acid (200 mg, 0.727 mmol, 1.00 eq), ethyl guanidine 
sulfate (396 mg, 1.45 mmol, 2.00 eq) and caesium carbonate (145 mg, 2.91 mmol, 4.00 
eq) were suspended in DMF (4 ml) under nitrogen and stirred for 5 minutes. Copper 
iodide (28.0 mg, 0.147 mmol, 0.200 eq) was added and the reaction heated to reflux 
for the specified time. The reaction was allowed to cool and filtered through celite. The 
filtrate was concentrated in vacuo and purified as specified. 
 
7.1.3 Preparative procedures 
Ethyl 4,6-dihydroxynicotinate123 44 
Diethyl 1,3-acetonedicarboxylate (6.5 ml, 29 mmol) was dissolved 
in acetic anhydride (5.5 ml, 61 mmol) and trimethylorthoformate 
(8.6 ml, 43 mmol) added. The resulting colourless mixture was 
heated to 120 °C for 3 hours during which time the solution developed an orange 
colour. The reaction mixture was allowed to cool to room temperature and excess 
acetic acid removed in vacuo. The resulting dark orange liquid was cooled to 0 °C and 
aqueous NH3 (33% solution, 5.3 ml) added dropwise over half an hour. A yellow 
precipitate formed. The resulting mixture was acidified to pH1 by addition of cHCl and 
the resulting off-white precipitate collected by filtration to afford the title compound 
(5.2 g, 28 mmol, 96%) as colourless microcrystals, m.p. 215.9-218.4 °C (from EtOH-
water, lit.123 m.p. 200-204 °C); Rf 0.34 (EtOAc); δH (300 MHz, DMSO-d6) 13.35 (br. s., 1 
H, 4-OH), 10.95 (br. s., 1 H, 6-OH), 8.21 (s, 1 H, 2-H), 5.95 (s, 1 H, 5-H), 4.38 (q, J 7.1 Hz, 
2 H, 3-CO2CH2CH3), 1.38 (t, J 7.1 Hz, 3 H, CO2CH2CH3); C (75 MHz, DMSO-d6) 168.2 (3-
CO2CH2CH3), 168.0 (6-C), 167.2 (4-C), 141.4 (2-C), 100.8 (5-C), 99.7 (3-C), 61.9 (3-
CO2CH2CH3), 14.1 (3-CO2CH2CH3); (Found C, 52.6; H, 4.90; N, 7.5; C8H7NO4 requires C, 
52.5; H, 4.95; N, 7.7%); νmax / cm
-1 (solid) 2671, 1662, 1573, 1403; m/z (ESI+) found MH+ 
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184.0605, C8H10NO4 MH requires 184.0604; HPLC = 1.30 mins. Spectroscopic data 
consistent with literature values.123 
 
Ethyl 4,6-dichloronicotinate123 45 
Compound 44 (5.0 g, 27 mmol) was suspended in POCl3 (25 ml) and 
the reaction heated to 80 °C for 18 hours. A further portion of POCl3 
was then added and the reaction mixture stirred at 80 °C for a 
further 4 hours. The reaction was allowed to cool and the volume reduced in vacuo 
and the resulting brown oil added carefully to a mixture of ice and water and allowed 
to warm to room temperature. The aqueous portion was extracted into DCM (6 × 20 
ml), the combined organic extracts were then washed with brine (30 ml), dried over 
MgSO4 and concentrated in vacuo to give a brown oil. Purification of this oil using 
column chromatography (1:15 EtOAcPetrol) afforded the title compound (3.4 g, 15 
mmol, 57%) as colourless crystals, m.p. 31.1-31.3 °C; Rf 0.68 (1:9 EtOAcPet); δH (300 
MHz, DMSO-d6) 8.85 (s, 1 H, 2-H), 7.47 (s, 1 H, 5-H), 4.44 (q, J 7.0 Hz, 2 H, 3-
CO2CH2CH3), 1.42 (t, 3 H, J 7.0 Hz, 3-CO2CH2CH3); C (75 MHz, DMSO-d6) 163.1 (3-
CO2CH2CH3), 154.6 (6-C), 152.3 (2-C), 145.9 (4-C), 126.0 (5-C), 124.9 (3-C), 62.2 (3-
CO2CH2CH3), 14.2 (3-CO2CH2CH3); (Found C, 43.8; H, 3.15; N, 6.3; C8H7Cl2NO2 requires 
C, 43.7; H, 3.20; N, 6.4%); νmax / cm
-1 (solid) 3091, 2977, 1732, 1570, 1538, 1448; m/z 
(ESI+) found MH+ 219.9924, C8H8Cl2NO2 MH requires 219.9927; HPLC RT = 3.05 mins. 
Spectroscopic data consistent with literature values.123 
 
4-chloro-6-[(ethylcarbamoyl)amino]pyridine-3-carboxylate123 46 
Palladium (II) acetate (203 mg, 0.908 mmol) was added to a 
solution of xantphos (653 mg, 1.14 mmol) in degassed, 
anhydrous 1,4-dioxane (20.0 ml) at room temperature. The 
mixture was stirred under nitrogen for 1 hour and treated with compound 45 (1.00 g, 
4.54 mmol), N-ethylurea (359 mg, 4.08 mmol), potassium tert-butoxide (763 mg, 6.81 
mmol) and degassed water (0.6 ml, 6.8 mmol). The mixture was heated under nitrogen 
to 80 °C for 2 hours and then cooled to room temperature, diluted with water (15 ml) 
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and extracted with EtOAc (3 × 20 ml). The combined organic extracts were then 
washed with brine (15 ml), dried with MgSO4 and concentrated in vacuo to give the 
crude product as an orange solid. Purification of this solid using column 
chromatography (1:2 EtOAcPetrol) afforded the title compound (460 mg, 1.69 mmol, 
41%) as colourless crystals, m.p. 163.8-164.3 °C; Rf 0.29 (1:2 EtOAcPetrol); δH (300 
MHz, CDCl3) 9.02 (br. s., 1 H, 6-NHCONHCH2CH3), 8.77 (s, 1 H, 5-H), 8.39 (s, 1 H 6-
NHCONHCH2CH3), 6.88 (s, 1 H, 2-H), 4.40 (q, J 7.2 Hz, 2 H, 3-CO2CH2CH3), 3.43 (qd, J 7.1, 
5.5 Hz, 2 H, 6-NHCONHCH2CH3), 1.41 (t, J 7.2 Hz, 3 H, 3-CO2CH2CH3), 1.26 (t, J 7.3 Hz, 3 
H, 6-NHCONHCH2CH3); δC (75 MHz, CDCl3) 163.6 (3-CO2CH2CH3), 156.1 (6-
NHCONHCH2CH3), 155.7 (2-C), 150.9 (6-C), 145.5 (4-C), 118.4 (5-C), 113.3 (3-C), 61.5 (3-
CO2CH2CH3), 34.9 (6-NHCONHCH2CH3), 15.2 (6-NHCONHCH2CH3), 14.2 (3-CO2CH2CH3); 
(Found C, 48.9; H, 5.00; N, 14.7; C11H14ClN3O3 requires C, 48.6; H, 5.19; N, 15.5%); νmax 
/ cm-1 (solid) 1688, 1549; m/z (ESI+) found MH+ 272.0789, C11H15ClN3O3 MH requires 




General method A using compound 46 (100 mg, 0.368 
mmols) and 2-aminophenol (36 mg, 0.331 mmol). The 
reaction mixture was concentrated in vacuo to afford a 
yellow oil. Purification using column chromatography 
(EtOAcPetrolNEt3 1:1:0.001) afforded the title compound (54 mg, 0.16 mmol, 47%) 
as colourless microcrystals, m.p. 227.3-224.7 °C (from EtOH); Rf 0.48 (3:1 
EtOAcPetrol); H (300MHz, DMSO-d6) 9.54 (s, 1 H, 6-NHCONHCH2CH3), 9.35 (s, 1 H, 
OH), 9.06 (s, 1 H, 4-NH), 8.56 (s, 1 H, 2-H), 7.73 (br. s., 1 H, 6-NHCONHCH2CH3), 7.07 (d, 
J 8.6 Hz, 2 H, 4-phenyl 2-H), 6.95 (s, 1 H, 5-H), 6.81 (d, J 8.6 Hz, 2 H, 4-phenyl 3-H), 4.29 
(q, J 7.1 Hz, 2 H, 3-CO2CH2CH3), 3.10 (qd, J 7.2, 5.8 Hz, 2 H, 6-NHCONHCH2CH3), 1.32 (t, 
J 7.1 Hz, 3 H, 3-CO2CH2CH3), 1.03 (t, J 7.2 Hz, 3 H, 6-NHCONHCH2CH3); δC (75 MHz, 
DMSO-d6) 166.9 (3-CO2CH2CH3), 160.5 (6-NHCONHCH2CH3), 155.3 (4-phenyl 4-C), 154.5 
(6-C or 4-C), 154.1 (6-C or 4-C), 151.7 (2-C), 129.1 (4-phenyl 1-C), 126.3 (2-phenyl 2-C), 
116.0 (4-phenyl 3-C), 102.6 (3-C), 90.9 (5-C), 60.3 (3-CO2CH2CH3), 33.7 (6-
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NHCONHCH2CH3), 15.2 (6-NHCONHCH2CH3), 14.1 (3-CO2CH2CH3); νmax / cm
-1 (solid) 
2973, 1687, 1562, 1513, 1487; m/z (ESI+) found MH+ 345.1562, C17H20N4O4 MH requires 
345.1557; HPLC RT = 2.62 min. 
 
6-[(ethylcarbamoyl)amino]-4-[(4-hydroxyphenyl)amino]pyridine-3-carboxylic acid 48 
Compound 47 (100 mg, 0.291 mmol) was dissolved in THF (3 
ml) and NaOH(aq) (2 M, 3 ml) was added. The reaction mixture 
was heated to 90 °C for 18 hours. The reaction was allowed to 
cool to room temperature and then THF was removed in 
vacuo. The resulting aqueous solution was acidified to pH4 by the dropwise addition of 
HCl (2 M). The resulting precipitate was collected by filtration to afford the title 
compound (86 mg, 0.27 mmol, 93%) as off-white microcrystals, m.p. > 250 °C; Rf 0.13 
(1:9 MeOHEtOAc); H (300 MHz, DMSO-d6) 12.82 (br. s., 1 H, 3-CO2H), 9.57-9.90 (m, 2 
H, 2 × NH or NH and OH), 9.19 (br. s., 1 H, NH or OH), 8.51 (s, 1 H, 2-H), 7.91 (br. s., 1 H, 
6-NHCONHCH2CH3), 7.06 (d, J 8.8 Hz, 2 H, 4-phenyl 2-H), 6.93 (s, 1 H, 5-H), 6.83 (d, J 8.8 
Hz, 2 H, 4-phenyl 3-H), 3.10 (qd, J 7.1, 6.0 Hz, 2 H, 6-NHCONHCH2CH3), 1.03 (t, J 7.1 Hz, 
3 H, 6-NHCONHCH2CH3); δC (75 MHz, DMSO-d6) 169.1 (3-CO2H), 155.3 (6-C), 154.8 (4-
phenyl 4-C), 154.3 (6-NHCONHCH2CH3), 151.4 (2-C), 129.2 (4-phenyl 1-C), 126.3 (4-C), 
126.0 (4-phenyl 2-C), 116.0 (4-phenyl 3-C), 104.1 (3-C), 90.7 (5-C), 33.7 (6-
NHCONHCH2CH3), 15.25 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 3135, 1661, 1597, 
1554, 1519; m /z (ESI+) found MH+ 317.1230, C15H17N4O4 MH requires 317.1244; HPLC 




Compound 48 (60 mg, 0.18 mmol) was dissolved in DMF 
and HOBt.H2O (35 mg, 0.29 mmol) and EDC (54 mg, 0.29 
mmol) were added. The resulting mixture was stirred for 
30 minutes and then 3-aminopyridine (20 mg, 0.21 mmol) 
was added. The reaction was stirred at room temperature for 16 hours and then 
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heated to 40 °C for 1 hour before being cooled to room temperature, diluted with 
water (10 ml) and extracted into EtOAc (3 × 10 ml). The combined organic extracts 
were washed with NaHCO3 (10 ml), water (10 ml) and brine (10 ml), dried over MgSO4 
and concentrated in vacuo to give an orange oil. Purification of this oil using column 
chromatography (1:9 MeOH‒EtOAc) afforded a pale yellow oil. Recrystallisation from 
MeOH afforded the title compound (9.4 mg, 0.024 mmol, 13%) as colourless crystals, 
m.p. 110.1-114.4 °C (from MeOH); Rf 0.45 (EtOAc); H (300 MHz, MeOD) 8.85-8.90 (m, 
1 H, 3-pyridiyl 2-H), 8.53 (s, 1 H, 2-H), 8.29 (d, J 4.9, 1 H, 3-pyridyl 6-H), 8.22 (d, J 8.5, 1 
H, 3-pyridyl 4-H), 7.42 (dd, J 8.1, 4.5 Hz, 1 H, 3-pyridyl 5-H), 7.08 (d, J 8.8 Hz, 2 H, 4-
phenyl 2-H), 6.85 (d, J 8.8 Hz, 2 H, 4-phenyl 3-H), 6.55 (s, 1 H, 5-H), 3.28 (q, J 6.9 Hz, 3 
H, 6-NHCONHCH2CH3), 1.18 (t, J 7.3 Hz, 3 H, 6-NHCONHCH2CH3); c (125 MHz, DMSO-
d6) 166.9 (3-CONH), 155.8 (4-phenyl 4-C), 154.9 (4-C, 6-C or 6-NHCONHCH2CH3), 154.2 
(4-C, 6-C or 6-NHCONHCH2CH3), 153.8 (4-C, 6-C or 6-NHCONHCH2CH3), 149.0 (2-C), 
144.5 (3-pyridyl 6-C), 142.3 (3-pyridyl 2-C), 135.5 (3-pyridyl 3-C), 129.5 (4-phenyl 1-C), 
127.7 (3-pyridyl 4-C), 125.7 (4-phenyl 2-C), 123.5 (3-pyridyl 5-C), 115.9 (4-phenyl 3-C), 
106.9 (3-C), 91.2 (5-C), 33.7 (6-NHCONHCH2CH3), 15.3 (6-NHCONHCH2CH3); νmax / cm
-1 
(solid) 3324, 2963, 2854, 1638, 1560, 1488; m/z (ESI+) found MH+ 393.1668, C20H21N6O3 




General method A using compound 46 (250 mg, 0.919 
mmols) and 3-aminophenol (100 mg, 0.919 mmol) afforded 
the title compound (184 mg, 0.534 mmol, 58%) as colourless 
crystals, m.p. 185.1-188.7 °C; Rf 0.45 (3:1 EtOAcPetrol); δH 
(300 MHz, DMSO-d6) 9.64 (s, 1 H, 6-NHCONHCH2CH3), 9.56 (s, 1 H, 4-NH), 9.19 (br. s., 1 
H, OH), 8.60 (s, 1 H, 2-H), 7.75 (br. s., 1 H, 6-NHCONHCH2CH3), 7.27 (s, 1 H, 4-phenyl 2-
H), 7.21 (t, J 8.0 Hz, 1 H, 4-phenyl 5-H), 6.71 (d, J 7.7 Hz, 1 H, 4-phenyl 6-H), 6.66 (s, 1 H, 
5-H), 6.62 (d, J 8.2 Hz, 1 H, 4-phenyl 4-H), 4.30 (q, J 7.1 Hz, 2 H, 3-CO2CH2CH3), 3.12 (dq, 
J 7.3, 6.0 Hz, 2 H, 6-NHCONHCH2CH3), 1.33 (t, J 7.0 Hz, 3 H, 3-CO2CH2CH3), 1.05 (t, J 7.1 
Hz, 3 H, 6-NHCONHCH2CH3); δC (75 MHz, DMSO-d6) 166.9 (3-CO2CH2CH3), 158.3 (6-
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NHCONHCH2CH3), 154.1 (4-phenyl 3-C), 152.9 (2-C), 139.3 (4-phenyl 1-C), 130.2 (4-
phenyl 5-C), 113.7 (4-phenyl 6-C), 112.1 (4-phenyl 4-C), 110.0 (4-C), 103.1 (4-phenyl 2-
C), 91.5 (2-C), 60.4 (3-CO2CH2CH3), 33.8 (6-NHCONHCH2CH3), 15.2 (6-NHCONHCH2CH3), 
14.1 (3-CO2CH2CH3), 3-C and 6-C not resolved; νmax / cm
-1 (solid) 3269, 1688, 1583, 
1489, 764, 751, 692; m/z (ESI+) found MH+ 345.1571, C17H20N4O4 MH
+ requires 




General method A using compound 46 (100 mg, 0.368 
mmols) and 2-aminophenol (36 mg, 0.33 mmol) afforded an 
off-white solid. The material was purified using column 
chromatography (1:1 EtOAcPetrol) to afford the title 
compound (156 mg, 0.455, 50%) as colourless crystals, m.p. 206.7-209.7 °C; Rf 0.52 (3:1 
EtOAcPetrol); δH (300 MHz, DMSO-d6) 10.19 (br. s, 1 H, 6-NHCONHCH2CH3), 9.99 (br. 
s, 1 H, 4-NH), 8.61 (s, 1 H, 2-H), 7.36 (br. s, 1 H, OH), 7.31 (dd, J 8.0, 1.4 Hz, 1 H, 4-
phenyl 6-H), 7.18 (t, J 7.0 Hz, 1 H, 4-phenyl 4-H), 7.04 (dd, J 8.2, 0.8 Hz, 1 H, 4-phenyl 3-
H), 6.91 (td, J 8.2, 0.8 Hz, 1 H, 4-phenyl 5-H), 6.57 (br. s, 1 H, 6-NHCONHCH2CH3), 4.37 
(q, J 6.9 Hz, 2 H, 3-CO2CH2CH3), 3.15 (qd, J 7.4, 5.8  Hz, 2 H, 6-NHCONHCH2CH3), 1.35 (t, 
J 7.1 Hz, 3 H, 3-CO2CH2CH3), 1.06 (t, J 7.1 Hz, 3 H, 6-NHCONHCH2CH3); C (125 MHz, 
DMSO-d6) 164.9 (3-CO2CH2CH3), 154.7 (6-NHCONHCH2CH3), 154.0 (6-C), 151.2 (2-C), 
150.1 (4-phenyl 2-C), 143.7 (4-C), 127.9 (4-phenyl 1-C), 125.1 (4-phenyl 4-C), 123.8 (4-
phenyl 5-C), 119.4 (4-phenyl 6-C), 116.6 (4-phenyl 3-C), 104.8 (3-C), 91.5 (5-C), 61.7 (3-
CO2CH2CH3), 34.1 (6-NHCONHCH2CH3), 14.9 (6-NHCONHCH2CH3), 14.0 (3-CO2CH2CH3); 
νmax / cm
-1 (solid) 2925, 2854, 1705, 1651, 1544; m/z (ESI+) found MH+ 345.1558, 










General method A using compound 46 (100 mg, 0.368 
mmol) and 4-aminobenzoic acid (73 mg, 0.33 mmol) 
afforded the title compound (264 mg, 0.680 mmol, 82%) as 
colourless microcrystals, m.p. 206.4-207.3 °C; Rf 0.10 (1:2 
EtOAcPetrol); δH (300 MHz, DMSO-d6) 9.52 (s, 1 H, 4-NH), 9.24 (br. s., 1 H, 6-
NHCONHCH2CH3), 8.60 (s, 1 H, 2-H), 7.79 (br. s., 1 H, 6-NHCONHCH2CH3), 7.15 (s, 1 H, 
5-H), 7.01 (d, J 8.7 Hz, 2 H, 4-phenyl 6-H), 6.94 (d, J 2.5 Hz, 1 H, 4-phenyl 2-H), 6.82 (dd, 
J 8.7, 2.5 Hz, 1 H, 4-phenyl 5-H), 4.32 (q, J 7.0 Hz, 2 H, 3-CO2CH2CH3), 3.79 (m, 6 H, 
OCH3), 3.12 (qd, J 7.1, 5.3 Hz, 2 H, 6-NHCONHCH2CH3), 1.34 (t, J 7.0 Hz, 3 H, 3-
CO2CH2CH3), 1.05 (t, J 7.1 Hz, 3 H, 6-NHCONHCH2CH3); C (125 MHz, DMSO-d6) 166.1 
(3-CO2CH2CH3), 154.4 (6-NHCONHCH2CH3 or 6-C), 154.2 (6-NHCONHCH2CH3 or 6-C), 
149.3 (2-C), 147.0 (4-phenyl 3-C), 130.5 (4-phenyl 4-C), 116.4 (4-phenyl 5-C), 112.3 (4-
phenyl 6-C), 108.9 (4-phenyl 2-C), 103.5 (3-C), 91.2 (5-C), 60.9 (3-CO2CH2CH3), 55.7 
(OCH3), 55.6 (OCH3), 33.9 (6-NHCONHCH2CH3), 15.1 (5-NHCONHCH2CH3), 14.1 (3-
CO2CH2CH3) 4-C and 4-phenyl 1-C not resolved; νmax / cm
-1 (solid) 2925, 2854, 1704, 
1650, 1588, 1546; m/z (ESI+) found MH+ 389.1833, C19H25N4O5 MH requires 389.1820; 
HPLC RT = 2.49 min. 
 
6-[(ethylcarbamoyl)amino]-4-[(3-hydroxyphenyl)amino]pyridine-3-carboxylic acid 54 
Compound 51 (177 mg, 0.515 mmol) was dissolved in THF (2 
ml) and NaOH(aq) (2 M, 2 ml) was added. The reaction mixture 
was heated to 80 °C for 18 hours and then cooled to 0 °C. The 
reaction mixture was acidified to pH 4 by the dropwise 
addition of HCl (2 M). The resulting precipitate was collected by filtration to afford the 
title compound (23 mg, 0.071 mmol, 93%) as dark red microcrystals, m.p. 248.8-250.3 
°C; Rf 0.13 (1:9 MeOH‒EtOAc); δH (300 MHz, DMSO-d6) 9.87 (br. s., 1 H, 6-
NHCONHCH2CH3), 9.62 (s, 1 H, 2-H), 9.13 (br. s., 1H, 4-NH), 8.57 (s, 1 H, 5-H), 7.84 (br. 
s., 1 H, OH), 7.25 (s, 1 H, 4-phenyl 2-H), 7.20 (t, J 8.2 Hz, 1 H, 4-phenyl 5-H), 6.70 (d, J 
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8.2 Hz, 1 H, 4-phenyl 2-H), 6.65 (br. s, 1 H, 6-NHCONHCH2CH3), 6.60 (d, J 8.2 Hz, 1 H, 4-
phenyl 4-H), 3.13 (qd, J 7.1, 5.8 Hz, 2 H, 6-NHCONHCH2CH3), 1.05 (t, J 7.1 Hz, 3 H, 6-
NHCONHCH2CH3); C 168.7 (3-CO2H), 158.4 (6-NHCONHCH2CH3), 154.2 (2-C), 153.6 (4-
phenyl 3-C), 139.2 (4-phenyl 1-C) 130.3 (4-phenyl 5-C), 113.8 (3-C), 112.4 (4-phenyl 6-
C), 110.2 (4-phenyl 6-C), 104.1 (4-phenyl 2-C), 91.5 (5-C), 33.9 (6-NHCONHCH2CH3), 
15.2 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 2973.1, 2882.9, 1703.7, 1667.2, 1584.3, 





Compound 67 (50 mg, 0.157 mmol) and 3-hydroxyaniline 
(17 mg, 0.157 mmol) were suspended in EtOH and cHCl (1 
drop) was added. The reaction was heated to 80 °C for 16 
hours before being cooled to 0 °C and neutralised to pH 7 
by careful addition of aqueous NaOH (2M). The reaction mixture was concentrated in 
vacuo and the resulting orange solid washed with water and dried under the air. 
Recrystallisation from EtOH afforded the title compound (20 mg, 0.051 mmol, 32%) as 
pale orange microcrystals. m.p. 238.2-242.1 (EtOH); Rf 0.03 (EtOAc); H (500 MHz, 
DMSO-d6)  10.45 (s, 1 H, 6-NHCONHCH2CH3), 9.79 (s, 1 H, 3-CONH), 9.57 (s, 1 H, 4-NH), 
8.88 (s, 1 H, 3-pyridyl 2-H), 8.62 (s, 1 H, 2-H), 8.33 (d, J 4.3 Hz, 1 H, 3-pyridyl 6-H), 8.13 
(d, J 8.1 Hz, 1 H, 3-pyridyl 4-H), 7.97 (br. s., 1 H, 4-phenyl-OH), 7.41 (dd, J 8.1 and 4.3 
Hz, 1 H, 3-pyridyl 5-H), 7.30 (s, 1 H, 5-H), 7.20 (t, J 7.8 Hz, 1 H, 4-phenyl 5-H), 6.71 (d, J 
7.8 Hz, 1 H, 4-phenyl 6-H), 6.67 (s, 1 H, 4-phenyl 2-H), 6.59 (d, J 7.8 Hz, 1 H, 4-phenyl 4-
H), 4.35 (t, J 4.6 Hz, 1 H, 6-NHCONHCH2CH3), 4.36 (qd, J 4.6 and 7.1 Hz, 2 H, 6-
NHCONHCH2CH3), 1.07 (t, J 7.1 Hz, 3 H, 6-NHCONHCH2CH3); δC (125 MHz, DMSO-d6) 
166.9 (3-CONH), 158.3 (6-NHCONHCH2CH3), 155.9 (4-phenyl 3-C), 154.3 (6-C), 152.2 (4-
C), 149.1 (5-C), 144.7 (3-pyridyl 2-C), 142.3 (3-pyridyl 6-C), 139.9 (3-pyridyl 3-C), 135.4 
(4-phenyl 1-C), 130.2 (4-phenyl 5-C), 127.8 (3-pyridyl 4-C), 123.5 (3-pyridyl 5-C), 113.0 
(4-phenyl 6-C), 111.5 (4-phenyl 4-C), 109.3 (4-phenyl 2-C), 107.7 (3-C), 92.3 (2-C), 33.8 
(6-NHCONHCH2CH3), 15.3 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 3414, 1731, 1628 and 
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Either: General method C using nicotinic acid (100 mg, 0.813 mmol) 
and 3-aminopyridine (84 mg, 0.89 mmol) afforded the title 
compound (115 mg, 0.578 mmol, 71%) as colourless microcrystals. 
Or: Nicotinic acid (100 mg, 0.813 mmol) was dissolved in DMF (5 ml) and HOBt.H2O 
(165 mg, 1.22 mmol) and EDC (233 mg, 1.22 mmol) were added. The resulting solution 
was stirred for 20 minutes and then 3-aminopyridine (84 mg, 0.89 mmol) was added. 
The reaction mixture was stirred at room temperature overnight. The reaction mixture 
was then diluted with water (5 ml), extracted with EtOAc (3 × 10 ml) and the combined 
organic extracts were washed with NaHCO3 (10 ml), water (10 ml) and brine (10 ml), 
dried over MgSO4 and concentrated in vacuo to give a tan gum. Purification of this gum 
using column chromatography (1:1 EtOAc‒Petrol) afforded the title compound (10 mg, 
0.050 mmol, 12%) as colourless microcrystals, m.p. 192.9-193.5 °C; Rf 0.29 (1:1 
EtOAcPet); δH (300 MHz, DMSO-d6) 10.67 (s, 1 H, 3-CONH), 9.13 (dd, J 2.2, 0.8 Hz, 1 H, 
6-H), 8.94 (d, J 2.2 Hz, 1 H, 3-pyridyl 5-H), 8.79 (dd, J 4.7, 1.6 Hz, 1 H, 2-H), 8.28-8.39 
(m, 2 H, 4-H and 3-pyridyl 6-H), 8.20 (ddd, J 8.2, 2.5, 1.6 Hz, 1 H, 3-pyridyl 4-H), 7.60 
(ddd, J 8.1, 4.8, 0.8 Hz, 1 H, 5-H), 7.43 (dd, J 8.2, 4.7 Hz, 1 H, 3-pyridyl 5-H); δC (75 MHz, 
MeOD-d4) 166.7 (3-CONH), 153.8 (6-C), 149.6 (2-C), 145.9 (3-pyridyl 6-C), 142.9 (3-
pyridyl 5-C), 137.5 (4-C or 3-pyridyl 3-C), 137.4 (4-C or 3-pyridyl 3-C), 132.2 (3-C), 130.1 
(3-pyridyl 4-C), 125.4 (5-C), 125.3 (3-pyridyl 5-C); (Found C, 66.2; H, 4.45; N, 20.7; 
C11H9N3O requires C, 66.3; H, 4.55; N, 21.1%); νmax / cm
-1 (solid) 1679, 1588, 1548; m/z 
(ESI+) found MH+ 200.0819, C11H10N3O MH requires 200.0818; HPLC RT = 0.663 mins. 









Compound 67 (30 mg, 0.09 mmol) and 2-hydroxyaniline 
(30 mg, 0.09 mmol) were dissolved in ethanol (2 ml) and 
NEt3 (5 drops) was added. The reaction was heated to 80 
°C for 3 hours. The reaction was then allowed to cool to 
room temperature and the solvent removed in vacuo. The resulting off white residue 
was taken up in EtOAc (10 ml), washed with water (3 × 10 ml) and brine (10 ml), the 
volume reduced in vacuo and the product collected by filtration to afford the title 
compound (7.5 mg, 0.191 mmol, 21%) as pale red microcrystals, Rf 0.03 (EtOAc); H 
(500 MHz, DMSO-d6) 10.43 (br. s., 1 H, 3-CONH), 9.85 (s, 1 H, 6-NHCONHCH2CH3), 9.77 
(s, 1 H, 4-NH), 9.14 (s, 1 H, 4-phenyl 6-H), 8.88 (s, 1 H, 3-pyridyl 2-H), 8.61 (s, 1 H, 2-H), 
8.33 (d, 1 H, J 4.6 Hz, 3-pyridyl 6-H), 8.14 (d, J 7.8 Hz, 1 H, 3-pyridyl 4-H), 8.00 (br. s., 1 
H, 4-phenyl OH), 7.41 (dd, J 8.5, 4.8 Hz, 1 H, 3-pyridyl 5-H), 7.32 (d, J 7.8 Hz, 1 H, 4-
phenyl 3-H), 7.23 (s, 1 H, 5-H), 6.91 - 7.03 (m overlapping, 2 H, 4-phenyl 4-H and 5-H), 
6.86 (t, J 6.9 Hz, 1 H, 6-NHCONHCH2CH3), 3.17 (qd, J 7.1, 6.9 Hz, 2 H, 6-
NHCONHCH2CH3), 1.09 (t, J 7.1 Hz, 3 H, 6-NHCONHCH2CH3); C (500 MHz, DMSO-d6) 
166.9 (3-CONH), 155.9 (4-phenyl 2-C), 154.4 (6-C), 152.1 (4-C), 149.6 (6-
NHCONHCH2CH3), 149.0 (5-C), 144.6 (3-pyridyl 2-C), 142.2 (3-pyridyl 6-C), 127.7 (3-
pyridyl 4-C), 126.5 (4-phenyl 1-C), 124.7 (4-phenyl 4-C), 123.5 (3-pyridyl 5-C), 122.1 (4-
phenyl 5-C), 119.2 (4-phenyl 6-C), 115.8 (4-phenyl 3-C), 108.0 (3-C), 92.0 (2-C), 33.8 (6-
NHCONHCH2CH3), 15.3 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 2969, 2811, 1698, 1642, 
1543, 1517; m/z (ESI+) found MH+ 393.1673, C20H20N6O3 MH requires 393.1670; HPLC 











Compound 52 (150 mg, 0.436 mmol) was suspended in THF (2.5 
ml) and NaOH(aq) (2 M, 2 ml) was added. The reaction mixture 
was heated to 80 °C for 18 hours and then cooled to 0 °C. The 
reaction mixture was acidified to pH4 by the dropwise addition 
of HCl (2 M). The resulting precipitate was collected by filtration to afford 6-
[(ethylcarbamoyl) amino]-4-[(2-hydroxyphenyl) amino] pyridine-3-carboxylic acid (25 
mg, 0.078 mmol, 90%) as a dark red solid. δH (300 MHz, DMSO-d6) 9.99 (br. s., 1 H, 6-
NHCONHCH2CH3), 8.57 (s, 1 H, 2-H), 7.70 (br. s., 1 H, 4-NH), 7.58 (br. s., 1 H, 6-
NHCONHCH2CH3), 7.32 (d, J 6.3Hz, 1 H, 4-phenyl 6-H), 7.16 (t, 1 H, 4-phenyl 4-H), 7.09-
6.84 (m, 4 H, 5-H, 4-phenyl 3-H, 5-H, OH), 3.15 (qd, J 6.9, 5.8 Hz, 2 H, 6-
NHCONHCH2CH3), 1.05 (t, J 7.3 Hz, 3 H, 6-NHCONHCH2CH3). 
1H NMR indicated that the 
material was sufficiently pure and the material was carried through to the next step 
without further analysis. General method C using 6-[(ethylcarbamoyl)amino]-4-[(2-
hydroxyphenyl) amino]pyridine-3-carboxylic acid (110 mg, 0.348 mmol) and 3-amino 
pyridine (36 mg, 0.38 mmol) After 16 hours, a further 5 equivalents of T3P (1 ml) was 
added and to the reaction mixture and the reaction mixture was stirred for a further 
48 hours. After this time no starting material was observed using TLC. The reaction 
mixture was basified to pH 11 by careful addition of aqueous NaOH (1 M) and stirred 
for 20 minutes during which time a precipitate formed. The precipitate was collected 
using filtration and washed with water to afford the title compound (56 mg, 0.19 
mmol, 56%) as yellow microcrystals, m.p. >250 °C; Rf 0.28 (1:1 EtOAcPet); H (300 
MHz, DMSO-d6) 9.65 (s, 1 H, 6-NHCONHCH2CH3), 9.35 (s, 1 H, 4-NH), 8.63 (s, 1 H, 2-H), 
7.41 (s, 1 H, 5-H), 7.27 (t, J 5.9 Hz, 1 H, 6-NHCONHCH2CH3), 7.07-7.21 (m, 4 H, ArH), 
3.16 (qd, J 7.0, 5.9 Hz, 2 H, 6-NHCONHCH2CH3), 1.08 (t, J 7.0 Hz, 3 H, 6-
NHCONHCH2CH3); (75 MHz, DMSO-d6) c 163.9 (6-NHCONHCH2CH3), 156.6 (2-C), 156.0 
(3-CO2), 154.6 (4-C or 6-C), 154.0 (4-C or 6-C), 141.3 (4-phenyl 2-C), 134.5 (4-phenyl 1-
C), 126.2 (4-phenyl 4-C or 4-phenyl 5-C), 124.6 (4-phenyl 4-C or 4-phenyl 5-C), 122.2 (4-
phenyl 3-C or 4-phenyl 6-C), 120.35 (4-phenyl 3-C or 4-phenyl 6-C), 105.5 (3-C), 96.2 (5-
C), 33.9 (6-NHCONHCH2CH3), 15.2 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 3107, 1696, 
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1571, 1513; m/z (ESI+) found MH+ 299.1146, C15H15N4O3 requires 299.1139; HPLC RT = 
3.14 mins. 
 
4-chloro-6-[(ethylcarbamoyl)amino]pyridine-3-carboxylic acid123 63 
Compound 46 (700 mg, 2.57 mmol) was suspended in NaOH (2 
M, 30 ml) and heated to 80 °C for 16 hours. The reaction 
mixture was then cooled to 0 °C and acidified to pH 4 by 
dropwise addition of cHCl. The resulting precipitate was collected using filtration, 
washed with water and dried under air to afford  the title compound (516 mg, 2.12 
mmol, 83%) as pale yellow microcrystals, Rf 0.05 (1:9 MeOHEtOAc); δH (300 MHz, 
DMSO-d6) 9.60 (1H, br. s., 6-NHCONHCH2CH3), 8.63 (s, 1 H, 2-H), 7.72 (s, 1 H, 5-H), 7.44 
(t, J 5.2 Hz, 1 H, 6-NHCONHCH2CH3), 3.12 (qd, J 7.1 and 5.2 Hz, 2 H, 6-NHCONHCH2CH3), 
1.03 (t, J 7.1 Hz, 3 H, 6-NHCONHCH2CH3); δC (75 MHz, DMSO-d6) 164.6 (3-CO2H), 155.9 
(6-NHCONHCH2CH3), 153.9 (6-C), 151.4 (2-C), 143.9 (4-C), 111.8 (5-C), 102.6 (3-C), 33.9 
(6-NHCONHCH2CH3), 15.1 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 2927, 1698, 1586, 
1542; m/z (ESI+) found MH+ 244.0483, C9H11ClN3O3 MH requires 244.0483; HPLC RT = 




General method C using compound 63 (100 mg, 0.411 
mmol) and 3,4-dimethoxyaniline (138 mg, 0.905 
mmol) afford the title compound (89 mg, 0.24, 57%) 
as off-white microcrystals, m.p. >250 °C; Rf 0.19 (1:1 EtOAcPet); 
H (300 MHz, DMSO-
d6) 10.35 (br. s, 1 H, 3-CONH), 9.57 (br. s, 1 H, 6-NHCONHCH2CH3), 8.40 (s, 1 H, 2-H), 
7.79 (s, 1 H, 5-H), 7.42 (d, J 2.4 Hz, 1 H, 3-phenyl 2-H), 7.23 (dd, J 8.6, 2.5 Hz, 1 H, 3-
phenyl 6-H), 6.93 (d, J 8.6 Hz, 1 H, 3-phenyl 5-H), 3.75 (s, 3 H, 3-phenyl 3-OCH3), 3.74 (s, 
3 H, 3-phenyl 4-OCH3), 3.18 (q, J 7.2 Hz, 2 H, 6-NHCONHCH2CH3), 1.09 (t, J 7.2 Hz, 3 H, 
6-NHCONHCH2CH3); C (75 MHz, DMSO-d6) 162.6 (6-C),  155.0 (3-CONH), 148.5 (5-
phenyl 3-C), 147.3 (2-C), 145.3 (5-phenyl 4-C), 142.1 (4-C), 132.4 (5-phenyl 1-C), 125.8 
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(C-3), 112.0 (3-phenyl 5-C), 111.4 (3-phenyl 6-C), 111.0 (5-C), 104.5 (3-phenyl 2-C), 55.7 
(3-phenyl 3-OCH3 or 4-OCH3), 55.4 (3-phenyl 3-OCH3 or 4-OCH3), 33.8 (6-
NHCONHCH2CH3), 15.12 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 3266, 1691, 1642, 





General method A using compound 65 (66 mg, 0.18 
mmol) and 3,4-dimethoxyaniline (29 mg, 0.19 mmol) 
afforded the title compound (40 mg, 0.080 mmol, 
46%) as pale pink microcrystals, m.p. 224.9-227.2 °C; 
Rf 0.16 (1:1 EtOAcPet); H (500 MHz, DMSO-d6) 10.09 (s, 1 H, 4-NH), 9.82 (br. s., 1 H, 
6-NHCONHCH2CH3), 9.06 (s, 1 H, 3-CONH), 8.53 (s, 1 H, 2-H), 8.06  (br. s, 1 H, 6-
NHCONHCH2CH3), 7.39 (d, J 2.6 Hz, 1 H 3-phenyl 2-H), 7.25 (dd, J 8.5, 2.1 Hz, 1 H, 3-
phenyl 5-H), 7.10 (s, 1 H, 5-H), 6.96 (d, J 8.5 Hz, 1 H, 3-phenyl or 4-phenyl 6-H), 6.91 (d, 
J 8.5 Hz, 1 H, 3-phenyl or 4-phenyl 6-H), 6.88 (d, J 2.6 Hz, 1 H, 4-phenyl 2-H), 6.76 (dd, J 
8.5, 2.6 Hz, 1 H, 4-phenyl 5-H), 3.77 (s, 3 H, OCH3), 3.76 (s, 3 H, OCH3), 3.74 (s, 3 H, 
OCH3), 3.73 (s, 3 H, OCH3), 3.14 (qd, J 7.3, 6.0, 2 H, 6-NHCONHCH2CH3), 1.06 (t, J 7.3 Hz, 
3 H, 6-NHCONHCH2CH3); δC (125 MHz, DMSO-d6) 166.2 (3-CONH), 155.6 (6-
NHCONHCH2CH3), 154.4 (6-C), 149.2 (2-C), 148.5 (3-phenyl or 4-phenyl 4-C), 148.4 (3-
phenyl or 4-phenyl 4-C), 145.9 (4-C), 145.3 (4-phenyl 1-C), 114.9 (4-phenyl 5-C), 112.7 
(4-phenyl 2-C), 112.4 (3-phenyl 5-C), 111.8 (3-phenyl or 4-phenyl 6-C), 107.8 (3-phenyl 
or 4-phenyl 6-C), 105.9 (3-C), 91.5 (5-C), 55.7 (OCH3), 55.6 (OCH3), 55.4 (OCH3), 55.3 
(OCH3), 33.6 (6-NHCONHCH2CH3), 15.3 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 3287, 
1686, 1633, 1582, 1509; m/z (ESI+) found MNa+ 518.2016, C25H29N5O6 MNa requires 








Compound 63 (100 mg, 0.411 mmol) and 3-amino 
pyridine (85 mg, 0.91 mmol) were dissolved in EtOAc (1 
ml), and pyridine (0.1 ml) and T3P (1 ml, 1.64 mmol, 50% 
solution in EtOAc) were added. The reaction mixture was stirred at room temperature 
for 18 hours and then basified to pH 10 by addition of aqueous NaOH (2M). The 
mixture was then stirred for 20 minutes and the product collected by filtration to 
afford the title compound (45 mg, 0.14 mmol, 34%) as pale orange microcrystals, m.p. 
210.4-215.6 °C; Rf 0.24 (1:1 EtOAcPet); H (300 MHz, DMSO-d6) 10.74 (s, 1 H, 4-NH), 
9.57 (s, 1 H, 6-NHCONHCH2CH3), 8.84 (d, J 2.2 Hz, 1 H, 3-pyridyl 2-H), 8.47 (s, 1 H, 2-H), 
8.33 (d, 1 H, J 3.8 Hz, 3-pyridyl 6-H), 8.15 (d, J 8.8 Hz, 1 H, 3-pyridyl 4-H), 7.80 (s, 1 H, 5-
H), 7.31-7.50 (m, 2 H, 3-pyridyl 5-H and 6-NHCONHCH2CH3), 3.18 (qd, J 7.2 and 5.5 Hz, 
2 H, 6-NHCONHCH2CH3), 1.09 (t, J 7.2 Hz, 3 H, 6-NHCONHCH2CH3); C (125 MHz DMSO-
d6) 163.1 (3-CONH), 155.0 (6-C), 154.0 (6-NHCONHCH2CH3), 148.0 (2-C), 144.8 (3-
pyridyl 6-C), 141.6 (3-pyridyl 2-C), 141.2 (3-pyridyl 3-C), 135.5 (4-C), 126.5 (3-pyridyl 4-
C), 124.8 (3-C), 123.7 (3-pyridyl 5-C), 111.2 (5-C), 33.9 (6-NHCONHCH2CH3), 15.2 (6-
NHCONHCH2CH3); νmax / cm
-1 (solid) 3179, 1669, 1548; m/z (ES+) found MH+ 320.0912 




General method A using compound 67 (40 mg, 0.13 
mmol) and 3,4-dimethoxyaniline (19 mg, 0.13 mmol) 
afforded the title compound (29 mg, 0.066 mmol, 53%) as 
pale pink microcrystals, m.p. >250 °C; Rf 0.13 (1:1 
EtOAcPet); H (300 MHz, DMSO-d6) 10.43 (s, 1 H 3-CONH), 9.73 (s, 1 H, 4-NH), 9.13 (s, 
1 H, 6-NHCONHCH2CH3), 8.87 (d, J 2.4, 1 H, 3-pyridyl 2-H), 8.60 (s, 1 H, 2-H), 8.31 (dd, J 
4.6, 1.4 Hz, 1 H, 3-pyridyl 6-H), 8.12 (ddd, J 8.3, 2.4, 1.4, 1 H, 3-pyridyl 5-H), 7.98 (br. s., 
1 H, 6-NHCONHCH2CH3), 7.39 (dd, J 8.3, 4.6 Hz, 1 H, 3-pyridyl 4-H), 7.15 (s, 1 H, 5-H), 
6.98 (d, J 8.7 Hz, 1 H, 4-phenyl 2-H), 6.90 (d, J 2.3 Hz, 1 H, 4-phenyl 5-H), 6.79 (dd, J 8.7, 
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2.3 Hz, 1 H, 4-phenyl 6-H), 3.74 - 3.86 (overlapping singlets 2 H, 2 × OCH3), 3.15 (dq, J 
7.1, 5.9 Hz, 2 H, 6-NHCONHCH2CH3), 1.06 (t, J 7.1 Hz, 3 H, 6-NHCONHCH2CH3); C (75 
MHz, DMSO-d6) 166.9 (3-CONH), 155.9 (6-NHCONHCH2CH3), 154.3 (4-C), 153.0 (6-C), 
149.1 (2-C), 146.0 (4-phenyl 5-C), 145.3 (3-pyridyl 6-C), 144.6 (4-phenyl 4-C), 142.3 (3-
pyridyl 2-C), 135.5 (4-phenyl 1-C), 131.6 (3-pyridyl 3-C), 127.7 (3-pyridyl 5-C), 123.5 (3-
pyridyl 4-C), 115.2 ( 4-phenyl 6-C), 112.2 (4-phenyl 2-C), 108.0 (4-phenyl 5-C), 107.1 (3-
C), 91.5 (5-C), 55.7 (OCH3), 55.4 (OCH3), 33.8 (6-NHCONHCH2CH3), 15.3 (6-
NHCONHCH2CH3); νmax / cm
-1 (solid) 3264, 1708, 1653, 1513, 1484, 1325; m/z (ESI+) 




Compound 67 (50 mg, 0.16 mmol) and p-anisidine (23 mg, 
0.18 mmol) were dissolved in EtOH (2 ml) and 1 drop of 
2 M HCl was added. The reaction was heated to 70 °C for 
18 hours. The reaction was then allowed to cool and 
neutralised by addition of NaOH (2M aqueous solution). The reaction mixture was 
concentrated in vacuo. Trituration with MeOH followed by recrystallisation from EtOH 
afforded the title compound (10 mg, 0.025 mmol, 15%) as colourless microcrystals, 
m.p. >250 °C; Rf 0.08 (EtOAc); H (300 MHz, DMSO-d6) 12.22 (br. s, 1 H, 3-CONH), 11.05 
(br. s., 1 H, 4-NH), 10.00 (br. s, 1 H, 6-NHCONHCH2CH3), 9.33 (d, J 2.3 Hz, 1 H, 3-pyridyl 
2-H), 8.78 (d, J 8.7 Hz, 1 H, 3-pyridyl 6-H), 8.61 - 8.73 (m, 2 H, 2-H and 3-pyridyl 5-H), 
8.02 (dd, J 8.7, 5.3 Hz, 1 H, 3-pyridyl 4-H), 7.46 (t, J 5.5 Hz, 1 H, 6-NHCONHCH3CH3), 
7.30 (d, J 8.7 Hz, 2 H, 4-phenyl 2-H), 7.05 (d, J 8.7 Hz, 2 H, 4-phenyl 3-H), 6.55 (s, 1 H, 5-
H), 3.80 (s, 3 H, 4-phenyl 4-OCH3), 3.15 (qd, J 7.2, 5.5 Hz, 2 H, 6-NHCONHCH2CH3), 1.07 
(t, J 7.2 Hz, 3 H, 6-NHCONHCH2CH3);  C (75 MHz, DMSO-d6) 164.3 (3-CONH), 158.0 (6-
NHCONHCH2CH3), 155.4 (4-phenyl 4-C), 153.8 (6-C), 148.8 (4-phenyl 1-C), 140.4 (2-C), 
138.1 (3-pyridyl 5-C), 137.7 (4-C), 134.8 (3-pyridyl 6-C), 134.6 (3-pyridyl 2-C), 129.4 (3-
pyridyl 3-C), 126.8 (4-phenyl 2-C and 3-pyridyl 4-C), 115.0 (4-phenyl 3-C), 109.3 (3-C), 
91.2 (5-C), 55.4 (4-phenyl 4-OCH3), 34.1 (NHCONHCH2CH3), 14.8 (6-NHCONHCH2CH3); 
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νmax / cm-1 (solid) 2977.0, 1768.7, 1698.1; m/z (ESI+) found MH+ 407.1825, C21H23N6O3 




Pyrazole (23.0 mg, 0.344 mmol) was dissolved in DMF (2 
ml) and the resulting solution was cooled to 0 °C. 
Potassium tert-butoxide (42.1 mg, 0.376 mmol) was 
added and the reaction stirred at 0 °C for 1 hour. 
Compound 67 (84 mg, 0.263 mmol) was added to the reaction mixture and the 
reaction mixture was heated to 70 °C for 18 hours. The reaction mixture was allowed 
to cool to room temperature, diluted with water (10 ml) and extracted into DCM (4 × 
10 ml). The combined organic extracts were dried over MgSO4 and concentrated in 
vacuo to afford a yellow oil. Trituration with CHCl3 afforded the title compound (23 mg, 
0.066 mmol, 17%) as off-white microcrystals. m.p. 225.4 – 228.7 °C; Rf 0.04 (EtOAc); H 
(500 MHz, DMSO-d6) 10.59 (s, 1 H, 3-CONH) 9.49 (s, 1 H, 6-NHCONHCH2CH3), 8.72 (d, J 
2.6 Hz, 1 H, 3-pyridyl 2-H) 8.44 (s, 1 H, 2-H), 8.28 (dd, J 4.7, 1.3 Hz, 1 H, 3-pyridyl 6-H), 
8.14 (d, J 2.1 Hz, 1 H, 4-pyrazolyl 5-H), 8.03 (d, J 8.3 Hz, 1 H, 3-pyridyl 4-H), 7.90 (s, 1 H, 
5-H), 7.73 (d, J 1.7 Hz, 1 H, 4-pyrazolyl 3-H), 7.49 (t, J 5.4 Hz, 1 H, 6-NHCONHCH2CH3), 
7.35 (dd, J 8.3, 4.7 Hz, 1 H, 3-pyridyl 5-H), 6.53 (dd, J 1.7, 2.1 Hz, 1 H, 4-pyrazolyl 4-H), 
3.19 (qd, J 7.2, 5.4 Hz, 3 H, 6-NHCONHCH2CH3), 1.09 (t, J 7.2 Hz, 3 H, 6-
NHCONHCH2CH3); C (125 MHz, DMSO-d6) 164.4 (3-CONH), 155.3 (6-NHCONHCH2CH3), 
154.1 (6-C), 148.3 (2-C), 145.2 (3-pyridyl 6-C), 144.5 (4-pyrazolyl 5-C), 142.1 (4-
pyrazolyl 3-C), 141.2 (3-pyridyl 2-C), 135.8 (4-C), 130.0 (4-pyrazolyl 5-C), 126.5 (3-
pyridyl 4-C), 123.6 (3-pyridyl 5-C), 119.2 (3-C), 108.6 (4-pyrazolyl 4-C), 103.4 (5-C), 33.9 
(6-NHCONHCH2CH3), 15.23 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 3209, 3120, 3042, 
2973, 1668, 1656, 1585, 1527, 1480, 1419; m/z (ESI+) found MH+ 352.1532, C17H18N7O2 
MH requires 352.1516; HPLC RT = 1.19 mins. 
 
 





General method B using 4-bromopyrazole (18.8 mg, 0.470 
mmol) and compound 67 (100 mg, 0.313 mmol). The 
reaction mixture was diluted with water (10 ml) and 
extracted into DCM (3 × 10 ml). The combined organic 
extracts were washed with brine (10 ml), dried over MgSO4 and concentrated in vacuo 
to afford an off-white solid. Recrystallisation from EtOH afforded the title compound 
(34 mg, 0.079 mmol, 25%) as colourless microcrystals, m.p. 239.4-241.8 °C; Rf 0.05 
(EtOAc); H (500 MHz, DMSO-d6) 10.61 (s, 1 H, 3-CONH), 9.55 (s, 1 H, 6-
NHCONHCH2CH3), 8.72 (s, 1 H, 3-pyridyl 2-H), 8.49 (s, 1 H, 2-H or 4-pyrazolidyl 5-H), 
8.48 (s, 1 H, 2-H or 4-pyrazolidyl 5-H), 8.29 (dd, J 4.5, 1.1 Hz, 1 H, 3-pyridyl 6-H), 8.02 
(d, J 8.5 Hz, 1 H, 3-pyridyl 4-H), 7.87 (s, 1 H, 5-H), 7.87 (s, 1 H, 4-pyrazolidyl 3-H), 7.41 
(t, J 4.8 Hz, 1 H, 6-NHCONHCH2CH3), 7.36 (dd, J 8.1, 4.7 Hz, 1 H, 3-pyridyl 5-H), 3.19 (qd, 
J 7.2, 4.8 Hz, 2 H, 6-NHCONHCH2CH3), 1.08 (t, J 7.2 Hz, 1 H, 6-NHCONHCH2CH3); C (125 
MHz, DMSO-d6) 163.9 (3-CONH), 155.4 (6-NHCONHCH2CH3), 154.1 (6-C), 148.6 (5-C), 
144.9 (3-pyridyl 6-C), 144.6 (3-pyridyl 2-C), 142.3 (4-pyrazolyl 3-C), 141.2 (2-C), 135.7 
(4-C), 130.5 (4-pyrazolyl 5-C), 126.5 (3-pyridyl 4-C), 123.6 (3-pyridyl 5-C), 119.3 (3-C), 
104.0 (5-C), 95.5 (4-pyrazolyl 4-C), 34.0 (6-NHCONHCH2CH3), 15.2 (6-NHCONHCH2CH3); 
νmax / cm
-1 (solid)  3307, 2975, 1667, 1607, 1589, 1518, 1480; m/z (ESI+) found MH+ 











carboxamide 73 and 6-[(ethylcarbamoyl)amino]-N-(pyridin-3-yl)-4-(1H-1,2,3-triazol-
1-yl)pyridine-3-carboxamide 74 
General method B using compound 67 (100 mg, 0.313 
mmol) and 1,2,3-triazole (20 µl, 0.345 mmol). The 
reaction mixture was diluted with water (10 ml) and the 
resulting precipitate was collected by filtration as 
colourless microcrystals which consisted of a mixture of 
the geometric isomers 73 and 74. Purification using 
column chromatography (1:19 MeOHEtOAc) afforded 
both of the title compounds 73 (10 mg, 0.027 mmol, 9%) 
and 74 (21 mg, 0.060 mmol, 19%) as colourless microcrystals. 73: m.p. >250 °C; Rf 0.18 
(5% MeOH in EtOAc); δH (500 MHz, MeOD) 8.74 (br. s., 1 H, NH), 8.68 (s, 1 H, 3-pyridyl 
2-H), 8.50 (s, 1 H, 2-H), 8.33 (d, J 4.4 Hz, 1 H, 3-pyridyl 6-H), 8.14 (d, J 8.1 Hz, 1 H, 3-
pyridyl 4-H), 7.93 (d, J 0.9 Hz, 1 H, 4-triazolyl 4-H), 7.84 (s, 1 H, 5-H), 7.71 (d, J 0.9, 1 H, 
4-triazolyl 5-H), 7.45 (dd, J 8.1, 4.4 Hz, 1 H, 3-pyridyl 5-H), 3.38 (q, J 7.3 Hz, 2 H, 6-
NHCONHCH2CH3), 1.26 (t, J 7.3 Hz, 2 H, 6-NHCONHCH2CH3); δC (125 MHz, DMSO-d6) 
163.2 (4-CONH), 155.6 (6-NHCONHCH2CH3), 154.0 (6-C), 148.8 (3-pyridyl 6-C), 144.7 (3-
pyridyl 4-C), 142.6 (3-pyridyl 3-C), 141.2 (3-pyridyl 2-C), 137.6 (4-triazolyl 4-C), 126.6 (3-
pyridyl 4-C), 125.7 (4-triazolyl 5-C), 123.6 (3-pyridyl 5-C), 119.9 (3-C), 105.5 (5-C), 34.0 
(6-NHCONHCH2CH3), 15.2 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 2966, 2667, 1750, 
1680, 1604, 1483; m/z (ESI+) found MH+ 353.1469, C16H17N8O3 MH requires 353.1469; 
HPLC RT = 1.12 mins. 74: m.p. >250 °C; Rf 0.48 (5% MeOH in EtOAc); δH (500 MHz, 
MeOD) 8.78 (d, J 2.3 Hz, 1 H, 3-pyridyl 2-H), 8.52 (s, 1 H, 2-H), 8.35 (d, J 6.0 Hz, 1 H, 3-
pyridyl 6-H), 8.18 - 8.22 (m, 1 H, 3-pyridyl 4-H), 8.01 (s, 2 H, 4-triazolyl 3-H), 7.48 (dd, J 
8.5, 4.8 Hz, 1 H, 3-pyridyl 5-H), 3.39 (q, J 7.0 Hz, 2 H, 6-NHCONHCH2CH3), 1.26 (t, J 7.3 
Hz, 3 H, 6-NHCONHCH2CH3); C (75 Hz, DMSO-d6) 164.2 (3-CONH), 155.2 (6-
NHCONHCH2CH3), 154.1 (6-C), 148.4 (3-pyridyl 6-C), 144.5 (2-C), 143.7 (3-pyridyl 3-C), 
141.1 (3-pyridyl 2-C), 137.6 (4-triazolyl 3-C), 135.9 (4-C), 126.4 (3-pyridyl 4-C), 123.6 (3-
pyridyl 5-C), 118.5 (3-C), 102.2 (5-C), 33.9 (6-NHCONHCH2CH3), 15.2 (6-
NHCONHCH2CH3); νmax / cm
-1 (solid) 3305, 3114, 2976, 1686, 1644, 1608, 1584, 1557, 
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General method B using 1,2,4-triazole (19 mg, 0.28 mmol) 
and compound 67 (80 mg, 0.25 mmol). The reaction 
mixture was diuted with water (10 ml) and extracted into 
DCM (5 × 10 ml). The combined organic extracts washed 
with water (2 × 10 ml) and brine (2 × 10 ml), dried over MgSO4, concentrated in vacuo 
and triturated with Et2O to afford a pale yellow solid. Recrystallisation from MeOH 
afforded the title compound (12 mg, 0.034 mmol, 14%) as colourless microcrystals, 
m.p. 232.5-235.5 °C; Rf 0.20 (5% MeOH in EtOAc); H (500 MHz, DMSO-d6) 10.69 (s, 1 H, 
3-CONH), 9.67 (s, 1 H, 4-triazolyl 5-H), 9.06 (s, 1 H, 6-NHCONHCH2CH3), 8.74 (s, 1 H, 3-
pyridyl 2-H), 8.61 (s, 1 H, 2-H), 8.32 (dd, J 4.4, 1.1 Hz, 1 H, 3-pyridyl 6-H), 8.23 (s, 1 H, 4-
triazolyl 3-H), 8.05 (d, J 8.2 Hz, 1 H, 3-pyridyl 4-H), 7.98 (d, J 1.8 Hz, 1 H, 5-H), 7.42 (br. 
s., 1 H, 6-NHCONHCH2CH3), 7.39 (dd, J 8.2, 5.0 Hz, 1 H, 3-pyridyl 5-H), 3.21 (q, J 7.1 Hz, 
2 H, 6-NHCONHCH2CH3), 1.12 (t, J 7.1 Hz, 3 H, 6-NHCONHCH2CH3); δC (125 MHz, DMSO-
d6) 163.3 (3-CONH), 155.6 (6-NHCONHCH2CH3), 153.9 (6-C), 152.6 (5-triazolyl 3-C), 
148.8 (2-C), 144.7 (3-pyridyl 5-C), 142.7 (3-pyridyl 6-C), 141.3 (3-pyridyl 2-C), 135.5 (4-
C), 126.6 (3-pyridyl 4-C), 123.6 (5-C), 119.4 (3-C), 105.0 (5-C), 33.8 (6-NHCONHCH2CH3), 
15.1 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 3094, 2925, 2379, 2343, 1682, 1650, 1611, 
1530; m/z (ESI+) found MH+ 353.1471, C16H17N8O3 MH requires 353.1469; HPLC RT = 
1.10 mins. 
 
ethyl 6-chloro-4-(1H-imidazol-1-yl)pyridine-3-carboxylate 76 
General method B using imidazole (340 mg, 5.0 mmol) and 
compound 45 (1.0 g, 4.5 mmol). An off-white solid was collected by 
filtration and extracted into EtOAc (3 x 10 ml). The combined 
organic extracts were washed with brine (10 ml), dried over Na2SO4 
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and concentrated in vacuo to an off-white residue. Purification using column 
chromatography (1:1 EtOAcPet) afforded the title compound (400 mg, 1.6 mmol, 
36%) as colourless microcrystals, m.p. 139.0-144.1 °C; Rf 0.4 (EtOAc); δH (400 MHz, 
CDCl3) 8.96 (s, 1 H, 2-H), 8.41 (s, 1 H, 4-imidazoyl 2-H), 7.64 (s, 1 H, 4-imidazoyl 5-H), 
7.44 (s, 1 H, 5-H), 7.23 (s, 1 H, 4-imidazoyl 4-H), 4.45 (q, J 7.1 Hz, 2 H, 3-CO2CH2CH3), 
1.44 (t, J 7.1 Hz, 3 H, 3-CO2CH2CH3); δH (100 MHz, CDCl3) 163.1 (3-CO2CH2CH3), 152.6 
(2-C), 151.1 (6-C), 146.9 (4-C), 135.4 (4-imidazoyl 2-C), 131.6 (4-imidazoyl 4-C), 123.8 
(3-C), 116.1 (4-imidazoyl 5-C), 113.7 (5-C), 62.1 (3-CO2CH2CH3), 14.2 (3-CO2CH2CH3); 
νmax / cm
-1 (solid) 3126, 2991, 1712, 1579; m/z (ESI+) found MNa+ 274.0351, 
C11H10ClN3O2 MNa requires 274.0354; HPLC RT = 1.20 mins. 
 
Ethyl 6-[(ethylcarbamoyl)amino-4-(1H-imidazol-1-yl)pyridine-3-carboxylate 77 
Palladium acetate (64 mg, 0.29 mmol) and xantphos (248 
mg, 0.429 mmol) were dissolved in degassed, anhydrous 1,4-
dioxane (5 ml) and the resulting solution was stirred under 
N2 for 20 minutes. N-Ethyl urea (189 mg, 2.15 mmol), 
compound 76 (360 mg, 1.43 mmol) and potassium tert-butoxide (240 mg, 2.15 mmol) 
were then added to the reaction mixture and the reaction mixture was heated to 100 
°C for 4 hours. The reaction mixture was then allowed to cool, filtered through celite 
and extracted into EtOAc (3 × 10 ml). The combined organic extracts were washed with 
water (10 ml), dried over MgSO4 and concentrated in vacuo to afford an orange 
residue. Purification using column chromatography (3:97 MeOH–DCM) afforded the 
title compound (62.7 mg, 0.206 mmol, 14%) as colourless microcrystals. m.p. 200-202 
°C (EtOH); Rf 0.06 (EtOAc); δH (500 MHz, CDCl3) 9.95 (br. s., 1 H, 6-NHCONHCH2CH3), 
9.05 (br. s., 1 H, 6-NHCONHCH2CH3), 8.84 (s, 1 H, 2-H), 7.67 (s, 1 H, 4-imidazoyl 2-H), 
7.20 (s, 1 H, 4-imidazoyl 5-H), 7.12 (s, 1 H, 4-imidazolyl 4-H), 6.90 (s, 1 H, 5-H), 4.23 (q, J 
7.33 Hz, 2 H, 3-CO2CH2CH3), 3.42 (qd, J 7.30, 5.50 Hz, 2 H, 6-NHCONHCH2CH3), 1.25 (t, J 
7.30 Hz, 3 H, 3-CO2CH2CH3), 1.20 (t, J 7.30 Hz, 3 H, 6-NHCONHCH2CH3); C (100 MHz, 
CDCl3) 163.7 (3-CO2CH2CH3), 156.0 (6-NHCONHCH2CH3), 155.5 (6-C), 151.7 (2-C), 145.7 
(4-C), 137.2 (4-imidazoyl 2-C), 129.9 (4-imidazoyl 5-C), 120.1 (4-imidazolyl 4-C), 115.5 
(3-C), 108.4 (5-C), 61.7 (3-CO2CH2CH3), 35.0 (6-NHCONHCH2CH3), 15.2 (3-CO2CH2CH3), 
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13.9 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 3214, 3120, 3136, 1725, 1686; m/z (ESI+) 
found MH+ 304.1416 C14H17N5O3 MH




Compound 67 (50 mg, 0.157 mmol) was dissolved in DMF 
(2 ml) and pyrrolidine (8.5 µl, 0.172 mmol) was added. 
The reaction was heated to 70 °C for 90 minutes and then 
stired at room temperature for 18 hours. The reaction 
mixture was then diluted with water (5 ml) and the resulting precipitate collected by 
filtration to afford the title compound (40.9 mg, 0.116 mmol, 74%) as colourless 
microcrystals, m.p. 237.4-240.2 °C; Rf 0.18 (5% MeOH in EtOAc); H (500 MHz, DMSO-
d6) 10.51 (s, 1 H, 3-CONH), 8.91 (s, 1 H, 6-NHCONHCH2CH3), 8.83 (d, J 2.6 Hz, 1 H, 3-
pyridyl 2-H), 8.27 (dd, 1 H, J 4.7, 1.7 Hz, 3-pyridyl 6-H), 8.21 (br. s., 1 H, 6-
NHCONHCH2CH3), 8.12 (d, J 8.5 Hz, 1 H, 3-pyridyl 4-H), 7.99 (s, 1 H, 5-H), 7.36 (dd, J 8.5, 
4.7 Hz, 1 H, 3-pyridyl 5-H), 6.64 (s, 1 H, 2-H), 3.20 - 3.27 (m, 2 H, 4-pyrrolidyl 2-H2), 3.16 
(qd, J 7.2, 5.8 Hz, 2 H, 6-NHCONHCH2CH3), 1.73 - 1.91 (m, 2 H, 4-pyrrolydyl 3-H2), 1.07 
(t, J 7.2 Hz, 3 H, 6-NHCONHCH2CH3); C (125 MHz, DMSO-d6) 166.9 (3-CONH), 154.7 (6-
NHCONHCH2CH3), 154.5 (C-4), 151.2 (C-6), 147.2 (5-C), 144.3 (3-pyridyl 6-C), 141.1 (3-
pyridyl 2-C), 136.0 (3-pyridyl 3-C), 126.3 (3-pyridyl 4-C), 123.6 (3-pyridyl 5-C), 113.8 (3-
C), 93.1 (2-C), 49.2 (4-pyrrolidyl 2-C), 33.7 (6-NHCONHCH2CH3), 25.1 (4-pyrrolidyl 3-C), 
15.4 (6-NHCONHCH2CH3); νmax / cm
-1 (solid) 3229, 3034, 2949, 1655, 1601, 1567, 1525; 










aminium trifluoroacetate 81 
Compound 85 (50 mg, 0.12 mmol) was dissolved in DCM 
(2 ml) and TFA (2 ml) was added. The reaction mixture 
was stirred at room temperature for 3 hours and then 
concentrated in vacuo to afford the title compound (49 
mg, 0.11 mmol, 98%) as a yellow glass. m.p. 138.9-141.0 °C; Rf 0.01 (EtOAc); δH (500 
MHz, MeOD) 8.94 - 9.02 (m, 1 H, 3-pyridyl 2-H), 8.36 (app. d, J 4.8 Hz, 1 H, 3-pyridyl 6-
H), 8.26 (app. d, J 6.0 Hz, 1 H, 3-pyridyl 4-H), 8.08 (s, 1 H, 2-H), 7.58 (dt, J 8.5, 4.8 Hz, 1 
H, 3-pyridyl 5-H), 6.32 (s, 1 H, 5-H), 3.95 (quin, J 5.4 Hz, 1 H, 4-pyrrolidyl 2-H), 3.83 (dd, 
J 12.0, 6.4 Hz, 1 H, 4-pyrrolidyl 2-H), 3.71 (dt, J 12.0, 7.5 Hz, 1 H, 4-pyrrolidyl 5-H), 3.59 
(dtd, J 8.1, 5.6, 5.6, 2.1 Hz, 1 H, 4-pyrrolidyl 5-H), 3.54 (dd, J 12.0, 4.3 Hz, 1 H, 4-
pyrrolidyl 3-H), 3.18 (q, J 7.2 Hz, 2 H, 6-NHCONHCH2CH3), 2.39 (qt, J 7.5, 6.0 Hz, 1 H, 4-
pyrrolidyl 4-H), 2.13 (td, J 12.9, 5.8 Hz, 1 H, 4-pyrrolidyl 4-H), 1.14 (t, J 7.2 Hz, 1 H, 6-
NHCONHCH2CH3); C (125 MHz, MeOD) 165.6 (3-CONH), 156.3 (6-NHCONHCH2CH3), 
154.7 (6-C), 150.2 (4-C), 144.2 (3-pyridyl 6-C), 140.1 (3-pyridyl 1-C),  139.1 (3-pyridyl 2-
C), 137.7 (C-2), 131.2 (3-pyridyl C-4), 126.3 (3-pyridyl C-5), 115.8 (C-3), 94.7 (5-C), 54.6 
(4-pyrrolidyl 2-C), 49.6 (4-pyrrolidyl 3-C), 35.7 (6-NHCONHCH2CH3), 29.9 (4-pyrrolidyl 4-
C), 15.1 (6-NHCONHCH2CH3). (4-pyrrolidyl 5-C under solvent peak). νmax / cm
-1 (solid) 
2981.9, 1673.1, 1650.51; m/z (ESI+) found MH+ 370.1990, C18H23N7O2 MH requires 
370.1986; HPLC RT = 0.77 mins. 
 
tert-butyl N-(1-benzylpyrrolidin-3-yl)carbamate130 83 
Boc anhydride (1.36 mg, 6.25 mmol) was dissolved in THF (10 ml) and 1-
benzyl-3-aminopyrrolidine (1.00 g, 5.68 mmol) and NEt3 (0.95 ml, 6.8 
mmol) were added. The reaction mixture was stirred at room 
temperature for 18 hours and then concentrated in vacuo. The resulting off-white 
residue was taken up into EtOAc (20 ml) and washed with NaOH(aq) (1 M, 20 ml). The 
combined organic extracts were dried over MgSO4, and concentrated in vacuo to 
afford a pale yellow solid. Recrystallisation from EtOAc afforded the title compound 
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(1.06 g, 3.83 mmol, 67%) as colourless needles, m.p. 108.1- 114.0 °C; Rf 0.14 (1:1 
EtOAc–Pet); H (300 MHz, CDCl3) 7.16 - 7.37 (m, 5 H, 1-benzyl CH), 4.88 - 5.04 (m, 1 H, 
NH), 4.05 - 4.25 (m, 1 H, CH), 3.58 (s, 2 H, 1-benzyl CH2), 2.68 - 2.86 (m, 1 H, CH), 2.45 - 
2.66 (m, 2 H, CH2), 2.13 - 2.36 (m, 2 H, CH2), 1.48 - 1.69 (m, 1 H, CH), 1.43 (s, 9 H, CH3); 
C (150 Hz, CDCl3) 155.4 (3-NHCO2), 138.8 (1-benzyl 1-C), 128.8 (1-benzyl 3-C), 128.3 (1-
benzyl 2-C), 127.0 (1-benzyl 4-C), 79.2 (OC(CH3)3), 61.0 (1-C), 60.2 (1-benzyl CH2), 52.6 
(5-C), 49.9 (3-C), 32.7 (4-C), 28.4 (CH3); (Found C, 69.6; H, 8.90; N, 10.1; C16H24N2O2 
requires C, 69.5; H, 8.75; N, 10.1%); νmax / cm
-1 (solid) 3199, 2969, 2810, 1699, 1538, 
1493; m/z (ES+) found MH+ 277.1909, C16H25N2O2 MH requires 277.1911; HPLC RT = 
1.78 mins. Spectroscopic data consistent with literature values.130 
 
tert-butyl N-(pyrrolidin-3-yl)carbamate130 84 
Compound 83 (1.00 g, 3.62 mmol) was dissolved in EtOH (10 ml) and THF 
(5 ml) and activated Pd on charcoal (100 mg) were added. The mixture was 
stirred under an atmosphere of H2 for 72 hours. The reaction mixture was 
then filtered through celite and the celite washed with EtOAc. The filtrate was 
concentrated in vacuo to afford the title compound (670 mg, 3.60 mmol, 97%) as 
colourless microcrystals, m.p. 76.4-78.9 °C; Rf 0.02 (EtOAc); δH (300 MHz, CDCl3) 4.82 
(br. s., 1 H, 3-NHCO2), 4.09 (br. s., 1 H, CH), 3.59 (s, 1 H, 3-H), 2.84 - 3.15 (m 
overlapping, 3 H, 3 × CH), 2.76 (dd, J 11.3, 3.8 Hz, 1 H, CH), 2.45 - 2.52 (m, 1 H, CH), 
2.10 (br. s., 1 H, NH), 1.63 - 1.73 (m, 1 H, CH), 1.44 (s, 9 H, CH3); δC (125 MHz, CDCl3) 
155.5 (3-NHCO2), 79.3 (OC(CH3)3), 62.9 (3-C), 60.8 (2-C), 45.5 (C-5), 32.3 (C-4), 28.4 
(CH3); νmax / cm
-1 (solid) 3308, 2974, 1683, 1520; m/z (ESI+) found MH+ 187.1442, 











Compound 67 (100 mg, 0.313 mmol) and compound 84 
(96 mg, 0.51 mmol) were dissolved in EtOH (4 ml) and the 
resulting solution was heated to 70 °C for 18 hours. 1 
drop of 2M HCl was added to the reaction mixture and 
the reaction mixture was then stirred for a further 72 hours. The reaction mixture was 
allowed to cool and concentrated in vacuo to afford an off-white residue. Purification 
using column chromatography (4% MeOHEtOAc) afforded the title compound (66 mg, 
0.14 mmol, 45%) as a colourless glass, Rf 0.05 (EtOAc); H (500 MHz, MeOD) 8.74 (br. 
s., 1 H, 3-pyridyl 2-H), 8.20 (dd, J 4.7, 1.3 Hz, 1 H,3-pyridyl 6-H), 8.13 (d, J 7.7 Hz, 1 H, 3-
pyridyl 6-H), 7.99 (s, 1 H, 2-H), 7.34 (dd, J 8.1, 4.7 Hz, 1 H, 3-pyridy 5-H), 6.30 (s, 1 H, 5-
H), 4.04 (br. s., 1 H, 4-pyrrolidy 2-H), 3.44-3.52 (m, 1 H, 4-pyrrolidy 2-H), 3.35 - 3.44 (m, 
1 H, 4-pyrrolidy 5-H), 3.24 - 3.31 (m, 1 H, 5-H), 3.16 - 3.24 (m, 4 H, 6-NHCONHCH2CH3, 
4-pyrrolidy 3-H and 5-H), 3.12 (dd, J 10.3, 4.7 Hz, 1 H, 4-pyrrolidyl 4-H), 2.07 (dq, J 12.5, 
6.4 Hz, 1 H, 4-pyrrolidy 4-H), 1.83 (dq, J 12.5, 6.4 Hz, 1 H, 4-pyrrolidy 4-H), 1.30 (s, 9 H, 
3 × CH3), 1.09 (t, J 7.1 Hz, 3 H, 6-NHCONHCH2CH3); C (125 MHz, MeOD) 169.7 (3-
CONH), 158.0 (4-pyrrolydiyl 3-NHCO2C(CH3)3), 157.7 (6-NHCONHCH2CH3), 156.0 (6-C), 
153.3 (4-C), 148.4 (3-pyridyl 6-C), 145.5 (6-pyridyl 1-C), 142.1 (3-pyridyl 2-C), 137.5 (C-
2), 129.2 (3-pyridyl 4-C), 125.3 (3-pyridyl 5-C), 115.2 (3-C), 94.7 (5-C), 80.3 (4-
pyrrolydiyl 3-NHCO2C(CH3)3), 56.1 (4-pyrrolidyl 3-C), 51.5 (4-pyrrolidyl 2-C), 35.4 6-
NHCONHCH2CH3), 31.8 (4-pyrrolidyl 4-C), 28.6 (4-pyrrolydiyl 3-NHCO2C(CH3)3), 15.5 (6-
NHCONHCH2CH3), (4-pyrrolidyl 5-C under solvent peak); νmax / cm
-1 (solid) 3221, 2973, 
1662, 1603; m/z (ESI+) found MH+ 470.2519, C23H32N7O4 MH requires 470.2510; HPLC 











Compound 63 (152 mg, 0.559 mmol) was suspended in 
pyridine (2 ml) and m-toluidine (0.133 ml, 1.23 mmol) 
and T3P solution (50% in EtOAc, 0.67 ml, 1.8 mmol) 
were added. The reaction mixture was heated to 70 °C 
for 18 hours. Further portions of T3P solution (0.26 ml, 0.67 mmol) and m-toluidine 
(0.133 ml, 1.23 mmol) were then added and the reaction mixture was heated to 90 °C 
for a further 10 hours. The reaction mixture was then allowed to cool to room 
temperature and concentrated in vacuo to afford an off-white solid. Trirturation with 
Et2O afforded the title compound (65.4 mg, 0.161 mmol, 29%) as colourless 
microcrystals. m.p. 235.4-238.8; Rf 0.17 (1:1 EtOAc-Pet); H (500 MHz, DMSO-d6) 10.18 
(br. s, 1 H, 3-CONH), 9.91 (br. s, 1 H, 6-NHCONHCH2CH3), 9.11 (br. s, 1 H, 4-NH), 8.55 (s, 
1 H, 2-H), 8.09 (br. s., 1 H, 6-NHCONHCH2CH3), 7.55 (s, 1 H, 3-phenyl 2-H), 7.46 (d, J 8.1 
Hz, 1 H, 3-phenyl 6-H), 7.27 (t, J 7.7 Hz, 1 H, 3-phenyl 5-H), 7.02 - 7.10 (m, 2 H, 5-H and 
4-phenyl 5-H), 7.02 - 7.10 (m, 2 H, 4-phenyl 2-H and 4-phenyl 6-H), 6.95 (d, J 7.7 Hz, 1 
H, 4-phenyl 4-H), 6.92 (d, J 7.7 Hz, 1 H, 3-phenyl 4-H), 3.15 (qd, J 7.1, 5.6 Hz, 2 H, 6-
NHCONHCH2CH3), 2.31 (s, 3 H, CH3), 2.30 (s, 3 H, CH3), 1.06 (t, J 7.1 Hz, 3 H, 6-
NHCONHCH2CH3); C (125 MHz, DMSO-d6) 166.5 (3-CONH), 155.8 (6-C), 154.4 (6-
NHCONHCH2CH3), 152.0 (4-C), 148.8 (2-C), 138.9 (4-phenyl 1-C), 138.8 (3-phenyl 1-C), 
138.6 (4-phenyl 3-C), 137.7 (3-phenyl 3-C), 129.2 (4-phenyl 5-C), 128.4 (3-phenyl 5-C), 
124.8 (4-phenyl 2-C), 124.5 (3-phenyl 2-C), 122.7 (4-phenyl 6-C), 121.3 (3-phenyl 6-C), 
119.9 (4-phenyl 4-C), 118.0 (3-phenyl 4-C), 108.3 (3-C), 92.0 (5-C), 33.8 (6-
NHCONHCH2CH3), 21.2 (4-phenyl CH3), 21.0 (3-phenyl CH3), 15.3 (6-NHCONHCH2CH3); 
νmax / cm
-1 (solid) 3395, 3341, 2968, 2860, 1713, 1682; m/z (ESI+) found MNa+ 
426.1906, C23H25N5O2 MNa requires 426.1900; HPLC RT = 3.43 mins. 
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tert-butyl N-[1-(6-amino-2-chloropyrimidin-4-yl)pyrrolidin-3-yl]carbamate 130 
Compound 84 (640 mg, 3.46 mmol) and 4-amino-2,6-dichloropyridine 
(567 mg, 3.46 mmol) were suspended in 1,4-dioxane (15 ml) and NEt3 
(0.96 ml, 6.92 mmol) was added. The reaction mixture was heated to 
100 °C for 3 hours and then allowed to cool to room temperature. The 
reaction mixture was concentrated in vacuo and the resulting off-white residue was 
purified using column chromatography (5:1 to 1:1 PetEtOAc) to afford the title 
compound (780 mg, 2.49 mmol, 73%) as colourless microcrystals. Rf 0.26 (2:5 EtOAc-
Pet); δH (300 MHz, CDCl3) 5.79 (s, 1 H, 1-pyrimidinyl C5-H), 4.81 (br. s, 2 H, NH2), 4.75 
(br. s, 1 H, NH), 4.27 (m, 1 H, CH), 3.76 (dd, J 11.8, 6.0 Hz, 1 H, C5-H), 3.52 - 3.65 (m, 2 
H, C5-H and ), 3.41 (dd, J 11.5, 2.7 Hz, 1 H, CH), 2.11 - 2.28 (m, 1 H, C4-H), 1.79 - 1.97 
(m, 1 H, C4-H), 1.44 (s, 9 H, CH3); δC (125 MHz, CDCl3) 164.1 (1-pyrimidinyl 6-C), 160.1 
(4-C), 159.9 (1-pyrimidinyl 2-C), 155.3 (3-NHCO2), 92.6 (1-pyrimidinyl 5-C), 79.74 
(CO2C(CH3)3), 52.5 (5-C), 50.2 (2-C), 44.6 (3-C), 31.7 (4-C), 28.4 (CH3);  νmax/cm
-1 (solid) 
3338, 3223, 2872, 1688, 1623; m/z (ESI+) found MH+ 314.1383, C13H21ClN5O2 MH 
requires 314.1378; HPLC RT = 1.88 mins. 
 
2-chloro-6-(pyrrolidin-1-yl)pyrimidin-4-amine 132 
4-amino-2,6-dichloropyrimidine (1.1 g, 6.1 mmol) was dissolved in 1,4-
dioxane (10 ml) and pyrrolidine (0.30 ml, 6.1 mmol) was added. The 
reaction mixture was heated to 100 °C for 5 hours and then allowed to 
cool. The reaction mixture was concentrated in vacuo to afford a colourless solid. 
Purification using column chromatography (1:1 EtOAcPet) afforded the title 
compound (750 mg, 3.79 mmol, 62%) as colourless microcrystals, Rf 0.25 (1:1 EtOAc–
Pet); δH (300 MHz, CDCl3) 5.76 (s, 1 H, 5-H), 4.64 (br. s., 2 H, NH2), 3.52 (br. s., 4 H, 4-
pyrrolidyl 2-H and 5-H) 1.82 - 2.10 (m, 4 H, 4-pyrrolidyl 3-H and 4-H); δC (500 MHz, 
CDCl3) 164.0 (4-C), 160.1 (2-C), 159.9 (6-C), 91.9 (5-C), 46.7 (4-pyrrolidyl 2-C), 25.4 (4-
pyrrolidyl 3-C); νmax/cm
-1 (solid) 3322, 3179, 2970, 2858, 163, 1547, 1510; m/z (ESI+) 
found MH+ 199.0750, C8H12ClN4 MH requires 199.0745; HPLC RT = 1.23 mins. 
  




Sodium (3.9 g, 170 mmol) was added to EtOH (100 ml) under N2. When 
the sodium was fully dissolved urea (5.15 g, 86 mmol) and ethyl 
cyanoacetate (9.15 ml, 86 mmol) were added to the solution and the 
reaction mixture was then heated to reflux for 18 hours. Hot water (100 ml) was then 
added to the reaction mixture. Once the precipitate had fully dissolved, the reaction 
was neutralised to pH 7 by addition of glacial acetic acid. The reaction mixture was 
then cooled to 0 °C and the precipitate collected by filtration to afford the title 
compound (5.56 g, 43.7 mmol, 51%) as pale yellow microcrystals, m.p. >250 °C; Rf 0.04 
(EtOAc); H (500 MHz, DMSO-d6) 10.09 (br. s, 2 H, 1-NH and 3-NH), 6.21 (br. s., 2 H, 
NH2), 4.43 (s, 1 H, 5-H); δC (150 Hz, DMSO-d6) 164.3 (C-4), 155.2 (6-C), 151.1 (C-2), 74.1 
(5-C); νmax/cm
-1 (solid) 3398, 3117, 2954, 2833, 1696, 16223, 1575, 1530, 1468; m/z 
(ESI+) found MH+ 128.0455, C4H6N3O2 MH requires 128.0455; HPLC RT = 0.83 mins. 
Spectroscopic data consistent with literature values.160 
 
2-amino-5-phenyl-4H,7H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one 150 
Ethyl benzoylacetate (874 µl, 5.05 mmol) and 2,5-
diaminotriazole (500 mg, 5.05 mmol) were suspended in AcOH 
(10 ml) and the reaction mixture was heated to 100 °C for 72 
hours. The reaction was then allowed to cool to room temperature and the resulting 
precipitate was collected by filtration and washed with methanol to afford the title 
compound (850 mg, 3.75 mmol, 74%) as colourless microcrystals. m.p. >250 °C;  Rf 0.04 
(EtOAc); H (500 MHz, DMSO-d6) 7.88 (s, 2 H, 5-phenyl 2-H), 7.46 - 7.57 (m, 3 H, 5-
phenyl 3-H and 4-H), 6.33 (br. s., 2 H, 2-NH2), 6.25 (s, 1 H, 6-H), 2.06 (br. s., 1 H, 4-NH); 
C (125 MHz, DMSO-d6) 155.3 (7-C), 150.3 (5-C), 130.4 (5-phenyl 4-C), 128.8 (5-phenyl 
3-C), 127.1 (5-phenyl 2-C), 97.9 (6-C); νmax / cm
-1 (solid) 3306, 3178, 3080, 2590, 1673; 








2,5-diaminotriazole (200 mg, 2.02 mmol) was suspended in 1,4-
dioxane (6 ml) and ethyl isocyanate (240 µl, 3.03 mmol) was 
added. The reaction mixture was stirred at room temperature for 
40 hours and the resulting precipitate was collected by filtration 
to afford the title compound (338 mg, 1.40 mmol, 92%) as colourless microcrystals, 
m.p. >250 °C; Rf 0.05 (1:1 EtOAc-Pet); H (300 MHz, DMSO-d6) 9.33 (br. s., 1 H, 5-
NHCONHCH2CH3), 8.14 (t, J 5.9 Hz, 1 H, 1-CONHCH2CH3), 7.84 (t, J 5.8 Hz, 1 H, 5-
NHCONHCH2CH3), 7.33 (br. s., 2 H, 3-NH2), 3.21 (m, 4 H, 1-CONHCH2CH3 and 5-
NHCONHCH2CH3), 1.11 (m, 6 H, 1-CONHCH2CH3 and 5-NHCONHCH2CH3); C (125 MHz, 
MeOD) 157.4 (3-C), 156.4 (1-CONHCH2CH3 or 5-NHCONHCH2CH3), 156.1 (1-
CONHCH2CH3 or 5-NHCONHCH2CH3), 152.7 (5-C), 35.7 (1-CONHCH2CH3 or 5-
NHCONHCH2CH3), 35.7 (1-CONHCH2CH3 or 5-NHCONHCH2CH3), 15.6 (1-CONHCH2CH3), 
15.1 (5-NHCONHCH2CH3); νmax / cm
-1 (solid) 3395, 3341, 2968, 2860, 1713, 1682; m/z 
(ESI+) found MH+ 242.1362, C8H15N7O2 MH requires 242.1360; 
 
3,5-diamino-N-ethyl-1H-1,2,4-triazole-1-carboxamide 154 
2,5-diaminotriazole (200 mg, 2.02 mmol) was suspended in 1,4-
dioxane (5 ml) and ethyl isocyanate (186 µl, 1.83 mmol) was added. 
The reaction mixture was then stirred at room temperature for 48 
hours and the resulting precipitate was collected by filtration to afford the title 
compound (316 mg, 1.86 mmol, 100%) as colourless microcrystals, m.p. 121.7-124.8 
°C; Rf 0.19 (EtOAc);  δH (500 MHz, MeOD) 3.33 (q, J 7.20 Hz, 1 H, 1-CONHCH2CH3), 1.22 
(t, J 7.10 Hz, 3 H, 1-NHCH2CH3); δC (125 MHz, MeOD) 161.9 (C-3), 157.9 (C-5), 153.1 (1-
CONHCH2CH3), 35.6 (1-CONHCH2CH3), 15.2 (1-CONHCH2CH3); νmax / cm
-1 (solid) 3419, 
3332, 3203, 2974, 1712, 1687 m/z (ESI+) found MH+ 171.0989, C5H11N6O MH requires 
171.0989; HPLC RT = 1.78 mins. Spectroscopic data consistent with literature values.161 
 
  




Either: compound 150 (180 mg, 0.79 mmol) was suspended in 
POCl3 (4 ml) and heated to 100 °C for 4 hours. The resulting 
reaction mixture was then poured onto a mixture of ice and 
water and neutralised by the addition of K2CO3. The resulting aqueous mixture was 
extracted into DCM (4 × 10 ml). The combined organic extracts were washed with 
brine (10 ml), dried over Na2SO4 and concentrated in vacuo to afford a dark orange 
residue. Purification by column chromatography (1:2 PetEtOAc) afforded the title 
compound (18 mg, 0.078 mmol, 10%) as off-white microcrystals. Or: compound 150 
(180 mg, 0.79 mmol) was suspended in phenyl phosphonic anhydride (4 ml) and 
heated to 140 °C for 4 hours. The resulting reaction mixture was then poured onto a 
mixture of ice and water and neutralised by the addition of K2CO3. The resulting 
aqueous mixture was extracted into DCM (4 × 10 ml). The combined organic extracts 
were washed with brine (10 ml), dried over Na2SO4 and concentrated in vacuo to 
afford a dark orange residue. Purification by column chromatography (1:2 PetEtOAc) 
afforded the title compound (11 mg, 0.043, 5%) as off-white microcrystals. Rf 0.2 (1:1 
EtOAc-Pet); H (300 MHz, CDCl3) 8.14 (dd, J 6.9, 3.0 Hz, 2 H, 5-phenyl 2-H), 7.49 - 7.59 
(m, 3 H, 5-phenyl 3-H and 5-phenyl 4-H), 7.47 (s, 1 H, 6-H), 4.84 (br. s., 2 H, 2-NH2); C 
(75 MHz, DMSO-d6) 167.7 (2-C), 157.5 (5-C), 155.5 (3’-C), 136.2 (5-phenyl 1-C), 135.8 
(7-C), 130.9 (5-phenyl 4-C), 128.9 (5-phenyl 3-C), 127.3 (5-phenyl 2-C), 105.1 (6-C); νmax 
/ cm-1 (solid) 3317, 3174, 1645; m/z (ESI+) found MH+ 246.0544, C11H9ClN5 MH requires 
246.0541; HPLC RT = 1.93 mins. 
 
N-[2-(ethylamino)-4-oxo-3,4-dihydroquinazolin-5-yl]-4-phenylbenzamide 158 
General method E using compound 172 (350 mg, 0.98 
mmol). Purification using column chromatography 
(1:1 PetEtOAc to EtOAc) followed by recrystallization 
from EtOAc afforded the title compound (12 mg, 0.032 mmol, 3%) as colourless 
microcrystals. m.p. >250 °C; Rf 0.62 (1:1 EtOAc-Pet); H (500 MHz, DMSO-d6) 8.51 (br. 
s., 1 H, 3-NH), 8.41 (d, J 8.7 Hz, 1 H, 5-NHCO), 8.01 - 8.18 (m, 2 H, 5-phenyl 3-H), 7.92 
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(d, J 8.2 Hz, 2 H, 4-phenyl 2-H), 7.80 (d, J 7.3 Hz, 2 H, 5-phenyl 2-H), 7.59 (t, J 8.0 Hz, 1 
H, 4-phenyl 4-H), 7.54 (t, J 7.6 Hz, 2 H, 4-phenyl 3-H), 7.45 (t, J 7.3 Hz, 1 H, 7-H), 7.01 (d, 
J 8.2 Hz, 1 H, 6-H), 6.39 (br. s., 1 H, 8-H), 5.77 (s, 1 H, 2-NHCH2CH3), 3.38 (qd, J 7.3, 6.8 
Hz, 2 H, 2-NHCH2CH3), 1.18 (t, J 7.3 Hz, 3 H, 2-NHCH2CH3); C (100 MHz, DMSO-d6) 
165.8 (5-NHCO), 164.7 (4-C), 153.0 (2-C), 130.4 (8’-C), 144.1 (5-phenyl 4-C), 141.0 (5-C), 
139.4 (4-phenyl 1-C), 135.7 (7-C), 133.8 (5-phenyl 1-C), 129.6 (4-phenyl 3-C), 128.7 (4’-
C), 128.1 (5-phenyl 3-C), 127.7 (5-phenyl 2-C), 127.6 (4-phenyl 2-C), 127.5 (4-phenyl 4-
C), 119.8 (6-C), 111.3 (8-C), 35.6 (2-NHCH2CH3), 15.1 (2-NHCH2CH3); νmax / cm
-1 (solid) 
3246, 3117, 3029, 1671, 1607; m/z (ESI+) found MH+ 385.1672, C23H20N4O2 MH requires 
385.1659; HPLC RT = 2.83 mins. 
 
N-[2-(ethylamino)-4-oxo-3,4-dihydroquinazolin-5-yl]quinoline-2-carboxamide 161 
General method E using compound 173 (235 mg, 0.721 
mmol). Purification using column chromatography (7:1 
EtOAcPet) afforded the title compound (6.1 mg, 0.017 
mmol, 2%) as pale yellow microcrystals. m.p. >250 °C; Rf 0.40 (1:7 EtOAc-Pet); δH (500 
MHz, DMSO-d6) 11.17 (br. s., 1 H, NH), 8.63 (d, J 8.1 Hz, 1 H, quinoline 4-H), 8.51 (d, J 
8.1 Hz, 1 H, quinazolinone 6-H), 8.28 (d, J 8.5 Hz, 1 H, quinoline 3-H), 8.15 (d, J 8.5 Hz, 1 
H, quinoline 8-H), 8.12 (d, J 8.5 Hz, 1 H, quinoline 5-H), 7.91 (t, J 7.7 Hz, 1 H, quinoline 
7-H), 7.76 (t, J 7.5 Hz, 1 H, quinoline 6-H), 7.58 (t, J 8.1 Hz, 1 H, quinazolinone 7-H), 7.00 
(d, J 8.1 Hz, 1 H, quinazolinone 8-H), 6.34 (br. s., 1 H, NHCH2CH3), 3.36 (qd, J 7.1, 5.0 Hz, 
2 H, NHCH2CH3), 1.16 (t, J 7.1 Hz, 3 H, NHCH2CH3), 3-NH not resolved; δC (125 MHz, 
DMSO-d6) 164.5 (quinazolinone 4-C), 163.1 (ArCONHAr), 152.6 (quinazolinone 2-C), 
150.0 (quinazolinone C-8’), 145.9 (quinoline C-8’), 139.7 (quinazolinone C-5), 138.2 
(quinoline 4-C), 134.8 (quinazolinone 7-C), 130.7 (quinoline C-4’), 129.3 (quinoline C-2 
or C-8), 129.0 (quinoline C-2 or C-8), 128.4 (quinoline C-5 or C-6), 128.1 (quinoline C-5 
or C-6), 119.6 (quinazoline C-8), 118.7 (quinoline C-3), 111.2 (quinazoline C-6), 105.3 
(quinazolinone C-4’), 35.1 (NHCH2CH3), 14.7 (NHCH2CH3); νmax / cm
-1 (solid) 2959, 2929, 
2860, 1726; m/z (ESI+) found MH+ 360.1459, C20H17N5O2 MH requires 360.1455; HPLC 
RT = 2.27 mins. 




General method E using compound 174 (193 mg, 
0.53 mmol). Purification using column 
chromatography (1:1 EtOAcPet to EtOAc) afforded 
the title compound (38 mg, 0.095 mmol, 18%), as colourless microcrystals, m.p. 233.9-
235.6; Rf 0.55 (EtOAc); H (500 MHz, DMSO-d6) 11.13 (br. s., 1 H, 3-NH), 8.38 (br. s., 1 
H, 5-NHCO), 8.02 (d, J 7.3 Hz, 2 H, 6-benzamido 2-H), 7.56 (t, J 7.9 Hz, 1 H, 7-H), 7.48 
(m, 2 H, 4-phenoxy 3-H), 7.26 (t, J 7.3 Hz, 1 H, 8-H), 7.16 (d, J 8.7 Hz, 4 H, 6-benzamido 
3-H and 4-phenoxy 2-H), 6.99 (d, J 7.8 Hz, 1 H, 6-H), 6.39 (br. s., 1 H, 2-NHCH2CH3) 3.35 
- 3.42 (m, 2 H, overlapped with H2O signal, 2-NHCH2CH3), 1.17 (t, J 7.1 Hz, 3 H, 2-
NHCH2CH3); C (125 MHz, DMSO-d6) 163.9 (5-NHCO), 163.6 (4-C), 160.2 (6-benzamido 
4-C), 155.5 (4-phenoxy 1-C), 154.0 (2-C), 142.5 (8’-C), 140.6 (5-C), 130.2 (6-benzamido 
2-C), 130.1 (6-benzamido 1-C), 129.4 (7-C), 129.2 (4-phenoxy 3-C), 124.4 (8-C), 124.3 
(4-phenoxy 4-C), 119.6 (4-phenoxy 2-C), 117.9 (6-C), 104.6 (6-benzamido 3-C), 35.1 (2-
NHCH2CH3), 14.6 (2-NHCH2CH3), 4’-C not resolved; νmax / cm
-1 (solid) 3251, 3068, 2978, 
1674, 1607; m/z (ESI+) found MH+ 401.1624, C23H20N4O2 MH requires 401.1608; HPLC 
RT = 2.69 mins. 
 
N-[2-(ethylamino)-4-oxo-3,4-dihydroquinazolin-5-yl]pyridine-3-carboxamide 163 
General method E using compound 175 (100 mg, 1.17 
mmol). Purification using column chromatography (5% 
MeOH in CHCl3) afforded the title compound (37 mg, 0.18 
mmol, 16%) as colourless microcrystals. m.p. >250 °C; Rf 0.09 (EtOAc); δH (500 MHz, 
DMSO-d6) 11.20 (br. s., 1 H, quinazolinone 3-NH),, 9.82 (br. s., 1 H, 5-NHCO) 9.15 (s, 1 
H, pyridyl 2-H), 8.80 (d, J 4.7 Hz, 1 H, pyridyl 6-H), 8.32 - 8.42 (m, 1 H, quinazolinone 6-
H), 8.30 (d, J 7.7 Hz, 1 H, pyridyl 4-H), 7.63 (dd, J 7.7, 4.7 Hz, 1 H, pyridyl 5-H), 7.56 
(app. t, J 8.1 Hz, 1 H, quinazolinone 7-H), 7.00 (d, J 8.1 Hz, 1 H, quinazolinone 8-H), 6.45 
(br. s., 1H, 2-NHCH2CH3), 3.35 (qd, J 7.1, 5.6 Hz, 2 H, 2-NHCH2CH3), 1.15 (t, J 7.1 Hz, 3 H, 
3-NHCH2CH3); δC (125 MHz, DMSO-d6) 163.1 (5-NHCO), 152.6 (pyridyl 6-C), 148.1 
(pyridyl 2-C), 140.1 (quinazolinone 5-C), 134.9 (quinazolinone 7-C), 134.8 (pyridyl 4-C), 
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130.2 (quinazolinone C-4’), 124.1 (pyridyl 3-C), 124.0 (pyridyl 5-C), 118.8 
(quinazolinone 8-C), 111.0 (quinazolinone 6-C) 104.5, 35.1 (2-NHCH2CH3), 14.6 (2-
NHCH2CH3); νmax / cm
-1 (solid) 3029, 1674, 1643; m/z (ESI+) found MH+ 310.1302, 
C16H15N5O2 MH requires 310.1299; HPLC RT = 0.83 mins. 
 
N-[2-(ethylamino)-4-oxo-3,4-dihydroquinazolin-5-yl]benzamide 164 
General method E using compound 176 (200 mg, 0.727 
mmol). Purification using column chromatography (1:1 to 
7:3 EtOAcPet) followed by recrystallisation from EtOH 
afforded the title compound (34 mg, 0.11 mmol, 15%), as colourless microcrystals m.p. 
>250 °C; Rf 0.29 (1:1 EtOAc-Pet); H (300 MHz, DMSO-d6) 11.12 (br. s., 1 H, 3-H), 8.41 
(d, J 7.9 Hz, 1 H, 5-NHCO), 8.00 (d, J 6.8 Hz, 2 H, 5-phenyl 2-H), 7.45 - 7.74 (m, 4 H, 7-H, 
5-phenyl 3-H and 5-phenyl 4-H), 6.99 (d, J 7.9 Hz, 1 H, 6-H), 6.43 (br. s., 1 H, 2-
NHCH2CH3, 8-H), 3.33 - 3.57 (m, 2 H, overlapped with H2O signal, 2-NHCH2CH3), 1.17 (t, 
J 7.2 Hz, 3 H, 2-NHCH2CH3); C (100 MHz, DMSO-d6) 165.1 (C-4), 155.8 (2-C), 150.3 
(8’C), 140.9 (5-C), 135.6 (5-phenyl 1-C), 135.1 (7-C), 132.6 (5-phenyl 4-C), 129.5 (4-
phenyl 3-C), 127.5 (4’-C), 127.4 (4-phenyl 2-C), 119.8 (6-C), 111.3 (8-C), 35.6 (2-
NHCH2CH3), 15.1 (2-NHCH2CH3) 5-NHCO not resolved; νmax / cm
-1 (solid) 3469, 3241, 
3024, 1682, 1612; m/z (ESI+) found MH+ 309.1353, C17H16N4O2 MH requires 309.1346; 
HPLC RT = 2.06 mins. 
 
5-amino-2-(ethylamino)-1,4-dihydroquinazolin-4-one 169 
General method E using 2-amino-6-chloro benzoic acid (200 mg, 
1.17 mmol). Purification using column chromatography (5% MeOH 
in CHCl3) afforded the title compound (37 mg, 0.18 mmol, 16%) as 
colourless microcrystals. m.p. 158.2 – 162.5 °C; Rf 0.25 (EtOAc); 
H (500 MHz, DMSO-
d6) 10.41 (br. s., 1 H, 1-H), 7.11 (t, J 7.9 Hz, 1 H, 7-H), 6.89 (br. s., 2 H, 5-NH2), 6.26 (d, J 
7.7 Hz, 1 H, 8-H), 6.20 (d, J 8.1 Hz, 1 H, 6-H), 6.05 (br. s., 1 H, 2-NHCH2CH3), 3.16 - 3.30 
(m, 2 H, 2-NHCH2CH3, overlapped with H2O signal), 1.11 (t, J 7.1 Hz, 3 H, 2-NHCH2CH3); 
C (100 MHz, DMSO-d6) 162.8 (4-C), 151.3 (2-C), 135.0 (7-C), 110.6 (4’-C), 107.0 (6-C), 
Chapter 7  Experimental 
167 
 
102.2 (8-C), 35.5 (2-NHCH2CH3), 15.2 (2-NHCH2CH3); νmax / cm
-1 (solid) 3409, 3040, 
2870, 1673, 1603; m/z (ESI+) found MNa+ 277.0901, C10H12N4O MNa requires 277.0903; 
HPLC RT = 1.36 mins. 
 
2-chloro-6-(4-phenylbenzamido)benzoic acid 172 
General method D using 4-phenyl benzoic acid (317 mg, 
1.61 mmol) and 2-amino-6-chlorobenzoic acid (250 mg, 
1.46 mmol). Purification using column chromatography 
(toluene) afforded the title compound (143 mg, 0.35 mmol, 24%) as colourless 
microcrystals, m.p. 227.6-231.3; Rf 0.57 (EtOAc); H (500 MHz, CDCl3) 8.30 (dt, J 8.7, 1.7 
Hz, 2 H, 6-phenyl 3-H), 7.68 (dt, J 8.7, 1.7 Hz, 2 H, 4-phenyl 2-H), 7.51 - 7.65 (m, 4 H, 6-
phenyl 2-H, 4-phenyl 4-H and 4-H), 7.30 - 7.48 (m, 4 H, 4-phenyl 3-H, 3-H and 5-H); C 
(75 MHz, DMSO-d6) 206.4 (1-CO2H), 156.9 (6-NHCO), 155.7 (6-phenyl 4-C), 144.3 (4-
phenyl 1-C), 136.6 (6-phenyl 1-C), 130.5 (6-C), 129.1 (4-C), 128.6 (2-C), 127.2 (1-C), 
126.9 (4-phenyl 2-C), 126.3 (4-phenyl 3-C), 114.8 (5-C); νmax / cm
-1 (solid) 2836, 2545, 
1675, 1606; m/z (ESI+) found MH+ 374.0549, C20H14ClNO3 MNa
+ requires 374.0554; 
HPLC RT = 3.35 mins. 
 
2-chloro-6-(quinoline-2-amido)benzoic acid 173 
General method D using quinaldic acid (227 mg, 1.61 mmol) 
and 2-amino-6-chloro benzoic acid (250 mg, 1.46 mmol). 
Purification using column chromatography (0.5% AcOH in 
EtOAc) afforded the title compound (227 mg, 0.85 mmol, 58%) as pale yellow 
microcrystals. m.p. 238.1-242.1 °C; Rf 0.40 (1:7 EtOAc-Pet); δH (500 MHz, DMSO-d6) 
11.46 (br. s, 1 H, COOH), 8.66 (d, J 8.5 Hz, 1 H, 6-quinoline 4-H), 8.41 (d, J 8.5 Hz, 1 H, 5-
H), 8.26 (d, J 8.5 Hz, 1 H, 6-quinoline 3-H), 8.17 (d, J 8.5 Hz, 1 H, 6-quinoline 8-H), 8.13 
(d, J 8.1 Hz, 1 H, 6-quinoline 5-H), 7.93 (app t, J 7.7 Hz, 1 H, 6-quinoline 7-H), 7.77 (app 
t, J 7.5 Hz, 1 H, 6-quinoline 6-H), 7.55 (t, J 8.1 Hz, 1 H, 4-H), 7.35 (d, J 7.7 Hz, 1 H, 3-H); 
δC (125 MHz, DMSO-d6) 166.5 (1-CO2H), 162.1 (6-NHCO), 148.8 (6-quinoline 2-C), 145.6 
(6-quinoline 8-C’), 138.7 (6-quinoline 4-C), 136.8 (6-C), 131.5 (4-C), 131.5 (2-C), 131.0 
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(6-quinoline 7-C), 130.9 (1-C), 129.3 (6-quinoline 8-C or 6-C), 129.2 (6-quinoline 8-C or 
6-C), 128.7 (6-quinoline 5-C), 128.2 (6-quinoline 4-C’), 125.5 (3-C), 119.8 (5-C), 118.4 
(6-quinoline 3-C); νmax / cm
-1 (solid) 3279, 2855, 1679, 1594; m/z (ESI+) found MH+ 
327.0539, C17H11ClN2O3 MH requires 327.0531; HPLC RT = 2.91 mins. 
 
2-chloro-6-(4-phenoxybenzamido)benzoic acid 174 
General method D using 4-phenyl benzoic acid (289 mg, 
1.35 mmol) and 2-amino-6-chloro benzoic acid (250 mg, 
1.46 mmol). MeOH (50 ml) was added to reaction 
mixture and the resulting precipitate was collected by filtration to afford the title 
compound (106 mg, 0.289 mmol, 21%) as colourless microcrystals, m.p. 165.7-168.4; Rf 
0.39 (toluene); H (500 MHz, CDCl3) 8.19 (dt, J 8.8, 2.0 Hz, 2 H, 6-benzamido 2-H), 7.60 
(t, J 7.9 Hz, 1 H, 4-H), 7.50 (dd, J 7.9, 1.1 Hz, 1 H, 3-H), 7.43 (dd, J 7.9, 1.1 Hz, 1 H, 5-H), 
7.35 (tt, J 7.8, 1.7 Hz, 2 H, 4-phenoxy 3-H), 7.15 (tt, J 7.9, 1.7 Hz, 1 H, 4-phenoxy 4-H), 
6.96 - 7.06 (m, 4 H, 6-benzamido 3-H and 4-phenoxy 2-H); C (125 MHz, DMSO-d6) 
161.7 (6-NHCO), 161.2 (1-CO2H), 156.7 (6-benzamido 4-C), 155.7 (4-phenoxy 1-C), 
155.0 (6-C), 149.0 (6-benzamido 1-C), 136.6 (4-C), 134.1 (2-C), 130.4 (6-benzamido 6-
C), 130.3 (4-phenoxy 3-C), 126.2 (1-C), 124.9 (3-C), 124.0 (5-C), 120.0 (4-phenoxy 2-C), 
117.7 (6-benzamido 3-C), 114.5 (4-phenoxy 4-C); νmax / cm
-1 (solid) 3071, 2923, 1756, 
1623; HPLC RT = 4.11 mins. 
 
2-chloro-6-(pyridine-3-amido)benzoic acid 175 
General method D using nicotinic acid (1.44 g, 11.7 mmol) and 2-
amino-6-chloro benzoic acid (1 g, 5.84 mmol). Purification using 
column chromatography (DCM–MeOH 99:1) afforded the title 
compound (341 mg, 1.24 mmol, 21%) as colourless microcrystals, m.p. 153.4-154.2 °C; 
Rf 0.18 (1:1 EtOAc-Pet); H (500 MHz, DMSO-d6) 9.31 (d, J 1.4 Hz, 1 H, 6-pyridyl 2-H), 
8.85 (dd, J 4.6, 1.4 Hz, 1 H, 6-pyridyl 6-H), 8.49 (d, J 8.2 Hz, 1 H, 6-pyridyl 4-H), 7.90 (t, J 
8.2 Hz, 1 H, 6-pyridyl 5-H), 7.68 - 7.76 (m, 2 H, 3-H and 4-H), 7.66 (dd, J 8.0, 4.8 Hz, 1 H, 
5-H); c (125 MHz, DMSO-d6) 155.8 (1-CO2H), 155.3 (6-NHCO), 153.13 (6-pyridyl 6-C), 
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148.7 (6-pyridyl 2-C), 148.4 (6-pyridyl 3-C), 136.7 (6-pyridyl 6-C), 135.4 (6-pyridyl 4-C), 
134.1 (6-C), 130.9 (4-C), 126.4 (3-C), 125.9 (2-C), 124.1 (5-C), 115.0 (1-C); νmax / cm
-1 
(solid) 3090, 1779, 1626; m/z (ESI-) found M-H 275.0220, C12H9ClN2O3 M-H requires 
275.0229; HPLC RT = 1.96 mins. 
 
2-benzamido-6-chlorobenzoic acid 176 
General method D using benzoic acid (227 mg, 2.27 mmol) and 2-
amino-6-chloro benzoic acid (250 mg, 1.46 mmol). Purification 
using column chromatography (toluene) afforded the title 
compound (213 mg, 0.775 mmol, 37%) as colourless microcrystals, m.p. 154.3-155.2 
°C; Rf 0.59 (1:4 EtOAc-Pet); H (300 MHz, CDCl3) 8.25 - 8.38 (m, 2 H, 2-phenyl 2-H), 7.71 
(t, J 7.9 Hz, 1 H, 4-H), 7.58 - 7.66 (m, 2 H, 2-phenyl 3-H), 7.48 - 7.58 (m, 3 H, 2-NHCO, 3-
H and 5-H); C (100 MHz, DMSO-d6) 159.4 (CONH), 137.9 (2-C), 137.1 (4-C), 134.6 (2-
phenyl 1-C), 133.5 (3-C), 131.0 (1-C), 130.1 (6-C), 129.6 (2-phenyl 4-C), 128.4 (2-phenyl 
3-C), 127.9 (2-phenyl 2-C), 126.8 (5-C), 1-C not resolved; νmax / cm
-1 (solid) 3065, 1755, 
1625; m/z (ESI+) found MNa+ 298.0204, C14H10ClNO3 MNa requires 298.0241; HPLC RT = 
3.60 mins. 
 
2-chloro-6-[4-(methoxycarbonyl)benzamido]benzoic acid 178 
Monomethyl terephthalate (1.00 g, 5.56 mmol) was 
suspended in DMF under N2 and NEt3 (2.31 ml, 16.7 mmol) 
and T3P solution (50% in DMF, 6.5 ml, 11 mmol) were 
added. The reaction mixture was stirred at room temperature for two hours and then 
2-amino-6-chlorobenzoic acid (613 mg, 5.56 mmol) was added. The reaction mixture 
was stirred for a further 18 hours and then a further 0.5 equivalents of T3P solution 
were added and the reaction mixture was heated to 75 °C for 18 hours. A further 
equivalent of NEt3 was then added and the reaction mixture was heated to 100 °C for 
three hours before being allowed to cool to room temperature. Water (5 ml) was 
added and the resulting precipitate was collected by filtration to afford the title 
compound (700 mg, 2.10 mmol, 38%) as colourless needles. m.p. 198.2-201.3; Rf 0.5 
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(1:4 EtOAc-Pet); δH (500 MHz, CDCl3) 8.38 (d, J 8.55 Hz, 2 H, 6-benzamido 2-H), 8.19 (d, 
J 8.55 Hz, 2 H, 6-benzamido 3-H), 7.72 (t, J 7.69 Hz, 1 H, 4-H), 7.64 (dd, J 7.70, 1.00 Hz, 
1 H, 3-H), 7.57 (dd, J 7.70, 1.07 Hz, 1 H, 5-H), 3.98 (s, 3 H, 6-benzamido-4-CO2CH3);  δC 
(125 MHz, CDCl3) 156.9 (6-NHCO), 155.7 (1-CO2H), 149.0 (6-benzamido-4-CO2CH3), 
136.2 (2-C), 136.0 (4-C), 133.8 (6-C or 6-benzamido 1-C), 133.6 (6-C or 6-benzamido 1-
C), 131.2 (5-C), 129.9 (6-benzamido 3-C), 128.4 (6-benzamido 2-C), 126.5 (3-C), 114.9 
(6-benzamido 4-C), 52.5 (6-benzamido-4-CO2CH3); νmax / cm
-1 (solid) 3039, 1767, 1725, 
1631; HPLC RT = 3.63 mins. 
 
2-chloro-6-(4-formylbenzamido)benzoic acid 183 
General method C using 4-formyl benzoic acid (1.00 g, 6.67 
mmol) and 2-amino-6-chlorobenzoic acid (1.04 g, 6.06 
mmol). A pale yellow precipitate was removed from the 
reaction mixture by filtration. The filtrate was concentrated in vacuo to afford a yellow 
solid. Recrystallisation from toluene afforded the title compound (263 mg, 0.888 
mmol, 14%) as pale yellow microcrystals. m.p. 207.4-210.2 °C; Rf 0.13 (EtOAc); δH (400 
MHz, DMSO-d6) 10.14 (s, 1 H, 6-phenyl 4-CHO), 8.38 (d, J 8.40 Hz, 2 H, 6-phenyl 3-H), 
8.12 (d, J 8.40 Hz, 2 H, 6-phenyl 2-H), 7.90 (t, J 7.80 Hz, 1 H, 4-H), 7.72 (d, J 7.82 Hz, 2 H, 
3-H and 5-H);  δC (100 MHz, DMSO-d6) 193.4 (6-phenyl 4-CHO), 156.6 (6-NHCO), 155.9, 
(1-CO2H), 149.0 (6-phenyl 1-C), 139.2 (6-C), 137.2 (4-C), 135.1 (6-phenyl 4-C), 134.6 (2-
C), 131.6 (5-C), 130.4 (6-phenyl 2-C), 129.4 (1-C), 129.0 (6-phenyl 3-C), 127.0 (3-C); νmax 
/ cm-1 (solid) 3085, 2820, 2736, 1760, 1697; m/z (ESI+) found MH+ 304.0375, 
C15H11ClNO4 MH requires 304.0371; HPLC RT = 2.49 mins. 
 
3-hydroxy-2-nitrobenzoic acid 185 
3-chloro-2-nitrobenzoic acid (1.0g, 5.0 mmol) and NaOH (2.0g, 60 mmol) 
were dissolved in water (10 ml) and the reaction mixture was heated to 
reflux for 40 hours. The reaction mixture was then allowed to cool to 
room temperature and acidified to pH 3 by dropwise addition of cHCl. The reaction 
mixture was extracted into EtOAc (4 × 30 ml) and the combined organic extracts were 
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washed with brine (20 ml), dried over MgSO4 and concentrated in vacuo to afford an 
orange residue. Recrystallisation from EtOAc afforded the title compound (492 mg, 
3.02 mmol, 60%) as pale yellow microcrystals. m.p. 163.5-165.8 °C; Rf 0.16 (EtOAc);  δH 
(500 MHz, DMSO-d6) 11.22 (s, 1 H, 3-OH), 7.49 (t, J 8.00 Hz, 1 H, 5-H), 7.41 (dd, J 7.79, 
0.92 Hz, 1 H, 6-H), 7.31 (dd, J 8.25, 0.92 Hz, 1 H, 4-H); δC (125 MHz, DMSO-d6) 163.6 (1-
CO2H), 148.1 (3-C), 138.5 (2-C), 129.3 (6-C), 123.5 (1-C), 119.9 (4-C), 119.5 (5-C); νmax / 
cm-1 (solid) 3298, 3091, 2835, 2578, 1689;  m/z (ESI+) found MNa+ 227.9875, C7H5NO5 
MNa requires 227.9879; HPLC RT = 1.19 mins. Spectroscopic data consistent with 
literature values.157 
 
4,6-dibromo-3-hydroxy-2-nitrobenzoic acid 187 
Compound 185 (1.23 g, 6.72 mmol) was dissolved in EtOH (10 ml) and 
cooled to 0 °C, sodium acetate trihydrate (3.06 g, 2.25 mmol) and 
bromine (0.85 ml, 16 mmol) were then added to the solution. The 
reaction mixture was stirred at room temperature for 4 hours. The reaction mixture 
was concentrated in vacuo and the resulting pale orange residue was purified by 
trituration with Et2O to afford the title compound (705 mg, 2.08 mmol, 31%) as pale 
orange microcrystals. m.p. 195.0-198.5 °C; Rf 0.10 (EtOAc);  δH (500 MHz, DMSO-d6) 
8.50 (s, 1 H, 5-H); δC (75 MHz, DMSO-d6) 165.2 (1-CO2H), 158.1 (3-C), 136.2 (2-C), 134.2 
(1-C), 128.8 (5-C), 110.9 (6-C), 109.6 (4-C); νmax / cm
-1 (solid) 3362, 3085, 2865, 1703, 
1522; m/z (ESI-) found M-H 339.8288, C7H3Br2NO5 M-H requires 339.8285; HPLC RT = 
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7.2 Biological Methods 
7.2.1 Instrumentation 
Media, buffer and other equipment were sterilised using either a Prestige Medical 
bench top autoclave or an LTE Touchclave-R autoclave. All contaminated glassware, 
plastic-ware and media containing genetically modified bacteria was disposed of by 
bleaching, using either Virkon or Presept for 24 h or autoclaved (120 °C for 20 min) 
before disposal as aqueous waste or for incineration. Bacterial cultures were incubated 
in a Kuhner ShakerX ISF1-X or a Stuart orbital incubator. LB Agar plates and 96 well 
assay plates were incubated in a Binder BD23 incubator at 37°C. Centrifugation was 
carried out in a Beckman Coulter Avanti J-301 centrifuge and in bench-top centrifuges 
Pico and Fresco 17/21 from Thermo electron corporation. Cells were disrupted using a 
Constant Systems Cell Disrupter (T2/40/AA/AA). Size exclusion chromatography was 
performed using an Äkta Purifier FPLC from GE Healthcare. Protein and DNA 
concentrations were determined using a Nanodrop2000 UV/Vis spectrophotometer 
(Thermo Scientific). SDS-PAGE electrophoresis was carried out using a Bio-Rad mini-
protean 3 apparatus and the polyacrylamide gels were imaged with both UV and white 
light using a Bio-Rad molecular imager Gel Doc XR. Broad range (2-212 kDa) protein 
marker from New England Biolabs (NEB) was used as a reference. Water was purified 
before use to 15 Mq using an ELGA PURLAB Classic purification system. Protein mass 
spectrometry was performed in original buffers on a Bruker MaXis impact 
spectrometer and the raw mass spectra were deconvoluted using a maximum entropy 
algorithm part of Bruker data analysis. Results are quoted as mass-charge ratios (m/z). 




Analytical grade reagents were purchased from Sigma Aldrich, VWR International, 
Fisher Scientific and Alfa Aesar unless otherwise stated. Ni-NTA agarose was purchased 
from Qiagen. Enzymes, buffers and molecular weight markers were supplied by New 
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England Biolabs. DNase I recombinant and Protease inhibitor cocktail (cOmpleteTM) 
were purchased from Roche Diagnostics.  
Media  
Lysogeny Broth (LB): LB pre-mix freeze dried powder (consisting of tryptone (10 g/L), 
yeast extract (5 g/L), NaCl (10 g/L)) was made up with purified water to a quantity of 
25 g/L, autoclaved at 121 °C for 20 minutes as required and allowed to cool before use. 
Agar  
Agar plates were made with agar (15 g/L) and LB (25 g/L) before being autoclaved at 
121 °C for 20 minutes and stored at 60 °C. Agar was allowed to cool for 15 minutes 
before being inoculated with the desired antibiotic, poured onto Petri dishes in 20 ml 
portions and left to set in a sterile environment. Plates were stored at 4 °C prior to use. 
Plasmids 
Plasmids used during the project are given in Table 7.1. 
Table 7.1 Plasmids used during the project 
Name Resistance Promotor Genes encoded 
pAM24 JM109 Ampicilin T7 GyrB24 
pAG111 Ampicilin T7 GyrB 
pPH3 JM109 Ampicilin T7 GyrA 
pNIC-GB1 Kanamycin T7 His6-GB1 
pNIC-GB1-GyrB24 Kanamycin T7 His6-GB1-GyrB24 
pNIC-GB1-GyrA Kanamycin T7 His6-GB1-GyrA 
pNIC-GB1-GyrB Kanamycin T7 His6-GB1-GyrB 
 
pAM24, pAG111 and pPH3 were generously provided to us by the Maxwell group at 
the John Innes centre. pNIC vectors were a kind gift from Dr. Charles Allerston and Dr. 
Opher Gileadi, at the Oxford site of the Structural Genomics Consortium 
(www.addgene.org/Opher_Gileadi/), to the Driscoll group at the NIMR, London. pNIC-
GB1 was constructed at the NIMR from pNIC-GST by Dr. TJ. Ragan. All other pNIC 
plasmids were produced with the assistance of Gemma Wildsmith at the University of 
Leeds according to the procedure described in Section 7.2.7. 
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Buffers and Stains  
Buffers for size exclusion chromatography were vacuum filtered through a 0.22 μM 
membrane prior to use. Buffers used in the manipulation of DNA described in section 
7.2.7 were purchased from New England Biolabs (NEB) or EMD Millipore as stated. 
5X assay buffer for coupled assay: 250 mM Tris pH 7.5, 5 mM EDTA, 25 mM MgCl2, 25 
mM DTT, 50% glycerol 
Dilution buffer for coupled assay: 50 mM Tris pH 7.5, 100 mM KCl, 2 mM DTT, 1 mM 
EDTA, 50% glycerol 
TGED buffer: 50 mM Tris pH 7.5, 10% glycerol, 1mM EDTA, 5 mM DTT 
High glycerol TGED: 50 mM Tris pH 7.5, 30% glycerol, 1mM EDTA, 5 mM DTT 
SDS-PAGE loading buffer: 100 mM Tris pH 6.8, 4% SDS, 400 mM DTT, 20% glycerol, 0.6 
mM bromophenol blue 
5 × SDS-PAGE running Buffer: 125 mM Tris, 960 mM glycine, 0.5% SDS 
Coomassie Stain: 0.25% Coomassie blue R-250, 40% methanol, 10% acetic acid 
Coomassie Destain: 40% methanol, 10% acetic acid  
Lysis buffer: 50 mM Tris pH 8, 500 mM NaCl 
Wash buffer: 50 mM Tris pH 8, 500 mM NaCl, 50 mM imidazole 
Elution buffer: 50 mM Tris pH 8, 500 mM NaCl, 300 mM imidazole 
7.2.3 Methods 
7.2.4 Malachite green assay4 
Gyrase converts ATP into ADP and inorganic phosphate. The released phosphate can 
be detected by the addition of malachite green solution and measured by monitoring 
the increase in absorbance at 600 nm.  The ATPase assay measures the amount of ATP 
being cleaved to ADP and Pi by reaction of the Pi with malachite green dye. For IC50 
determinations each compound was tested once at multiple concentrations. Singlicate 
                                                     
4 Malachite green assay was performed at Biota Europe Ltd., Begbroke Business & Science 
Park, Sandy Lane, Yarnton, Oxfordshire, OX5 1PF. 
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samples were taken after 60 minutes and IC50 values were determined. Enzyme 
supplied by Inspiralis was used in all assays.  
The ATPase assay was carried out in a buffer containing 2 mU/µl Gyrase enzyme (A2B2 
complex from S. aureus), 0.08 mg/ml double stranded DNA, 8 mM HEPES.KOH pH 7.6, 
100 mM potassium glutamate, 2 mM magnesium acetate, 2 mM DTT, 0.01 mg/ml BSA, 
and 5% DMSO solution containing the inhibitor. Alternatively, the ATPase assay was 
carried out in a buffer containing 4.8 µg/ml Gyrase enzyme (A2B2 complex from E. coli), 
0.08 µg/ml ssDNA, 35 mM Tris pH 7.5, 24  mM KCl, 2 mM MgCl2, 6.5% Glycerol, 2 mM 
DTT, 1.8 mM Spermidine, 0.5 mg/ml BSA and 5% DMSO solution containing the 
inhibitor. The reaction is started by adding ATP to a final concentration of 1 mM and 
allowed to incubate at 30 °C for 60 minutes. The reaction was stopped by adding 
200 µl of malachite green solution (0.034% malachite green, 10 mM ammonium 
molybdate, 1 M HCl, 3.4% ethanol, 0.01% tween 20). Colour was allowed to develop 
for 5 minutes and the absorbance at 600 nm was measured spectrophotometrically. 
The IC50 values were determined from the absorbance readings using no compound 
and no enzyme controls.  
7.2.5 Coupled assay 
The coupled enzyme ATPase assay is based on the conversion of phosphoenolpyruvate 
(PEP) to pyruvate by pyruvate kinase (PK) coupled to the conversion of pyruvate to 
lactate by lactate dehydrogenase (LDH). This step requires NADH which is oxidized to 
NAD+. NADH absorbs strongly at 340 nm but NAD+ does not, enabling the reduction of 
NADH over time to be followed by monitoring the decrease in absorbance at 340 nm 
(A340). 
A typical 96 well plate set-up would contain 3 repeats of each of the following 
conditions: a no-enzyme control containing all components of the assay except the 
Gyrase of topoisomerase IV enzyme; a no-compound control containing water instead 
of an inhibitor. Four dilution series comprising seven concentrations of inhibitor 
(novobiocin was always used as one of the four as a control, as it is a commercially 
available inhibitor of known activity). The six remaining wells in the plate could be used 
to measure activity of two inhibitors at a single concentration. 
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An assay mix was prepared immediately prior to use; components of the assay mix and 
quantities needed are given in Table 7.2. Stock solutions were stored at -20 °C until 
needed. PK/LDH solution purchased from Aldrich as a buffered aqueous glycerol 
solution containing 900-1400 units/ml of LDH and 600-1000 units/ml of PK from rabbit 
muscle. NADH solutions were made up fresh immediately prior to each assay and kept 
in the dark on ice until all other preparations were complete. NADH was the last 
component added to the assay mix and was only added immediately prior to use. 
Table 7.2 Components of a typical assay mix with quantities needed per well and per 96 well 
plate. 
Component 
Quantity required per well/ 
μL 
Quantity needed to 
provide sufficient mixture 
for a 96 well plate/ μL 
5X assay buffer 20 2000 
2 mg/ ml DNA solution 3 300 
80 mM PEP solution 1 100 
PK/LDH solution 1.5 150 
10 mM NADH 2 200 
water 47.5 4750 
total 75 7500 
 
To each well of a 96 well plate 10 μl of water or an inhibitor solution at the appropriate 
concentration, 75 μl of assay mix and 10 μL of enzyme solution (500 nM in dilution 
buffer) (or dilution buffer in the case of the no-enzyme control) was added and the 
contents of each well mixed. Absorbance at 340 nm was monitored once per minute 
for 5 minutes and then 5 μL of ATP solution (40 mM) added to each well. Absorbance 
at 340 nm was monitored once per minute for 20-30 minutes as required to see a 
significant decrease in absorbance in all wells except the no-enzyme control. 
IC50 curves were plotted using GraphPad Prism 6
162 and are shown in Figure 7.1 and 
Figure 7.2. 




Figure 7.1 IC50 curves for novobiocin and compounds 69, 71, 72, 73, 74, 75 and 80. 




Figure 7.2 IC50 curves for compounds 81, 85, 158, 161, 162, 163 and 164.  
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7.2.6 MIC determination5 
The minimal inhibitory concentration (MIC) is the lowest compound concentration 
needed to inhibit visible bacteria growth or to inhibit growth based on absorbance 
readings.  The bacterial strains tested were: Klebsiella pneumoniae ATCC 13882; 
Acinetobacter baumannii ATCC 19606; Pseudomonas aeruginosa ATCC 27853, 
Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213.  All strains were 
grown in Müller-Hinton (MH) broth. Compounds were tested by doubling dilutions 
over the concentration range: 0.12-64 µg/ml. Compounds were tested for 
antimicrobial activity by susceptibility testing in liquid media. MICs for compounds 
against each strain were determined by the broth microdilution method according to 
the guidelines of the Clinical Laboratories and Standards Institute (CLSI) Methods for 
Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically163. 
7.2.7 Cloning of DNA gyrase genes into pNIC 
The GyrB24, GyrB and GyrA genes were subcloned from the pAM24, pAG111 and pPH3 
plasmids generously provided by the Maxwell group at the John Innes Centre into a 
pNIC plasmid using ligation independent cloning (LIC).  
7.2.7.1 Linearisation of vector by digestion with BsaI 
The pNIC vector (5 μg) was combined with 5 μl of 10× NEB buffer 4, 1 μl of BSA and 3 
μl of BsaI-HF (10 units/ μl) and the volume made up to 50 μl with water. The digestion 
mix was incubated for 2 hours at 37 °C and the digested DNA isolated by agarose gel 
electrophoresis and purified using a QIAquick gel extraction kit. 
7.2.7.2 T4 DNA polymerase treatment of the vector 
The vector was then treated with T4 polymerase to generate sticky ends. 600 ng of the 
linearised vector were added to a 1.5 ml Eppendorf tube along with 2 μl of 10× NEB 
buffer 2, 2 μl of 25 mM dGTP, 2 μl of 50 mM DTT, 0.5 μl of BSA and 0.5 μl of T4 DNA 
polymerase (3 units/μl) and the volume made up to 20 μl with water. The digestion 
mix was incubated for 30 minutes at 22 °C and 20 minutes at 75 °C. 
                                                     
5 MIC determination was initially performed at Biota Europe Ltd., Begbroke Business & Science 
Park, Sandy Lane, Yarnton, Oxfordshire, OX5 1PF and later at the University of Leeds by 
Anna Lipell or Victoria Lee. 
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7.2.7.3 PCR amplification of the Insert 
DNA for the proteins of interest was amplified from an expression plasmid: pAM24, 
pAG111 and pPH3 were the plasmid containing the GyrB24, GyrB and GyrA genes 
respectively. PCR reactions were prepared in thin walled PCR tubes on ice using the 
KOD Hotstart Polymerase Kit (Novagen). An example of a typical PCR reaction is shown 
in Table 7.3, a typical PCR program is shown in Table 7.4. 
Table 7.3 PCR reaction for insert preparation in 100 µl 
Reagent Final Concentration Volume 
Template DNA 20 ng Up to 1 μl 
KOD Hotstart buffer 1x 10 μl 
dNTP mix 200 μM 10 μl 
MgSO4 1.5 mM 6 μl 
Forward primer 0.5 μM 5 μl of 10 μM stock 
Reverse primer 0.5 μM 5 μl of 10 μM stock 
KOD enzyme 1 U 2 μl 
H2O N/A Up to 100 μl 
 
Table 7.4 A typical PCR program for insert preparation 
Step Time Temperature (oC) Cycles 
Denaturation 2 min 95 1 
Denaturation 30 sec 95  
30 Annealing 30 sec 56 
Extension 30 seca 72 
Extension 10 min 72 1 
Hold  4 1 
a) one minute per 1 kB. 
Clean amplification of the insert was checked by agarose gel electrophoresis and the 
DNA purified using a Qiagen PCR clean-up kit.  
7.2.7.4 T4 polymerase treatment of the insert 
The insert was then treated with T4 polymerase to generate sticky ends. 0.2 pmol of 
the insert were added to a 0.5 ml Eppendorf tube along with 2 μl of 10× NEB buffer 2, 
2 μl of 25 mM dCTP, 2 μl of 50 mM DTT, 0.5 μl of BSA and 0.5 μl of T4 DNA polymerase 
(3 units/μl) and the volume made up to 20 μl with water. The digestion mix was 
incubated for 30 minutes at 22 °C and 20 minutes at 75 °C. 
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7.2.7.5 Annealing of the vector and insert 
The concentration of the vector and the insert were determined using a 
Nanodrop2000 UV/Vis spectrophotometer (Thermo Scientific) at measuring 
absorbance at 260 nm and 320 nm and the following equations: 
              (       ) = (     −     ) × 50      
   
      (  ) =               (       ) ×        (  ) 
      (      ) =
      (  )
                     × 0.65
 
 0.1 pmol of the vector and 0.2 pmol of the insert were combined and incubated at 
room temperature for 20 minutes. 
7.2.7.6 Transformation of the annealing product into ultracompetent E. coli 
A tube of XL10-gold ultracompetent cells (Agilent) was thawed on ice for 10 minutes. 
20 μl of cells were added to 2 μl of the annealing mixture and gently mixed. The cells 
were incubated for 30 minutes on ice and then heat shocked for 30 seconds at 42 °C. 
The cells were immediately cooled on ice for 5 minutes and then 950 μl of SOC 
medium added to the tube and the tubes incubated in a shaking incubator at 37 °C for 
an hour. The tubes were centrifuged at 5000 rpm for 2 minutes and 850 μl of the 
supernatant removed. The cells were resuspended in the remaining supernatant and 
plated onto LB agar plates containing 50 μg/ml kanamycin pre-warmed to 37 °C. The 
plates were incubated at 37 °C overnight. 
7.2.7.7 DNA purification and sequence determination 
Two colonies were chosen to confirm that subcloning had occurred successfully. The 
colonies were used to inoculate 10 ml of sterile LB medium containing kanamycin and 
grown overnight at 37 oC in a shaking incubator. Plasmid DNA was purified from 
overnight cultures using the Qiaprep miniprep kit and purified plasmids sent to GATC 
Biotech for Sanger sequencing. Plasmid DNA was sent away at the concentration of 30-
75 ng/μl in 30 μl aliquots. Sequencing confirmed the presence of the desired gene in 
the pNIC plasmid.  
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7.2.7.8 Preparation of E. coli glycerol stocks 
The plasmid was extracted from the frozen cell stock and transformed into BL21-Gold 
(DE3) (Agilent) cells for protein expression using the method described in Section 
7.2.7.6. A well isolated colony from a fresh transformation was used to inoculate 10 ml 
of sterile LB medium containing kanamycin in a 50 ml Falcon tube. The culture was 
grown in a shaking incubator at 37 oC for 4-6 hours until the optical density at 600 nm 
had reached 0.6, 1 ml of culture was mixed vigorously with 400 μl of sterile glycerol 
(40% w/v) in 1.5 ml cryovials and stored at -80 oC. 
 
7.2.8 Production and purification of GyrB24, GyrB and GyrA proteins 
A starter culture was produced by inoculation of 2 × 20 ml of sterile LB media in a 50 
ml falcon tube with cells from a frozen glycerol stock. Kanamycin was added and the 
culture was incubated over night at 37 °C with shaking at 230 rpm. 
The starter culture was pelleted at 3000 rpm for 10 minutes and the supernatant 
discarded. The cell pellets were resuspended in sterile LB media and added to 0.5 L of 
LB media containing kanamycin (60 μg/ml). The cell culture was incubated at 37 °C 
with shaking at 200 rpm and 1 ml aliquots taken at regular intervals to measure the 
optical density at 600 nm (OD600). Once the OD600 reached ~0.6, protein expression was 
induced by the addition of IPTG to a concentration of 0.5 mM. The cell culture was 
incubated at 20 °C for 18 hours with shaking at 200 rpm and the cells harvested by 
centrifugation at 6000 rpm at 4 °C for 10 minutes.  
The supernatant was decanted and the cell pellets resuspended in lysis buffer (50 ml 
per litre of cell culture). Protease inhibitor cocktail was added prior to cell lysis. Cells 
were lysed using a constant cell disrupter (20 psi, 5 ml injections). Cell lysate was 
clarified by centrifugation at 16000 rpm for 30 minutes at 4 °C. The supernatant was 
decanted and DNase (Roche) added.  
Hexahistidine-tagged proteins were purified by Ni-NTA (Qiagen) chromatography. 4 ml 
of Ni-NTA resin was packed into a gravity-driven column (BioRad Econopac) and 
equilibrated with 10 column volumes (CV) of lysis buffer. The supernatant was applied 
to the column and the flow-through loaded onto the column a second time. The resin 
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was washed with 5 CV of lysis buffer followed by 5 CV of wash buffer and eluted with 
elution buffer. Elution was monitored using the Bio-rad Bradford protein assay. Elution 
buffer was applied until protein was no longer detected. 15 μl of each step was 
collected and analysed by SDS-PAGE. Fractions containing the desired protein were 
concentrated by centrifugal concentration to a volume of <10 ml using Amicon Ultra-
15 centrifugal filter devices (Millipore) with a 10000 Da molecular weight cut off. 
After every four uses of the column the column was stripped and regenerated by 
washing with the following sequence of solutions: 5 CV of 0.1% SDS, 5 CV of 0.1 M 
NaOH, 5 CV of 10 mM EDTA, 20 CV water, 2 CV 500 mM NiSO4 and 20 CV of water. The 
column was stored in 20% EtOH at 4 °C between uses. 
The pNIC-GB1 plasmid contains a tobacco etch virus (TEV) cleavage site (ENLYFQ*S) to 
enable removal of the H6 and GB1 tags. Treatment with TEV protease yields a non-
native N-terminal serine. Recombinant H6-TEV protease was prepared in-house. 
TEV protease was added to the concentrated eluate obtained from the Ni-NTA column 
at an approximate ratio of 1:100 by volume. The eluate was then dialysed for 18 hours 
at 5 °C into 200× the sample volume of 20 mM Tris-HCl, 300 mM NaCl, 1 mM DTT pH 8. 
The dialysis bag was then transferred into 200× the sample volume of 20 mM Tris-HCl, 
150 mM NaCl, pH 8 and dialysed at 4 °C for 18-24 hours. The TEV-cleaved sampled was 
then loaded into a pre-equilibrated Ni-NTA column and washed with lysis buffer. 
Samples of the flow-through and wash were analysed by SDS-PAGE. Fractions 
containing the desired protein were combined and concentrated by centrifugal 
concentration to a volume <10 ml. 
Size exclusion chromatography was carried out as a final purification step using an 
AKTA purifier chromatography system (GE Healthcare) with a prepacked HiLoad 26/60 
Superdex 200 or HiLoad 16/60 Superdex 75 prep grade column (GE healthcare) 
equilibrated with the appropriate buffer. Fractions were analysed by SDS-PAGE and 
fractions containing the desired protein were concentrated to the desired volume by 
centrifugal concentration. 
Protein concentration was determined using a Nanodrop2000 UV/Vis 
spectrophotometer (Thermo Scientific). Absorbance at 280 nm is measured and the 
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Beer-Lambert Law (A=εCL) used to calculate concentration. A is the absorbance at 280 
nm, C is the protein concentration (M), ε is the molar extinction coefficient (M-1 cm-1) 
and L is the path length (cm). Molar extinction coefficients for each protein constructs 
were predicted using the Expasy ProtParam server. 
To produce the full DNA gyrase protein for use in assays, equimolar portions of the 
GyrB and GyrA proteins were combined in high glycerol TGED buffer and placed on a 
shaker at room temperature for half an hour. The mixture was then divided into 
aliquots and flash frozen. Enzyme activity was measured using the coupled assay (as 
described in Section 7.2.5) and was consistent with reported values. DNA gyrase 
protein was stored at -80 °C 
7.2.9 SDS-PAGE analysis 
Protein samples were mixed in a 3:1 ratio with 4 × loading buffer (typically 15 μl of 
protein and 5 μl of loading buffer) and heated to 95 °C for 5 minutes. Samples were 
allowed to cool before loading 10 μL onto the gel. A molecular weight marker was 
added to one lane of the gel.  
Stacking and resolving gels were prepared using the quantities given in Table 7.5. All 
components were mixed thoroughly by inversion and TEMED was added immediately 
prior to casting. The resolving gel was poured to fill ~80% of the mould and methanol 
added to fill the remaining space. After 20 minutes the methanol was removed by 
blotting and the stacking gel added to the mould on top of the resolving gel and a 
comb of 10 or 15 lanes was inserted into the mould and left to set for 20 minutes. 
Table 7.5 Component quantities needed to make two SDS-PAGE gels. 
Component Stacking gel Resolving gel 
Water (ml) 3.32 4.257 
0.5 M Tris (pH 6.8) (ml) 0.945 - 
1.5 M Tris (pH 8.8) (ml) - 2.533 
40% acrylamide (ml) 0.624 3 
10% SDS (ml) 0.05 0.1 
15% APS (ml) 0.1 0.2 
TEMED (ml) 0.01 0.01 
Total (ml) 5 10 
 
The set gel was incorporated into a running vessel and the inner chamber filled with 
running buffer (5× SDS-PAGE running buffer diluted 1:4 with water). The gel was 
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loaded with the required samples and the outer chamber filled to the appropriate level 
with running buffer. The gel was run at 180 V for 45 minutes. 
Gels were stained by immersion in Coomassie stain for 1-2 hours at room temperature 
with rocking and then destained by immersion in Coomassie destain for 3 hours with 
rocking or in Coomassie destain for 1 hour followed by immersion in water over night. 
Gels were washed with water before being photographed. 
7.2.10 Crystallography 
Instrumentation 
Optimisation of crystallisation conditions was set up using an Oryx8 Protein 
Crystallisation Robot from Douglas Instruments and crystallisation was monitored 
using a CrystalMation Gallery DT Minstrel DT protein crystal drop imager from Rigaku. 
Crystallographic data was collected at the Diamond light source, Oxfordshire, UK using 
either beamline I24 or I04. 
Methods 
GyrB24 was crystallised at 10 mg/ml in high glycerol TEGD buffer in the presence of 
1 mM of inhibitors 69, 71, 72 or 86 with or without seed crystals. All crystallisations 
were carried out at a constant temperature of 20 °C. Conditions previously reported in 
the literature (20% PEG400, 100 mM Hepes pH 6.5) were optimised using an Oryx8 
Protein Crystallisation robot (Douglas Instruments) in 96 well MRC sitting drop plates 
(Molecular Dimensions) with a reservoir volume of 60 μl and drops consisting of 0.3 μl 
of protein and 0.3 μl of well solution. In the presence of 72 crystals appeared after a 
few days from conditions containing 25-30% PEG400 and 100 mM Hepes pH 6.5.  
In order to obtain suitable crystals for GyrB 24 with inhibitors 69, 71 and 86 
microseeding was required.  A seed stock was prepared by taking a drop containing 
crystals formed in the presence of compound 72 and crushing them in 60 µl of well 
solution. Optimisation was then carried out using the same conditions except the 
drops consisted of 0.3 μl of protein, 0.3 μl of well solution and 0.1 μl of the seed stock.  
A range of improved crystals were obtained and these were then used to prepare a 
new seed stock in the same manner.  Useable crystals were obtained for GyrB24 in the 
presence of each of the inhibitors from 25-30% PEG400 and 100 mM Hepes pH 6.5.     
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Crystals were manipulated using LithoLoops (Molecular Dimensions) and transferred to 
a cryoprotectant solution containing of 36% PEG400 and 100mM Hepes pH 6.5 with 
addition of 1 mM of each inhibitor. Crystals were flash-cooled in liquid nitrogen and 
stored in Unipuck cassettes (MiTeGen) prior to transport to the synchrotron. Crystals 
were subsequently transferred robotically to the goniostat on the beamline at the 
Diamond Light Source (Oxfordshire, UK) and maintained at -173 °C with a Cryojet 
cryocooler (Oxford Instruments). Diffraction data were recorded on beamline I24 or 
I04. For each crystal a total of 3600 x 0.1° oscillation images were recorded in a single 
sweep.   
All X-ray data were processed using Xia2164,165 and the resultant data collection 
statistics are summarised in Table 7.6. The crystals belonged to either space group 
P3121 or P3221 with approximate cell parameters of a = b = 99, c = 50 Å. All subsequent 
data processing was carried out using programs from the CCP4 suite144. Estimation of 
the content of the asymmetric unit (ASU) suggested that 1 copy of the TEV cleaved 
protein (molecular weight 24,242 Da) was present giving a solvent content of 59.7 
%).166 
The compound 72 crystal structure was solved using molecular replacement with PDB 
entry chain A of 4URO141 with Novobiocin and waters removed using Phaser167. The 
top solution was for space group P3221. Rigid body refinement following restrained 
refinement was then carried out giving initial Rwork and Rfree values of 0.446 and 0.422 
respectively and a figure-of-merit (FOM) of 0.50 at 1.9X Å resolution. Clear density 
could be seen for the presence of compound 72. This was drawn using Libcheck168 and 
Prodrug169 was then used to create pdb file and dictionary entry. Compound 72 was 
successfully built into the density.  Several iterations of model building with COOT170 
and restrained refinement with REFMAC5168,171 were carried out.  For the final stages 
of refinement TLS refinement was carried out using the suggested 8 TLS domain from 
the pdb redo server.172 The final model consisted of 204 residues, 84, water molecules, 
one inhibitor molecule and one PEG molecule with Rwork and Rfree values of 0.201 and 
0.223 respectively.  This structure was then used as the starting model for refinement 
of the other 3 structures.  Full refinement statistics for all four structures are given in 








X-Ray Data Collection and Refinement Statistics for GyrB24 protein crystal structures. 
  69 71 72 86 
Data collection     
 Crystal GyrB24_28 GyrB24_12 GyrB24_6 GyrB24_35 
 Beamline I04, Diamond Light 
Source, UK 
I24 Diamond Light 
Source, UK 
I24, Diamond Light 
Source, UK 
I04, Diamond Light 
Source, UK 
 Wavelength  (Å) 0.9795 0.9790 0.9790 0.9795 
 Detector Pilatus 6M-F Pilatus3 6M Pilatus3 6M Pilatus 6M-F 
 Resolution range (Å) 50.27 – 2.50 (2.57 – 2.50) 49.90 – 1.95 (2.00 – 1.95) 49.67 – 1.90 (1.95 – 1.90) 49.68 – 2.35 (2.41 – 2.35) 
 Space Group P3221 P3221 P3221 P3221 
 Cell parameters (Å) a = b = 100.20, c = 50.27 a = b = 99.79, c = 50.21 a = b = 99.34, c = 50.21 a = b = 99.36, c = 50.03 
 Total no. of measured intensities 101076 (7177) 209856 (14777) 221669 (15948) 117906 (8962) 
 Unique reflections 10325 (735) 21281 (1561) 22689 (1657) 12122 (878) 
 Multiplicity 9.8 (9.8) 9.9 (9.5) 9.8  (9.6) 9.7 (10.2) 
 Mean I/(I) 10.6 (1.4) 7.2 (1.4) 8.0 (1.3) 8.5 (1.5) 
 Completeness (%) 100.0 (100.0) 99.9 (99.2) 99.7 (99.0) 100.0 (100.0) 
 Rmerge
a 0.177 (1.599) 0.188 (1.470) 0.178 (1.426) 0.188 (1.490) 
 Rmeas
b 0.197 (1.784) 0.210 (1.646) 0.198 (1.594) 0.210 (1.655) 
 CC½
c 0.997 (0.528) 0.993 (0.468) 0.996 (0.506) 0.996 (0.485) 
 Wilson B value (Å2) 33.4 28.6 21.5 34.8 
Refinement     
 Resolution range (Å) 50.27 – 2.50 49.90 – 1.95 49.67 – 1.90 49.68 – 2.35 
 Reflections: working/freed 687: 42 1490: 65 1581: 72 834: 44 
 Rwork/ Rfree

















 Ramachandran plot: 
favoured/allowed/disallowedf (%) 
98.4/100.0/0.0 98.9/100.0/0.0 98.4/100.0/0.0 98.9/100.0/0.0 
 R.m.s. bond distance deviation (Å) 0.011 0.013 0.013 0.007 
 R.m.s. bond angle deviation (º) 1.584 1.651 1.687 1.285 
 No. of protein residues: chain A 204 204 204 204 
 No. of water 
molecules/Compound/PEG 
53/1/1 84/1/1 84/1/1 73/1/1 
 Mean B factors: 
protein/water/overall  (Å2) 
37.7/45.5/36.9  25.9/40.6/26.2 37.7/51.4/37.8 
Values in parentheses are for the outer resolution shell. 
a
 Rmerge = ∑hkl ∑i |Ii(hkl)  I(hkl)|/ ∑hkl ∑iIi(hkl).  
b 
Rmeas = ∑hkl [N/(N  1)]
1/2
 × ∑i |Ii(hkl)  I(hkl)|/ ∑hkl ∑iIi(hkl), where Ii(hkl) is the ith observation of reflection hkl, I(hkl) is the weighted average intensity for all 
observations i of reflection hkl and N is the number of observations of reflection hkl.  
c
 CC½ is the correlation coefficient between symmetry equivalent intensities from random halves of the dataset.  
d
 The data set was split into "working" and "free" sets consisting of 95 and 5% of the data respectively. The free set was not used for refinement.  
e
 The R-factors Rwork and Rfree are calculated as follows: R = (| Fobs - Fcalc |)/| Fobs | x 100, where Fobs and Fcalc are the observed and calculated structure factor amplitudes, 
respectively.  
f
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